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 Abstract 
 
The C-type lectin-like receptor, CLEC-2, is constitutively expressed on platelets, with 
reported expression on a number of leukocyte subsets in adult mice. Constitutive or 
platelet-specific deletion of CLEC-2 in mice induces cerebral haemorrhaging by mid-
gestation. In this thesis, I investigated the basis of this defect, hypothesising that it is 
mediated by the loss of CLEC-2 activation by its endogenous ligand, podoplanin, 
expressed on the developing neural tube. Podoplaninfl/fl mice were crossed to mice 
expressing PGK-Cre to induce deletion of podoplanin at the two-cell stage. Developing 
blood vessels were visualized by 3-dimensional microscopy and found to be aberrantly 
patterned in CLEC-2- and podoplanin-deficient mice, culminating in widespread cerebral 
haemorrhaging by mid-gestation. Haemorrhages were also observed following Nestin-Cre 
driven deletion of podoplanin on neural progenitors and following deletion of the platelet 
integrin, αIIbβ3. Together these studies support that neuro-epithelial-derived podoplanin 
interacts with platelet-CLEC-2 to guide the maturation and integrity of the cerebral 
vasculature and to prevent haemorrhage by stimulating platelet aggregation. Using 
tamoxifen-inducible deletion of CLEC-2 in adult mice, the expression profile of CLEC-2 
was investigated and shown to be restricted to platelets and circulating B-lymphocytes and 
CD11bhigh Gr1high myeloid cells. Furthermore, loss of CLEC-2 in adult mice was shown to 
be dispensable for maintaining blood-brain barrier permeability.  
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CHAPTER 1 
GENERAL INTRODUCTION 
                                
 2 
1.1  Platelet function and physiology 
1.1.1 Overview of platelet function  
Platelets are anucleate blood cells that continually circulate the vascular system in a 
resting state ready to respond and plug areas of vascular damage to fulfill their major role 
in haemostasis. Platelets are packed with signalling proteins and surface receptors that are 
primed to mediate a robust activation response when in contact with exposed endothelial 
matrix (Gibbins, 2004). Their contact with the vessel wall is dependent on their small size 
(2-3 µm) that allows their margination towards vascular endothelial cells within the 
laminar flow of the blood vessels (Green, 2011). Inappropriate activation of platelets is 
associated with atherothrombotic disease such as myocardial infarction or stroke and is 
responsible for over 25% of deaths globally, making it the leading cause of mortality (Ho-
Tin-Noe et al., 2011). 
 
1.1.2 Platelet production  
Platelets are derived from megakaryocytes, which in the embryo arise in the fetal liver and 
the yolk sac. In the adult, platelets reside in the osteoblastic niche of the bone marrow 
where they are formed from common myeloid progenitors (Figure 1.1) (Green, 2011). 
Platelets are released directly into the blood stream from megakaryocyte pro-platelet 
processes that extend between sinusoidal endothelial cells of the bone marrow (Italiano & 
Shivdasani, 2003). The rapid, dynamic nature of this process is highlighted by the short 
lifetime (5-7 days in mice and 8-10 days in humans) and large volume of circulating 
platelets (90-160 x 1010 in mice and 15-40 x 1010 in humans) (Kaushansky, 2005). 
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Figure 1.1. Hematopoietic stem cell lineages. Hematopoietic stem cells (HSCs) are 
multi-potent cells that self-renew to continually generate new HSCs to replenish cells of 
the blood system. HSCs can differentiate to commit to the myeloid or lymphoid lineage, 
giving rise to common myeloid progenitors or common lymphoid progenitors, 
respectively. Progenitor cells differ from stem cells in that they lack self-renewal capacity 
but can be multipotent or unipotent. Common lymphoid progenitors predominantly 
generate B- and T- lymphocytes as well as natural killer cells (and some dendritic cell 
subsets). Common myeloid progenitor lineage pathways include the generation of 
erythrocytes, the megakaryocyte pathway to generate platelets, or the myeloblast pathway 
to generate monocyte derived macrophages, dendritic cell subsets and granulocytes, 
including basophils, neutrophils and eosinophils. Figure reconstructed from (Katsura, 
2002). 
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1.1.3 Platelet signalling   
Platelet adhesion and activation involves a multi-step cascade of receptor interactions. The 
initial tethering of platelets to exposed collagen in the vessel wall is mediated through the 
platelet glycoprotein GPIb-V-IX binding to von Willebrand factor (VWF). This 
interaction brings the platelet receptor GPVI in close proximity to collagen, mediating 
platelet activation and the release of the secondary mediators, thromboxane and adenosine 
diphosphate, which in combination with locally generated thrombin creates a feedback 
loop to initiate further platelet activation and platelet capture. Stable adhesion and platelet 
aggregation relies on the major platelet integrins, αIIbβ3 and α2β3, reviewed in (Green, 
2011; Nieswandt et al., 2011). 
 
1.1.4 Roles of platelets outside of haemostasis and thrombosis  
Platelets have been shown to critically contribute to a range of both inflammatory and 
developmental processes. Inflammation is tightly coupled to thrombosis and relies on an 
imbalance in the pro- and anti-coagulant properties of the endothelium (Wagner & 
Burger, 2003). Platelets have been shown to contribute to both the onset and progression 
of atherosclerosis amongst other thrombo-inflammatory disorders, such as ischaemic 
stroke and inflammatory bowel disease (Nieswandt et al., 2011; McNicol & Israels, 2008; 
Gawaz et al., 2005). Platelets have also been shown to facilitate the growth of tumour 
cells, their extravasation into the blood stream and their evasion from the immune system 
to promote cancer metastasis, reviewed in (Lowe et al., 2012; Gay & Felding-Habermann, 
2011). Furthermore, platelet interactions with bacteria have been implicated in infective 
endocarditis, coronary artery disease and atherosclerosis, reviewed in (Fitzgerald et al., 
2006). Interestingly, thrombi have also been implicated in immune defense, whereby 
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pathogens are captured and contained within a platelet rich thrombus, limiting their 
dissemination and effectively compartmentalising them for immune cell targeting 
(Engelmann & Massberg, 2013). Platelet receptors that signal through a specific, 
conserved motif, known as the immunoreceptor tyrosine-based activation motif (ITAM), 
are particularly implicated in these pathways (Boulaftali et al., 2013). Of particular 
interest is the platelet C-type lectin-like receptor 2 (CLEC-2) and its endogenous ligand 
podoplanin. During development, CLEC-2 has been shown to interact with podoplanin to 
mediate the separation of the blood and lymphatic vasculatures, which will be discussed in 
Section 1.4 (Suzuki-Inoue et al., 2010). 
 
1.2  C-type lectin-like receptor 2 (CLEC-2) 
1.2.1 Identification of CLEC-2 
CLEC-2 (gene name Clec-1b) was first identified in a bioinformatics study and found on 
chromosome 12 of the human genome in a cluster of six other C-type lectin receptors 
(Colonna et al., 2000). Years later CLEC-2 was identified on platelets as a novel receptor 
for the snake venom toxin rhodocytin and further isolated as a 30kDa protein by mass 
spectrometry (Suzuki-Inoue et al., 2006). Subsequently, CLEC-2 mRNA was found to be 
abundantly expressed in the megakaryocyte/platelet lineage of the mouse genome through 
use of serial analysis of gene expression (SAGE) (Senis et al., 2006). CLEC-2 has since 
been reported to be expressed on subsets of murine myeloid cells, such as neutrophils, 
dendritic cells (DCs) and natural killer cells, however, the reliability of this data is now 
questionable and will be discussed in Chapter 4 (Mourao-Sa et al., 2011; Kerrigan et al., 
2009). 
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1.2.2 CLEC-2 signalling 
CLEC-2 is a type II transmembrane glycoprotein, however its C-type lectin-like 
extracellular domain lacks the conserved structural features required for binding to 
carbohydrate moieties, which suggested its endogenous ligand may be a protein (A. A. 
Watson et al., 2006). CLEC-2 signals through its cytoplasmic tail in a sequential multi-
step pathway similar, yet distinct, to that of the major platelet collagen receptor, GPVI (S. 
P. Watson et al., 2010). A single YxxL motif found downstream of a conserved triacidic 
amino acid sequence in the CLEC-2 cytoplasmic tail is known as a hem-ITAM. Two 
ITAM sequences are found in the GPVI-FcRγ complex amongst other immunoglobulin 
receptors that play a critical role in platelet, B- and T-lymphocyte signalling. CLEC-2 is 
expressed as a dimer on the platelet surface where it interacts with its only known 
endogenous ligand, podoplanin (Section 1.3). Ligand engagement triggers the 
phosphorylation of the signalling molecule SYK by SRC family kinases (SFKs). 
Activated SYK phosphorylates the YxxL motifs in the CLEC-2 cytoplasmic tail, allowing 
its association to the dimeric form of CLEC-2 through its tandem SH2 domains. A 
complex signalling cascade ensues, resulting in the formation of the LAT signalasome 
encompassing an array of adaptor proteins and other effector molecules that mediate 
activation of PLCγ2, culminating in platelet activation (Figure 1.2), reviewed in (S. P. 
Watson et al., 2010; Underhill & Goodridge, 2007). 
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Figure 1.2. CLEC-2-podoplanin signalling axis. CLEC-2 interacts with podoplanin 
stimulating phosphorylation of the tyrosine kinase SYK, by SRC family kinases (SFKs). 
Activated SYK phosphorylates (P) the YxxL motifs in the CLEC-2 cytoplasmic tails, 
permitting their association with dimeric CLEC-2 through its tandem SH2 domains. A 
complex signaling pathway ensues involving the adaptor proteins LAT, SLP-76, Grb2, 
Tec family kinases, including Btk, and the Vav family of guanine exchange factors, which 
together support the activation of a number of effector molecules, including the enzyme 
PLCγ2, culminating in platelet activation. Meanwhile podoplanin signals through its short 
cytoplasmic tail through the interaction with the ezrin, radaxin & moeisin (ERM) family 
proteins, influencing actin cytoskeletal re-arrangements. Figure reconstructed from (S. P. 
Watson et al., 2010). 
Figure 1.2. CLEC-2-podoplanin signalling axis. CLEC-2 interacts with 
podoplanin stimulating phosphorylation of the tyrosine kinase molecule, Syk 
by src family kinases (SFKs). Activated Syk phosphorylates the YxxL motif in 
the CLEC-2 cytoplasmic tail permitting its association with dimeric CLEC-2 
via its tandem SH2 dom ins. A complex signaling pathway ensues involving 
the adaptor proteins LAT, SLP-76 and the enzyme PLCγ2, culminating in 
platelet activation. Meanwhile podoplanin signals through its short cytoplasmic 
tail through the interaction with the ezrin, radaxin & moeisin (ERM) family 
proteins, influencing actin cytoskeletal re-arrangements. Figure reconstructed 
from Watson 2010. 
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1.3  Podoplanin 
 1.3.1 Identification of podoplanin as a ligand for CLEC-2 
Evidence for an endogenous ligand for CLEC-2 came from studies investigating the 
causative receptor mediating the viral capture of human immunodeficiency virus-1 (HIV-
1) by platelets, found to be CLEC-2 (Chaipan et al., 2006). The capture of HIV-1 by 
CLEC-2 on platelets was independent of a viral envelope protein and was instead found to 
be a protein from the virus producing cell line, human embryonic kidney 293T (HEK-
293T), incorporated during viral budding (Christou et al., 2008). Podoplanin was later 
identified on the surface of tumour cells as a potent inducer of platelet aggregation (Kato 
et al., 2003). Furthermore, induction of platelet aggregation was shown to rely on a key 
amino acid sequence within the highly glycosylated extracellular domain (EDxxVTPG)3, 
designated the platelet aggregation (PLAG) stimulating domain (Kaneko et al., 2004). 
Independently, Suzuki-Inoue et al (2007) were able to show the ligand for podoplanin to 
be CLEC-2 by demonstrating that tumour cells induce platelet aggregation with similar 
kinetics to the exogenous ligand for CLEC-2, rhodocytin, and through a similar signalling 
pathway involving SRC and PLCγ2 (Suzuki-Inoue et al., 2007). Using podoplanin-
expressing Chinese hamster ovary (CHO) cells they were able to confirm the interaction 
between CLEC-2 and podoplanin, and further show that lymphatic endothelial cells 
(LECs) that endogenously express podoplanin, were able to initiate platelet aggregation in 
a CLEC-2-dependent manner (Suzuki-Inoue et al., 2007). Following the identification of 
podoplanin as an endogenous ligand for CLEC-2, the HEK-293T protein ligand for 
CLEC-2 was also confirmed to be podoplanin, with an interaction affinity of 25 µM, as 
confirmed by surface plasmon resonance (Christou et al., 2008).  
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1.3.2 Tissue expression pattern of podoplanin 
Podoplanin is a 36-43 kDa type-1 transmembrane glycoprotein first identified in kidney 
podocytes (Breiteneder-Geleff et al., 1997). Its expression is however widespread, with 
varying names connected to its pattern of discovery. It was identified on thymic epithelial 
cells and lymphoid fibroblastic reticular cells as gp38 (Farr et al., 1992), on alveolar type-
1 epithelial cells, the cerebral choroid plexus, ciliary epithelium of the eye, oesophagus 
and intestine as T1α (M. C. Williams et al., 1996), on osteoblasts as 0TS-8 (Nose et al., 
1990), on LECs as the E11 antigen (Wetterwald et al., 1996), on induced skin 
keratinocytes as PA2.26 (Scholl et al., 1999) and on tumour cells as the platelet 
aggregating protein, aggrus (Kato et al., 2003). Podoplanin has since been shown to be 
expressed on mucosal epithelial cells of the salivary glands (Hata et al., 2010), the 
myocardium, pericardium and epicardium of the heart (Mahtab et al., 2008; Gittenberger-
De Groot et al., 2007) and on T-helper 17 (TH17) cells and inflammatory macrophages (A. 
Peters et al., 2011; Hou et al., 2010; Kerrigan et al., 2012). However, the function of 
podoplanin in each of these tissues remains speculative.  
 
During development, the expression pattern of podoplanin is more transient than in 
adulthood. In tissues such as the heart, brain, oesophagus, intestine and kidney, expression 
is high early in development (around embryonic day (E) 9.0), and becomes more spatially 
restricted in adulthood. For example, podoplanin is expressed throughout the central 
nervous system (CNS) at E9.0 and becomes restricted to the choroid plexus by mid-
gestation.  The opposite pattern is seen in the lung, where expression in early development 
is negligible, with a dramatic increase on alveolar type I cells by postnatal day (P)0 (M. C. 
Williams et al., 1996; Mahtab et al., 2008). 
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1.3.3 Podoplanin signalling  
The extracellular domain of podoplanin is a highly glycosylated, rigid structure that 
makes up over 90% of its molecular weight. This is followed by a single transmembrane 
domain, leaving only a short 9 amino acid cytoplasmic tail for intracellular signalling 
(Cueni et al., 2010; Martin-Villar et al., 2006). Despite this, podoplanin is able to 
dynamically regulate cell motility through its interaction with ezrin-radaxin-moesin 
(ERM) family proteins, forming a bridge between the integral membrane surface and the 
actin cytoskeleton (Fehon et al., 2010; Martin-Villar et al., 2006) (Figure 1.2). Rho-
dependent kinase phosophorylates ERM proteins, initiating a conformational change that 
exposes binding sites to permit their association with integral membrane proteins and F-
actin (Bretscher et al., 2002). Overexpression of podoplanin is associated with increased 
phosphorylation of ERM proteins (Martin-Villar et al., 2006; Wicki et al., 2006). 
Furthermore, when upregulated in keratinocytes, podoplanin was shown to co-localise 
with ERM family proteins at filopodia and lamellipodia to mediate an increase in cell 
motility (Scholl et al., 1999).  In cancer cell lines, up-regulation of podoplanin is 
associated with an increase in RhoA activity and the acquisition of a migratory phenotype. 
As expression of epithelial markers such as E-cadherin decrease, these cells undergo an 
epithelial to mesenchymal transition (EMT), during which they are transformed from non-
invasive cells into having an invasive pro-migratory phenotype (Martin-Villar et al., 
2006). Similarly, siRNA knockdown of podoplanin on LECs correlates with a decrease in 
RhoA expression (Navarro et al., 2008). Conversely, Wicki et al (2006) found that up-
regulation of podoplanin led to a decrease in RhoA activity while still promoting tumour 
invasion. Furthermore, the acquisition of a migratory phenotype was in the absence of 
EMT (Wicki et al., 2006). In the absence of EMT, mucin-like proteins have been shown 
to increase the migratory properties of cells by masking adhesion receptors with their 
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extensive ectodomains, thereby inhibiting their function (Komatsu et al., 1997). These 
conflicting mechanisms likely reflect the multiple roles of podoplanin, depending on the 
cell type in which it is expressed. 
1.3.4 Binding partners of podoplanin 
Podoplanin has been shown to associate with transmembrane domains 1 and 2 of the 
tetraspanin CD9, through homophillic interactions. The full impact of this interaction 
remains to be explored, but has been shown to directly suppress the platelet aggregating 
ability of podoplanin (Nakazawa et al., 2008). The major hyaluronan receptor CD44 
(otherwise known as Lyve-1) has also been found as a novel binding partner for 
podoplanin. During EMT in cancer cell lines, podoplanin and CD44 are mutually 
upregulated and co-associate at cell protrusions to mediate cell migration (Martín-Villar et 
al., 2010).  
1.3.5 Other endogenous ligands for podoplanin 
Given the vast expression pattern of podoplanin and the highly restricted expression of 
CLEC-2, it is feasible to assume a number of ligands exist for podoplanin, which, in time, 
will unravel its physiological role and function. Two such ligands have been identified, 
galectin-8 and CCL21, whose interaction with the podoplanin ectodomain is glycosylation 
dependent. Galectin-8 is highly expressed on LECs, where it promotes LEC migration and 
adhesion. Physiologically, galectin-8 is suggested to associate with podoplanin on 
lymphatic endothelium and promote its association with the extracellular matrix (ECM) 
(Cueni & Detmar, 2009). CCL21 is a lymphatic specific chemokine and although the 
significance of its association with podoplanin is unknown, its expression on LECs and 
fibroblastic reticular cells gives interesting potential in light of recent studies 
demonstrating a role for podoplanin in the trafficking of DCs to lymph nodes (Kerjaschki 
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et al., 2004; Acton et al., 2012).  
1.4  Podoplanin and CLEC-2 in the development of the lymphatic 
vasculature 
(Refer to Table 1.1 for summary) 
Nearly two decades ago, mice deficient in the tyrosine kinase SYK were shown to present 
with subcutaneous haemorrhaging in the skin and oedema throughout the back at E14.5 
(Turner et al., 1995; Cheng et al., 1995). The same phenotype was observed in mice 
deficient in the adaptor protein SLP-76 (Clements, 1998; Clements et al., 1999; Pivniouk 
et al., 1998) and the effector enzyme PLCγ2 (Wang et al., 2000). This phenotype was 
later shown to result from defective lymphatic function, attributable to erroneous 
connections between the blood and lymphatic circulations (Abtahian et al., 2003; Ichise et 
al., 2008). In the same time frame, mice deficient in podoplanin were generated and found 
to die at birth due to respiratory failure (Ramirez et al., 2003). Pups also developed severe 
lymphedema at birth resulting from impaired lymphatic drainage (Schacht et al., 2003) 
and were later shown to harbour blood filled lymphatic vessels in the skin and gut (Fu et 
al., 2008). CLEC-2-deficient mice were further shown to die within the first postnatal 
week, attributable to impaired lung inflation (Finney et al., 2012). Embryonic studies 
found both CLEC-2- and podoplanin-deficient mice to harbour the characteristic 
phenotype of blood-filled lymphatic vessels in the skin from E13.5 and oedema in the 
back and limbs, phenocopying SYK-, SLP-76- and PLCγ2-deficient mice (Suzuki-Inoue 
et al., 2010; Bertozzi, Schmaier, et al., 2010b). All surviving podoplanin, CLEC-2-, SYK-
, SLP-76- and PLCγ2-deficient pups developed chylous ascites in the abdomen, further 
highlighting impaired lymphatic function, with many dying in the early postnatal period. 
The glycosylation of the podoplanin extracellular domain is dependent on the activity of a 
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key glycosyltransferase enzyme T-synthase, which catalyses the biosynthesis of O-
glycans. Mice constitutively deficient in T-synthase are embryonic lethal by E14.5, while 
endothelial specific deletion (Tie2-Cre) results in the characteristic blood-filled lymphatic 
phenotype (Xia et al., 2004; Fu et al., 2008). The requirement for podoplanin expression 
specifically on the endothelium is shown in Tie2-Cre transgenic mice, which exhibit 
blood-filled lymphatic vessels, while no phenotype is observed in radiation chimeric mice 
reconstituted with podoplanin-deficient fetal liver (Bertozzi, Schmaier, et al., 2010b; 
Herzog et al., 2013). These data support a role for the podoplanin on the endothelium with 
a specific requirement for its glycosylated extracellular domain. 
1.4.1 Identifying the CLEC-2-expressing cell type 
The group of Mark Kahn initially pinpointed the activity of SYK and SLP-76 signalling in 
a circulating cell to be involved in the defective separation of the blood and lymphatic 
vasculatures, later suggesting this to be a bone marrow-derived circulating lymphatic 
endothelial progenitor cell (Abtahian et al., 2003; Sebzda et al., 2006). Lineage tracing 
studies later identified cells of the myeloid lineage, within the haematopoietic 
compartment, to be the causative cell type (Bohmer et al., 2010). This was supported 
through the generation of a range of cell-specific Cre deleters, showing that mice deficient 
in SLP-76 or SYK in the haematopoietic lineage (Vavi-Cre), and not in endothelial cells 
(Tie2-Cre), present with the characteristic blood-filled lymphatic phenotype, albeit this 
phenotype was of varying severity with a low level of perinatal mortality (Finney et al., 
2012; Bertozzi, Schmaier, et al., 2010b). Furthermore, a role for SYK in macrophages, T- 
and B-lymphocytes was eliminated, while the loss of CLEC-2, SYK and SLP-76 in the 
megakaryocyte/platelet lineage (PF4-Cre) was shown to be indispensable for blood-
lymphatic separation (Finney et al., 2012; Bertozzi, Schmaier, et al., 2010b). The severity 
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of the phenotype resulting from PF4-Cre–mediated deletion of CLEC-2, SYK or SLP-76 
was variable, mimicking that seen using the Vavi-Cre transgene, and is suggested to be 
attributable to the onset of Cre activity. Although Bertozzi et al (2010) find the activity of 
the PF4-Cre transgene to be specific to the megakaryocyte/platelet lineage, other studies 
suggest this not to be the case, opening up the possibility for the contribution of another 
haematopoietic lineage (Calaminus et al., 2012; Bertozzi, Schmaier, et al., 2010b). 
However, a role for platelets is supported by the description of a blood-lymphatic mixing 
phenotype in mice lacking functional megakaryocytes, owing to a deficiency in the 
transcription factor Meis-1, following selective ablation of the megakaryocyte/platelet 
lineage using diphtheria toxin, or through treating with the anti-platelet agent aspirin 
(Carramolino et al., 2010; Uhrin et al., 2010). Furthermore, the contribution of platelet-
specific effects over contributions by megakaryocytes is shown in the development of 
blood-lymphatic mixing in the intestines of radiation chimeric mice reconstituted with 
SYK-, SLP-76-, PLCγ2- or CLEC-2-deficient bone marrow, where the numbers of 
circulating megakaryocytes are negligible (Bertozzi, Schmaier, et al., 2010b; Finney et 
al., 2012; Ichise et al., 2008).  
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Table 1.1. Mouse models portraying blood-lymphatic separation defects 
Reference     Background    Lethality                  Reported phenotype 
CLEC-2 
 
Tang et al 
(2010)  
 
 
C57BL/6* 
 
 
 
The majority of 
pups die in the first 
postnatal weeks 
 
 
Subcutaneous haemorrhages 
throughout the embryo at E13.0. 
Haemorrhages in the developing 
brain at E12.0 
Bertozzi et 
al (2010) 
C57BL/6; 
129sv 
100% lethality 
within the first 
postnatal weeks 
 
Blood-filled lymphatic vessels at 
E14.5. Oedema through the back 
and limbs. Reduced airspaces in the 
lungs. Chylous ascites in the 
abdomen of pups 
Suzuki Inoue 
et al (2010) 
 
C57BL/6*  
 
 
Mendelian up to 
E15.5, majority of 
pups die at birth, 
99.4% lethality at 
8 weeks 
Blood filled lymphatic vessels at 
E13.5. Oedema in the back 
Finney et al 
(2012) 
C57BL/6* 
 
Mendelian up to 
P0, the majority of 
pups die at birth, 
98.6% lethality at 
4 weeks 
Blood-filled lymphatic vessels at 
E14.5. Oedema through the back 
and limbs. Reduced airspaces in the 
lungs. Chylous ascites in the 
abdomen of pups. Haemorrhaging 
in the brain at E12.5  
Podoplanin 
 
Ramirez et 
al (2003) 
Schacht et al 
(2003) 
Fu et al 
(2008) 
 
 
129sv* 
 
 
Mendelian up to 
P0. 100% lethality 
within 4 hours 
 
 
Death due to respiratory failure. 
Impaired formation of alveolar 
spaces. Oedema in the limbs of 
neonates. Blood-filled lymphatic 
vessels 
Bertozzi et 
al (2010) 
C57BL/6; 
129sv 
 Blood-filled lymphatic sacs and 
cutaneous vessels at E11.5 and 
E14.5, respectively. Oedema 
through the back at E14.5. Chylous 
ascites in the small intestine of 
neonates 
Mahtab et al 
(2008) 
 
129sv; 
Swiss 
 
40% lethality by 
E16.5 and 50% 
lethality within 1 
week 
Myocardial pathology related to 
reduced epithelial to mesenchymal 
transitions 
Uhrin et al 
(2010) 
C57BL/6 55% lethality 
within 1 week. 
20% had a normal 
life span 
 
 
Blood-filled cutaneous lymphatic 
vessels at E13.5. Chylous ascites in 
the small intestine of neonates 
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T-synthase 
 
Xia et al 
(2004) 
C1galt1 
 
C57BL/6*  
 
 
100% lethality by 
E14.5 
 
 
Haemorrhaging in the central 
nervous system at E12.0 (See text 
on lineage specific deletions). 
SYK 
 
Turner et al 
(1995) 
 
 
(B6D2)F1*  
 
 
Mendelian up to 
E18.5. Only 1 pup 
survived >3 weeks 
 
 
Subcutaneous haemorrhages 
throughout embryo at E16.5 in 45% 
of knockouts. Chylous ascites in the 
small intestine. 
Cheng et al 
(1995) 
 Majority of pups 
die by P1, all pups 
die within 3 weeks 
Subcutaneous haemorrhages 
throughout the embryo at E14.5 
Oedema in the limbs at E14.5 and 
in neonates. 
SLP-76 
 
Clements at 
al (1998) 
Clements et 
al (1999) 
 
 
C57BL/6* 
 
 
Mendelian up to 
P0. Majority of 
pups die by P7 
 
 
Subcutaneous haemorrhages 
throughout the embryo. Bleeding in 
abdominal cavity of neonates. 
Pivniouk et 
al (1998) 
 Majority of pups 
die by P7 
Subcutaneous haemorrhages, 
swollen footpads and bleeding in 
abdominal cavity of pups 
PLCγ2 
 
Wang et al 
(2000) 
 
 
C57BL/6* 
 
 
Mendelian up to 
E19.0. One third 
of pups die at birth 
 
 
Subcutaneous haemorrhages at 
E12.0. Bleeding in the small 
intestine and the abdominal cavity. 
Ishise et al 
(2009) 
C57BL/6; 
129Sv 
 Blood-filled lymphatic sacs at 
E13.5. Adults have blood-
lymphatic shunts in the intestine, 
heart, diaphragm and skin and 
chylous ascites in the abdomen 
* No detail into the number of backcrosses is given 
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1.4.2 Function and development of the lymphatic system  
The primary function of the lymphatic system is to regulate tissue homeostasis, lipid 
absorption and facilitate immune cell trafficking (Figure 1.5). Fluid from lymphatic 
vessels drains into the venous system through either one of only two points of contact 
with the subclavian vein, the thoracic duct and the right lymphatic vein, both of which 
encompass bicuspid lympho-venous valves to prevent backflow into the venous system, 
reviewed in (Tammela & Alitalo, 2010; Schulte-Merker et al., 2011). It was suggested in 
1902 that the lymphatic system develops from the venous system, which has since been 
confirmed by lineage tracing studies (Srinivasan et al., 2007). The current mechanism 
underlying the initial specification of the lymphatic system is complex and involves over 
20 genes, reviewed in (Tammela & Alitalo, 2010; Schulte-Merker et al., 2011). Briefly, 
lymphatic progenitor cells can be detected at the cardinal vein at E10.0 by the activity of 
the transcription factor Sox18, which induces expression of prox-1, both of which are 
indispensible for lymphatic specification and function (François et al., 2008; Wigle et al., 
2002). Prox-1-expressing lymphatic progenitor cells migrate from the dorsal side of the 
cardinal vein as a polarised stream of cells that rapidly acquire a pro-migratory phenotype. 
This is dependent on the expression of vascular endothelial growth factor receptor 3 
(VEGFR-3), its co-receptor neuropilin-2 (Nrp-2) and the presence of the growth factor 
VEGF-C (Xu et al., 2010; Dumont et al., 1998; Karkkainen et al., 2003). From E11.0, 
these ‘immature’ LECs, now expressing podoplanin, rapidly coalesce to form a luminised 
vessel from which the superficial lymphatic vessels develop, further differentiating into 
dermal lymphatics in the skin from E12.0. Simultaneously, the primary thoracic duct 
forms adjacent to the cardinal vein from a subset of aggregating LECs (Hägerling et al., 
2013; Yang et al., 2012).  
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1.4.3 Unraveling the mechanism behind the blood-lymphatic mixing phenotype 
The mechanism by which podoplanin on LECs interacts with and induces signalling in a 
CLEC-2-expressing cell to mediate blood and lymphatic vessel separation remains 
controversial. Direct interactions between platelets and newly specified LECs at the 
cardinal vein at E11.5 were initially proposed to ‘clot off’ and aid the budding of primary 
lymphatic structures (Uhrin et al., 2010; Bertozzi, Hess, et al., 2010a). This was disputed 
because of the presence of blood-filled lymphatic shunts in adult radiation chimeric mice 
reconstituted with CLEC-2- or SYK-deficient bone marrow, in which the lymphatic 
system is already developed (Bertozzi, Schmaier, et al., 2010b; Finney et al., 2012). The 
requirement for platelet aggregation is disputed because of the presence of a non-
separation phenotype in mice lacking the gene kindlin-3, essential for platelet aggregation, 
while no requirement was found for the major platelet integrin αIIβ3 (Hodivala-Dilke et 
al., 1999; Uhrin et al., 2010). Recently, it was proposed that podoplanin-induced CLEC-2 
signalling in platelets stimulates thrombus formation at the joining of the thoracic duct 
and subclavian vein. This interaction was shown to be required throughout development 
and adulthood to prevent backflow of lymphatic fluid into the venous system. However, 
no explanation as to how a thrombus can prevent backflow while permitting flow through 
from the lymphatic system was provided (Hess et al., 2014). Alternatively, any of the vast 
array of bioactive molecules and growth factors released from platelet secretory granules 
upon their activation could influence LEC behaviour (Suzuki-Inoue, 2011). Finney et al 
(2012) observed an inhibition in LEC migration when crosslinking podoplanin, which 
may result from a direct effect, the effect of a secretory molecule, or from podoplanin 
signalling within the LEC, whereby the CLEC-2 interaction is suggested to induce 
receptor clustering to sustain or enhance signalling events (Finney et al., 2012). 
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1.5  Podoplanin and CLEC-2 in the development of cerebral 
haemorrhages  
 
In addition to the blood-filled lymphatic phenotype, mice deficient in CLEC-2 or SYK are 
reported to develop haemorrhages within the CNS. In CLEC-2-deficient embryos, 
multiple haemorrhages were first reported in the midbrain parenchyma from E12.0 (Tang 
et al., 2010).  Similar findings were reported by Finney et al (2012) at E12.5, although 
haemorrhages appeared more severe (Finney et al., 2012). In the initial paper describing a 
SYK-deficient mouse, brain haemorrhages were visible in embryos at E14.0, yet they 
were not reported in the text (Cheng et al., 1995). Later, characterisation of these embryos 
by our group showed that these haemorrhages were consistently present from E12.0, but 
appeared less severe than in CLEC-2-deficient embryos. Furthermore, haemorrhages were 
also observed in megakaryocyte/platelet specific CLEC-2- and SYK-deficient mice, 
although they were less severe (Finney et al., 2012). Haemorrhages in the CNS have 
never been reported in podoplanin-deficient mice, yet the loss of T-synthase caused severe 
haemorrhaging through the brain parenchyma, ventricles and spinal column between 
E12.0-E14.0, with mice perishing by E14.0 (Xia et al., 2004). These haemorrhages were 
not observed in endothelial specific T-synthase deficient mice, suggesting the 
involvement of podoplanin, or another substrate, on a different cell type (Fu et al., 2008).  
 
1.5.1 Podoplanin expression in the CNS through development 
The expression of podoplanin on the choroid plexus at E16.5 is well documented (M. C. 
Williams et al., 1996; Kaji et al., 2012), albeit its function on this structure, which forms 
the blood-cerebrospinal fluid (CSF) barrier, is not known. Williams et al (1996) detected 
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podoplanin mRNA in the neural tube at E13.5 and visualised podoplanin expression 
diffusely through the neural tube by immunohistochemistry, with increased expression on 
cells close to the ventricular lumen between E13.0-E15.0 (M. C. Williams et al., 1996). 
Podoplanin was later shown to be expressed throughout the neural tube at E10.5 by 
immunofluoresence, yet the specific cell type and function remains unknown (Schacht et 
al., 2003).  
1.6  Development of the mouse brain  
 
The development of the nervous system is a highly complex process, involving the 
simultaneous, highly regulated expression of thousands of genes. The spatio-temporal 
pattern of gene expression allows a multitude of different structures to develop alongside 
one another, culminating in the formation of a highly specialised, functional nervous 
system (Liscovitch & Chechik, 2013).  
 
1.6.1 Development of the neural tube and ventricular system  
In the early stages of embryogenesis, a double-layered structure is formed termed the 
‘primitive streak stage embryo’, consisting of an inner layer of ectoderm cells enclosing 
the pro-amniotic canal, surrounded by a mesoderm layer and outer endoderm layer. A 
critical ‘turning’ step is required to re-organise the layers such that the ectodermally-
derived neural plate becomes situated at the outer aspect of the embryo, while the 
endodermally derived gastro-intestinal tract becomes centrally located. The amniotic canal 
inverts to form the characteristic sac surrounding a now fetal-like embryo (Figure 1.3A), 
reviewed in (Kaufman, 1992). 
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The neural plate is an unpatterned, undifferentiated primordium that through the process 
of neuralation will go on to form the brain and spinal cord. At around E8.0, bilateral folds 
develop in the neural plate at its junction with the surrounding non-neural ectodermal 
layer that fuses to form the neural tube (Figure 1.3B) (Copp et al., 2003; Greene & Copp, 
2009). Between E8.5-9.0 neural folds overlaying the primitive fore-, mid- and hindbrain 
appose and subsequently fuse at either end to form vesicles, the walls of which form the 
prosencephalon, mesencephalon and rhombencephalon, respectively. Between E9.0-10.0, 
the primitive forebrain vesicle expands, culminating in the subdivision of the 
prosencephalon into the diencephalon and the telencaephalon (Figure 1.3C). Within the 
telencephalon, two telenphalic vesicles develop, encompassing the lateral ventricles 
connected to the third ventricle within the developing diencephalon by a canal named the 
intraventricular foramen. Within the mesencephalon, the cerebral aqueduct forms 
connecting the lateral and third ventricles to the developing fourth ventricle within the 
rhombencephalon. As development progresses, the telencephalon subdivides into the 
cerebral cortex, the caudate putamen and the palidium. Several thalmic structures develop 
within the diencephalon, including the thalamus and hypothalamus. The substantia nigra 
develops within the primitive midbrain (mesencephalon), and the pons, cerebellum and 
medulla oblongata are differentiated within the developing hindbrain (Figure 1.3D) 
(Kaufman, 1992; C. Watson et al., 2012).  
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Figure 1.3. Development of the CNS. (A) A simplified diagram to illustrate the 
beginning and end point of embryonic ‘turning’ visualised as vertical sections looking 
towards the caudal aspect of the embryo. 1, neural tube (ectoderm); 2, notochord; 3, 
prospective midgut endoderm; 4, yolk sac; 5, yolk sac cavity; 6, amniotic cavity; 7, 
endoderm layer. Reconstructed from (Kaufman, 1992). (B) Neural tube formation from 
the neural plate. Reconstructed from (Copp et al., 2003). As development progresses the 
primitive fore-, mid- and hindbrain regions are formed (C) which are further differentiated 
into their unique structured compartments (D). Reconstructed from (C. Watson et al., 
2012). 
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1.6.2 Neuro-epithelial cell fate  
Prior to the onset of neurogenesis, the neural tube consists of a single layer of neuro-
epithelial cells. This neuro-epithelium has characteristic epithelial properties in that it is 
highly polarised and pseudostratified. The term stem cell can only be loosely associated 
with neuro-epithelial cells because their ability to self-renew is often restricted to a limited 
time and they have an undefined uni- or multi-potency. 
Subsequent to the onset of neurogenesis, a multi-layered neuro-epithelium is formed with 
a dense progenitor cell layer forming adjacent to the apical ventricular wall, termed the 
ventricular zone. This region is abundant in neuro-epithelial-derived radial glial cells 
(Figure 1.4). Characteristically, radial glial cells maintain some neuro-epithelial cell 
properties, such as their apical to basal polarity, the association of the zonula occludin 
protein 1 (ZO-1) with apical adherens junctions and the expression of the intermediate 
filament protein, nestin. Conversely, radial glial cells adopt some astroglial properties, 
expressing the glial fibrillary acidic protein, GFAP. Radial glial cells differ from neuro-
epithelial cells in that their progeny are fate-restricted to form neurons or glial cells, such 
as astrocytes, oligodendrocytes or ependymal cells (Figure 1.4). Astrocytes have a 
multitude of functions in the brain, providing structural support at the blood-brain barrier 
and assisting in synaptic transmission through their close association with the surrounding 
neurons. Oligodendrocytes form the basis of the myelin sheath, an electrical insulation 
layer surrounding the axons of the CNS. Ependymal cells line the ventricle walls and the 
choroid plexus, where their apical surface is abundant in cilia to promote the circulation of 
CSF (Figure 1.4). Between E10.0 and E12.0, most neuro-epithelial cells within the brain 
will become radial glial cells. In contrast, neuro-epithelial cells of the retina and spinal 
cord are less fate-restricted, since they retain some neuro-epithelial cell characteristics.  
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A second important progenitor of neuro-epithelial cells is the basal progenitor cell. 
Following cell division, basal progenitors migrate away from the ventricular zone to form 
a second germinal layer named the sub-ventricular zone, providing an important source of 
neurons. Reviewed in (Götz & Huttner, 2005; Farkas & Huttner, 2008). 
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Figure 1.4. Cell lineages within the CNS parenchyma. Microglia are the only 
haematopoietic cells found in the parenchyma of the CNS in the steady state. On entering 
neurogenesis, neuro-epithelial cells can differentiate into neurons or the more fate-
restricted progenitors, radial glial cells, which give rise to neurons, astrocytes, 
oligodendrocytes or ependymal cells. Reconstructed from (Ransohoff & Cardona, 2010). 
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Figure 1.4. Cell lineages within the CNS parenchyma. Microglia are are 
the only haematopoietic lls foun  in the parenchyma of the CNS in the 
steady state. On entering neurogenesis, neuro-epithelial cells can differentiate 
into neurons or more fate restricted progenitors, radial glial cells which give 
rise to neurons, astrocytes, oligodendrocytes or ependymal cells. 
Reconstructed from Ransohoff 2010. 
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1.6.3 Development of the cerebral vascular system 
The cardiovascular system is the first functional organ system to develop, with the first 
mesodermally derived ‘haemangioblasts’ emerging around E7.0. Haemangioblasts are 
said to be common precursor cells that migrate to the mesoderm where they differentiate 
to form haematopoietic stems cells or angioblasts (non-lumenised vascular endothelial cell 
precursors). During differentiation, blood islands are formed, consisting of an inner core 
of haematopoietic cells surrounded by clusters of endothelial cells. By E8.0, a primitive 
vascular network is formed by the coalescence of neighbouring blood islands to form the 
heart, dorsal aorta and the yolk sac plexus, which subsequently remodel to form a 
complex vascular tree (Marcelo et al., 2013; Anon, 1998; Kaufman, 1992). Meanwhile, 
some angioblasts can migrate to distant sites to commence the vasculogenesis of organs, 
such as the formation of the perineural vascular plexus (PNVP) that surrounds the neural 
tube and the spinal cord between E8.5-E9.5, where it provides essential nutrients and 
oxygen to developing neural tissue (Walls et al., 2008). 
 
The brain is distinct from most other organs in that the entire vascularisation of the neural 
tube subsequent to the formation of the PNVP is derived through angiogenesis. 
Angiogenesis is distinct from vasculogenesis in that new vessels are formed by sprouting, 
bridging and intussuscepted growth from existing vessels, which can all occur 
concurrently (Jain, 2003). In the brain, angiogenesis occurs predominantly through 
sprouting angiogenesis due to the absence of pre-existing angioblasts in the neural tissue 
itself (Risau, 1997). The first blood vessels invade the neural tube around E10.0, 
stimulated by a multitude of signalling pathways. VEGF is highly expressed in the 
ventricular zone where it is shown to provide an important signal to stimulate the 
migration of invading capillaries from the PNVP along the pre-formed lattice network of 
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neuro-epithelial cells (Breier & Risau, 1996; Walls et al., 2008). The Wnt-β-catenin 
pathway also plays an important role in CNS specific angiogenesis. Wnt ligands are 
released from the neuro-epithelium and bind to endothelial cells to influence the 
transcription of genes involved in angiogenesis through the stabilisation of the 
intracellular signal transducer, β-catenin. Inhibition of Wnt or β-catenin results in 
impaired invasion of endothelial cells into the neural tube from the PNVP, culminating in 
widespread cerebral haemorrhaging by E12.5 (Daneman et al., 2009; Stenman et al., 
2008). The role of Wnt-β-catenin signalling has also been shown to be important post-
natally in maintaining the integrity of tight junctions between cerebral endothelial cells 
(Liebner et al., 2008). 
 
1.6.4 Development of the blood-brain barrier (BBB) 
The formation of the blood-brain barrier (BBB) is a complex multi-step pathway, whereby 
nascent angiogenic vessels are transformed into a structurally supported and functional 
vascular network. As nascent angiogenic vessels form they are characteristically ‘leaky’, 
since their formation relies on the degradation of the existing ECM by matrix 
metalloproteases in order to free endothelial cells so that they can migrate and proliferate 
to form new lumenised vessel tubes (Winkler et al., 2011). Their transformation into a 
functional vascular network requires the recruitment of a wide range of ECM proteins 
forming a basement membrane coat over the albuminal vessel wall. Among the ECM 
proteins are integrins that mediate the adhesion, migration and the organisation of cells to 
the vessel wall (Proctor et al., 2005). Among these cells are mural cells which include 
vascular smooth muscle cells and pericytes, both of which are perivascular cells of 
mesenchymal origin and to date cannot be definitively distinguished from one another but 
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are instead identified on the basis of their location and protein expression. In general, 
vascular smooth muscle cells predominantly line the larger arteries and veins, while 
pericytes function to support smaller arterioles, capillaries and venules. Pericytes overlay 
endothelial cell junctions and their processes intimately associate with the underlying 
basement membrane, providing structural support. The density of pericytes is highest in 
the cerebral vasculature highlighting their critical role in supporting vascular integrity, 
reviewed in (Armulik et al., 2010). The ensheathed vessel is then coated in astrocytes, 
neurons and microglia to form what is referred to as the neurovascular unit (NVU). The 
NVU is a tightly regulated interface between the CNS and the circulation that forms the 
basis of a functional BBB. The NVU critically enables efficient nutrient and oxygen 
exchange through the CNS to establish proper brain function (Hawkins & Davis, 2005). A 
number of key molecules and signalling pathways which regulate the recruitment, 
association and proliferation of mural cells to the developing cerebral vasculature will be 
discussed, since their disruption often leads to extensive haemorrhaging and embryonic 
lethality. 
 
1.6.4.1 Integrins 
To date, only integrins containing subunits β8 or α5 have been shown to be specifically 
involved in cerebral vascular development, where their loss results in severe haemorrhage 
and neonatal death. No gross abnormalities in brain development or in the initial 
angiogenic endothelial cell proliferation, migration and sprouting were observed. Instead, 
cerebral haemorrhage results from the severe distension and aberrant patterning of vessels 
resulting in their ‘leakiness’ (McCarty et al., 2002; Bader et al., 1998; Zhu et al., 2002). 
Furthermore, deletion of integrin β8 specifically from the neuro-epithelium (driven by the 
Nestin-Cre8 promoter) results in altered capillary morphology and cerebral haemorrhage, 
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proposed to result from aberrant connections between capillaries and the surrounding 
neuro-epithelial cells and glial cells (Proctor et al., 2005). Integrin α5β8 is also expressed 
on astrocytic processes where it activates transforming growth factor β (TGFβ) which acts 
on endothelial cells to influence the transcription of anti-angiogenic factors (Cambier et 
al., 2005).  
 
1.6.4.2 Tyrosine kinase pathways  
The receptor tyrosine kinase family are fundamental to the formation of a secure cerebral 
vascular network. Of specific relevance are the VEGF-VEGFR-1 and -2 axis and the 
angiopoietin (Ang)-Tie receptor axes. Mice deficient in Tie2, which is expressed 
throughout the developing vasculature, die at E9.5 resulting from impaired survival and 
maturation of angiogenic endothelial cells (Dumont et al., 1994; Sato et al., 1995). The 
lethality is prior to the development of the cerebral vasculature, however, the loss of Tie1, 
for which the expression is later, results in widespread cerebral haemorrhage by E13.0, 
thought to result from the defective integrity of the angiogenic derived microvasculature 
(Puri et al., 1995; Partanen et al., 1996). Such defects are subsequent to those seen in mice 
deficient in VEGFR-1 and VEGFR-2, where defects arise during early vasculogenesis 
resulting in lethality between E8.5-9.5 (Ferrara et al., 1996).  
 
1.6.4.3 Platelet derived growth factor β (PDGFβ) 
The platelet derived growth factor β (PDGFβ)-PDGFβ receptor (PDGFRβ) axis is 
involved in the recruitment, proliferation and longitudinal spreading of mural cells across 
vessels. Pericytes express PDGFRβ allowing them to migrate towards endothelial cells 
that actively secrete PDGFβ. PDGFRβ-/- mice fail to recruit pericytes to nascent blood 
vessels, leading to endothelial hyperplasia and aberrant morphology and architecture of 
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the microvasculature, culminating in embryonic lethality. Importantly, the density, length 
and branching of vessels was unchanged, showing that the PDGFβ-PDGFRβ axis 
functions after the formation of a primitive vascular network (Hellström et al., 2001). 
 
1.6.4.4 Sphingosine-1-Phosphate (S1-P) 
Sphingosine-1phosphate (S1-P) is a blood borne bioactive lipid stored at a high 
concentration in platelets and secreted upon platelet activation. Sphingosine is generated 
from ceramide and further phosphorylated by sphingosine kinases (SPK) 1 and 2. S1-P 
binds to a family of G protein-coupled receptors, the endothelial differentiation gene 
(Edg) family, referred to as S1-P receptors (S1PRs). S1PRs 1-3 are widely expressed, 
including on embryonic endothelial cells and have roles in directing growth, survival, 
migration and morphogenesis. S1PRs 4 and 5 have a more restrictive expression pattern, 
on lymphoid tissue or lung and in the CNS, respectively, reviewed in (Gaengel et al., 
2009). Deletion of S1PR1 results in extensive haemorrhaging and embryonic lethality 
between E12.5 and E14.5, thought to be due to the defective recruitment of mural cells to 
developing vessels (Liu et al., 2000). This defect was later shown to specifically involve 
S1PR1 expression on endothelial cells (Allende et al., 2003). Furthermore, whereas the 
loss of S1PR2 and S1PR3 alone exhibit no phenotypic abnormalities, the loss of S1PRs1-3 
exacerbate the phenotype, highlighting their co-operative functions in stabilising the 
developing vasculature (Kono et al., 2014). Interestingly, the loss of SPKs 1 and 2 was 
shown to eliminate circulating S1-P levels and caused severe defects in neurogenesis and 
in cerebral angiogenesis, as shown by delayed neural tube closure and haemorrhaging in 
the brain and spinal cord at E11.5. The cerebral phenotype is more severe than that seen in 
S1PR1 -deficient mice, suggesting the involvement of additional S1PRs (Mizugishi et al., 
2005). However, the distribution and function of S1PRs in the brain is largely 
 32 
uncharacterised, with the majority of work based on in vitro studies that demonstrate 
multiple functions for S1PRs, including in the growth and survival of oligodendorocytes 
and in the activity of hippocampal neurons, reviewed in (Bryan et al., 2008). 
Consequently, a mechanistic role for S1-P in neurogenesis has not yet been investigated. 
 
1.6.5 Connections between the nervous and blood vascular system 
It has long been recognised that the vascular and nervous systems are intricately 
connected, both through observations of their perfect overlay and the functional 
requirement for the vascular system to provide oxygen and nutrients, while the nervous 
system controls vascular tone and blood flow, reviewed in (Tam & Watts, 2010; Chauvet 
et al., 2013). From a developmental aspect, the patterning of nerves is driven by a unique 
axon ‘growth cone’ that forms at the leading edge of migrating neurons. The axon ‘growth 
cone’ has a distinct morphology that has been shown to be remarkably similar to 
structures identified on the terminal end of migrating blood vessels, ‘tip cells’. Both are 
rich in lamellipodia and filopodia and respond to an array of environmental factors to 
guide their growth (de Castro et al., 2007; Gerhardt et al., 2003). While the role of 
VEGFs/VEGFRs are critical in guiding developing capillaries (Ruhrberg et al., 2002), 
endothelial tip cells also respond to a range of neural guidance signals, including the 
Slit/Robo, semaphorin/plexin/neuropilin, Netrin/Unc5/DCC and Ephrin/Eph signalling 
axes, reviewed in (Chauvet et al., 2013; Tam & Watts, 2010). Briefly, neuropilin-1 (Nrp-
1) is an axon guidance molecule expressed on neurons and endothelial cells where it can 
act as a co-receptor for VEGFR2. In Nrp-1 deficient mice, while blood vessels can extend 
into the neural tube from the PNVP to the sub-ventricular zone (albeit this is delayed from 
E9.0 to E10.0), they experience defects in tip cell guidance and sprouting resulting in 
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aberrant vessel patterning and lethality by E13.0 (Kawasaki et al., 1999; Gerhardt et al., 
2004; Fantin et al., 2013).  
1.6.6 Maintenance of the blood-brain barrier 
Once formed, the BBB constitutes a unique interface between the circulation and the 
CNS. Its key function is to control leukocyte trafficking and the passage of molecules and 
ions across the endothelium. Although the BBB exists at all levels of the CNS vascular 
tree, environmental factors influence vessel function, for example, capillaries adjacent to 
neurons become specialised in nutrient transport, while post-capillary venules protruding 
into perivascular spaces adapt to regulate leukocyte trafficking. Despite this, the 
fundamental principles of a functional BBB are conserved, where endothelial cells are 
sealed together by tight junctions (e.g. claudins, occludins and ZO-1), adherens junctions 
(e.g. VE-cadherin) and junctional adhesion molecules. This endothelial barrier is overlaid 
with the multiple cellular components that constitute the NVU. Many studies have shown 
that disrupting the intimate associations within the NVU leads to BBB permeability and is 
associated with a range of neurological disorders, including ischemic stroke, multiple 
sclerosis (MS), Alzheimer’s disease, HIV-induced dementia, epilepsy and intra-
ventricular haemorrhage in premature infants. In many cases, it is unknown as to whether 
the onset of neurological damage instigates vascular permeability, or vice versa. In 
general, endothelial damage is associated with cytokine release, a loss of tight junctional 
molecules and an increase in leukocyte migration into the CNS. For this reason, BBB 
permeability is rarely associated with the resolution of disease and more often its 
progression, reviewed in (Obermeier et al., 2013; Engelhardt & Sorokin, 2009; Hawkins 
& Davis, 2005; Ballabh et al., 2004). Therapeutic targets are focused on restoring BBB 
permeability with an aim to resolve neurological symptoms. Platelets have become a key 
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candidate in this area and will be discussed in more detail in Chapter 5.  
 
1.7  CLEC-2 and podoplanin in inflammation 
 
Beyond their roles in development, podoplanin and CLEC-2 have been implicated in a 
range of inflammatory processes. To better understand the nature of their roles, first, some 
key principles will be summarised. 
1.7.1 Innate vs adaptive immunity 
The innate immune system forms the first line of defense against foreign pathogens. This 
is non-specific targeting that is mediated mostly by phagocytic macrophages that engulf 
bacteria and microorganisms that have penetrated epithelial barriers. Tissue resident 
inflammatory cells such as DCs release inflammatory mediators such as cytokines, which 
stimulate the recruitment of neutrophils and monocytes (see Figure 1.1 for haematopoietic 
cell tree). The build up of immune cells and inflammatory mediators that function to clear 
foreign pathogens is the hallmark of ‘inflammation’. Key players in this initial line of 
defense become critical to prime the adaptive arm of the immune response, which is an 
antigen-specific system that functions to allow the host to discriminate between self and 
non-self. This system relies on antigen presenting cells (APCs) that can be in the form of 
B-lymphocytes in the blood system, DCs in the lymphatic system or tissue resident 
stromal cells and DCs. The key characteristics of APCs are their ability to present foreign 
antigens on major histocompatibility complex (MHC) proteins and to express co-
stimulatory molecules to activate T-lymphocytes. DCs are derived from the bone marrow 
and are released as immature cells that survey the local environment until they interact 
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with an antigen, at which point they are activated to become an APC. Once activated, 
APCs migrate to secondary lymphoid organs to initiate the adaptive immune response, 
reviewed in (Janeway, 2001; Alberts, 2008). 
1.7.2 Secondary lymphoid organs 
Secondary lymphoid organs include the spleen, lymph nodes, tonsils and Peyers patches. 
Each secondary lymphoid organ is uniquely designed to provide an optimal environment 
for B- and T-lymphocytes to survey circulating antigens. These secondary lymphoid 
organs are critically connected by the blood and lymphatic vasculatures (Turley et al., 
2010). Lymphatic vessels start as blind ended capillaries, drawing in fluid and DCs from 
the interstitial fluid in surrounding tissues. These initial lymphatic vessels drain into 
collecting vessels that converge at multiple points at lymph nodes (Figure 1.5) (Randolph 
et al., 2005). Lymph enters the lymph node in ‘afferent’ lymphatic vessels that carry DCs 
and flow them through the sinuses, bringing them into contact with naïve lymphocytes, 
which are imported from the blood system. The interaction between DCs and naïve 
lymphocytes is facilitated by the fibroblastic reticular cell (FRC) network in the T-
lymphocyte rich paracortex, which serves as a highway for migrating cells. The FRC 
network is lined with macrophages, which mop up bacteria and debris, while also 
functioning as APCs alongside the FRCs themselves and circulating DCs. Lymphocytes 
enter the FRC network through high endothelial venules (HEVs), the permeability of 
which are heavily influenced by inflammatory mediators. T-lymphocytes then survey 
APC niches before either leaving through the efferent lymphatics to continue their search 
for antigen in other secondary lymphoid organs, or, they become activated, stimulating 
their proliferation. Dispersed around the paracortex are follicles, rich in B-lymphocytes 
and tissue resident follicular DCs that present antigen to B-lymphocytes. Upon antigen 
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recognition, B-lymphocytes proliferate to form germinal centres and can additionally be 
induced to transform into antibody secreting plasma cells in response to secondary 
stimulation by helper T-lymphocytes, reviewed in (Willard-Mack, 2006; Turley et al., 
2010).  
 
Like the lymph nodes, the spleen is uniquely compartmentalised to maximise interactions 
between APCs and circulating lymphocytes, however, there are a few key differences in 
its structure. B- and T-lymphocytes do not enter through HEVs but instead, they enter 
through the afferent artery. Specific chemokines direct the migration of B- and T-
lymphocytes through a meshwork of APCs within the marginal zone, towards the B-cell 
follicles or the T-cell zone, respectively. DCs can migrate towards the T-cell zone and 
activate T-lymphocytes, which, in turn, hover at the periphery of B-cell follicles to 
activate B-lymphocytes. Activated B-lymphocytes can proliferate within follicles or 
migrate out to be further induced to form plasma cells by DCs or T-lymphocytes. 
Interestingly, S1-P receptors have been implicated in both the organisation of the marginal 
zone and the migratory capacity of B- and T-lymphocytes, reviewed in (Mebius & Kraal, 
2005).  
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Figure 1.5. Lymphatic vascular networks connect secondary lymphoid organs to 
mediate effective immune regulation. (A) The lymphatic system consists of a vast 
network of lymph nodes connected by lymphatic vessels. A key function of the lymphatic 
vasculature is to circulate immune cells between secondary lymphoid organs, such as the 
lymph nodes, spleen and peyers patches. Immune cells are initially generated in primary 
lymphoid tissues such as the bone marrow. T-lymphocyte precursors subsequently 
migrate to the thymus to mature. Figure reconstructed from (Janeway, 2001). (B) Immune 
cells in the lymph enter lymph nodes through afferent lymphatic vessels and percolate 
through the parenchymal tissue, which is lined with phagocytic macrophages, before 
being directed towards the T-cell rich paracortex or B-cell follicles. Lymphocytes enter 
the T-cell zone through high endothelial venules (HEVs) that are positioned within the 
fibroblastic reticular cell (FRC) network, in close proximity to dendritic cells (DCs). 
Immune cells leave the lymph through the efferent lymphatic vessels to continue their 
search, or prime other immune cells in other secondary lymphoid organs. Blood vessels 
carry antigens, antibodies and patrolling lymphocytes and antigen presenting cells (APCs) 
in and out of secondary lymphoid organs to survey the immune system. Figure 
reconstructed from (Turley et al., 2010). (C) The spleens major function is to filter blood, 
which flows through the cords of the ‘red pulp’ before filtering into the venous sinuses 
through a unique fibrous membrane. Aged erythrocytes are then phagocytosed by red pulp 
macrophages. Immune modulation occurs in the ‘white pulp’, where B- and T-
lymphocytes enter the marginal zone from the afferent blood system and are screened by a 
network of APCs, before being directed towards the follicles or T-cell zone, respectively. 
Figure reconstructed from (Mebius & Kraal, 2005). 
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1.7.3 Podoplanin in inflammation 
Podoplanin was identified on FRCs within the splenic white pulp and the medullary and 
paracortical areas of the lymph node over two decades ago (Farr et al., 1992), yet the 
significance of its expression within secondary lymphoid organs was, until recently, 
largely unexplored. Podoplanin is now used as a common marker for FRCs, where it is 
critical for the correct separation of B- and T-lymphocyte compartments in the spleen 
(Bekiaris et al., 2007). Podoplanin was further shown to be highly expressed on human 
follicular DCs, yet its function on these cells is unknown (Yu et al., 2007). More recently 
podoplanin expression on lymphatic endothelium and on FRCs was shown to be 
specifically required to mediate the entry and trafficking of CLEC-2 expressing DCs to 
the lymph nodes in mice (Acton et al., 2012). In an independent study, podoplanin 
expressing FRCs were shown to interact with CLEC-2 on platelets, inducing the release of 
a number of mediators, including S1-P, that were shown to be critical in maintaining the 
integrity HEV’s. In this model, platelets were delivered to FRCs on the back of migrating 
lymphocytes (Herzog et al., 2013). In contrast to these positive regulatory roles, 
podoplanin expression has been shown to be specifically induced in the inflamed 
synovium of patients with rheumatoid arthritis, while absent from healthy controls (Del 
Rey et al., 2014). Additionally, podoplanin has been shown to be expressed on TH17 cells 
which, when transferred into mice, can simulate the pathogenesis of MS, known in mice 
as experimental autoimmune encephalomyelitis (EAE). Blocking podoplanin significantly 
reduced the number of lymphoid aggregates forming adjacent to inflamed blood vessels in 
the EAE model, suggesting an important regulatory role for podoplanin in T-lymphocyte 
physiology during inflammation (A. Peters et al., 2011). Podoplanin has also been shown 
to be expressed on F4/80+ phagocytic macrophages in the splenic red pulp and in the 
inflamed peritoneum, where they are proposed to aid the resolution of inflammation (Hou 
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et al., 2010). These F4/80+ macrophages were further shown to induce CLEC-2-mediated 
platelet aggregation, proposed to enhance the recruitment of inflammatory cells (Kerrigan 
et al., 2012). Together these findings indicate that podoplanin has many immunological 
roles varying from day to day-immune homeostasis, to either the onset, or resolution of 
inflammation, depending on the tissue and cell types involved. Whether the podoplanin-
CLEC-2 axis is immunologically beneficial or detrimental to the host remains 
controversial, which is reflected in the growing wealth of literature debating their roles in 
tumour progression and metastasis, reviewed in (Lowe et al., 2012; Gay & Felding-
Habermann, 2011). Given the recent acceleration in this field, the mechanisms behind 
these processes are likely to be unraveled in the near future. Although CLEC-2 expression 
is much more restricted, within the haematopoietic compartment, the specific CLEC-2-
expressing cell subsets involved in these immune processes is equally as controversial and 
will be discussed in detail in Chapter 5.  
 
1.7.4 Immune surveillance in the CNS 
While secondary lymphoid organs are specifically designed to enhance immune cell 
interactions, the CNS functions to limit these interactions and is often considered 
‘immune privileged’. However, this is only partial and regulated transfer of immune cells 
between the circulation and parenchymal tissue is fundamental for CNS immune 
homeostasis. The most abundant immune cells in the CNS are macrophages, with 
microglial constituting 5-12% of all the cells within the CNS (D’Agostino et al., 2012). 
Microglia are yolk sac derived macrophages, typically high in Cd11b and F4/80, which 
infiltrate the neuro-epithelium as early as E8.0 (Figure 1.6) (Perry & Teeling, 2013). The 
mechanism that regulates the renewal of microglia is highly controversial, but it is thought 
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that the vast majority of microglia self-renew, with only minimal replenishment from 
infiltrating bone marrow-derived monocytes, in the steady state. Microglia are highly 
plastic molecules with long projections that function to sense and respond to their 
environment, stimulating shape change and cytokine secretion, which enable them to 
prime neighbouring microglia. A key function of microglia is their capacity to mop up 
cellular debris, the importance of which is echoed in Alzheimer’s patients, where the 
defective clearance of amyloid β peptide results from impaired microglial activity (Prinz 
et al., 2011). In addition to microglia, distinct macrophage subsets also occupy 
perivascular spaces, the meninges, as well as the choroid plexus and other 
circumventricular organs. These macrophages are generally derived from blood 
monocytes and have a much more rapid turnover than microglia, where as few as 1% of 
cells turn over in 90 days (K. Williams et al., 2001). In the steady state, non-microglial 
macrophages are excluded from the CNS parenchyma, yet they hover at the parenchymal 
borders providing key signals to parenchymal cells (Figure 1.6). The exclusion of immune 
cells from the CNS parenchyma is determined by a unique set of barriers that function 
within the CNS. Foremost is the BBB, which in the steady state is largely impenetrable to 
immune cells, but is critical for immune surveillance by allowing circulating T- and B-
lymphocytes, as well as free antigens, to communicate systemic messages across the 
endothelium to the underlying microglial cells and vice versa (Figure 1.6) (Schwartz et 
al., 2013). Within the CNS, several distinct structures, termed circumventricular organs, 
lack a BBB. The choroid plexus is the main circumventricular organ, located throughout 
the four interconnecting ventricles of the brain, where it forms the blood-CSF interface. 
The choroid plexus is formed from an epithelial membrane which encloses a highly 
vascularised core of connective tissue, consisting fibroblasts, macrophages, DCs and a 
rich supply of fenestrated capillaries (Figure 1.6). Fenestrated capillaries lack endothelial 
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tight junctions, thereby facilitating the interaction between circulating cytokines and 
inflammatory mediators with resident macrophages and DCs (Wolburg & Paulus, 2010). 
However, the passage of molecules into the CNS parenchyma at the circumventricular 
organs is selectively regulated, depending on the requirements of the CNS. A unique 
population of CD4+ T-lymphocytes, specific for CNS antigens, reside in the choroid 
plexus and regulate trafficking by controlling local cytokine levels (Schwartz et al., 2013). 
This equilibrium can become disturbed during ageing, or in certain neurological disorders, 
resulting in the inappropriate influx of lymphocytes, e.g. in MS or its animal model, EAE. 
The specific subsets of lymphocytes and other inflammatory cells that occupy different 
niches of the CNS is still a developing field. The underlying dogma is the balance 
between regulated infiltration of immune cells to clear infection, as apposed to 
inappropriate uncontrolled entry (Ransohoff & Brown, 2012). In the context of 
neurodegenerative diseases, the lab of Hugh Perry have recently communicated the 
principle of ‘microglial priming’, whereby microglia become primed by an on-going 
pathology, appearing activated, but exhibiting a ‘anti-inflammatory’ phenotype with 
decreasing functional responses. A second systemic stimulus can re-activate microglia, 
but overtime may exacerbate this response and severely advance disease severity (Perry et 
al., 2007). 
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Figure 1.6. Immune barriers in the adult brain. Unique cellular environments exist 
within the brain to regulate immune homeostasis. Under pathological conditions these 
barriers can become increasingly permeable. The meninges is abundant in monocyte- 
derived macrophages and dendritic cells (DCs) that continually enter perivascular 
compartments to communicate with circulating leukocytes and antigens in parenchymal 
vessels. Parenchymal vessels are characteristically impermeable due to the tight interplay 
between adjacent endothelial cells (EC) and the surrounding glia and neurons that 
constitute the blood-brain barrier. Perivascular macrophages (PVMs) and microglia 
resident in the apical compartments communicate environmental signals to circulating 
immune cells across the endothelium and vice versa to influence blood-brain barrier 
permeability. The choroid plexus is the hub of CNS immune surveillance with a highly 
vascularised stroma formed of permeable fenestrated capillaries allowing continued 
crosstalk between circulating and resident immune cells. Despite the inherent permeability 
within the stroma, the trafficking of molecules across the epithelium and into the CSF is 
highly regulated. Reconstructed from (D’Agostino et al., 2012; Hawkins & Davis, 2005; 
Emerich et al., 2005). 
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1.8  Aims  
The role of podoplanin and its receptor CLEC-2 in the separation of the blood and 
lymphatic vasculatures during development has now been well characterised. However, 
their role in the development of the cerebral vasculature, which forms independently of a 
lymphatic system, remains largely unexplored. Furthermore, the expression of podoplanin 
in the adult brain has only recently been investigated, and its function in this tissue 
remains unknown. Therefore, the aim of the work undertaken in this thesis was; 
 
1. To investigate a role for podoplanin and CLEC-2 in the development of the brain 
vasculature. 
2. To explore a role for podoplanin and CLEC-2 in the adult brain in the steady state 
and in response to inflammatory challenge. 
3. To characterise a range of CLEC-2- and podoplanin-deficient mouse models to 
investigate points 1 and 2. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1  Materials 
2.1.1 Antibodies and reagents 
The antibodies used during the course of this thesis are listed in Table 2.1. If unstated, 
materials used are from Sigma (Poole, UK). 
 
Table 2.1 Antibodies 
Antibody Host species Dilution Source  
PRIMARY     
Podoplanin   Hamster IF – 1/600* 
IHC – 1/400* 
WM-IF – 1/200 
EBioscience (Hatfield, UK) 
PECAM-1 Rat WM-IF – 1/200 
IF – 1/200* 
Dr S Butz (Max Planck 
Institute for Molecular 
Biomedicine, Germany) 
Endomucin Rat IF – 1/200** Santa Cruz Biotechnology 
(Heidelberg, Germany) 
Pre-albumin Sheep IF – 1/200** Abcam (Cambridge, UK) 
F480 Rat IF – 1/100** AbD Serotech (Kidlington, 
UK) 
CD11b Rat IF – 1/100** AbD Serotech (Kidlington, 
UK) 
CD41 Rat IF – 1/100** BD Pharmingen™ (Oxford, 
UK) 
NG2 
 
Rabbit IF – 1/200** Millipore (Co Durham, UK) 
F(ab)2-IgG-H&L Goat IF – 1/50** Thermo Scientific 
(Loughborough, UK) 
Nestin Rat IF – 1/50** Developmental studies 
hybridoma bank (Iowa, US) 
TER-119 Rat IF – 1/200** Cambridge Bioscience 
(Cambridge, UK) 
ZO-1 
 
Rabbit IF – 1/200** Invitrogen (Paisley, UK) 
CD41-FITC Rat FC – 1/100 BD Bioscience (Oxford, 
UK) 
CD41-PE 
 
Rat FC - 1/800 EBioscience (Hatfield, UK) 
CLEC-2 (17D9) 
(AlexaFluor®488 
conjugated – see text) 
Rat 
 
 
FC – 1/100 
 
 
Reis e Sousa (Cancer 
Research UK, London, UK)  
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INU1-FITC 
 
 
INU1 
(AlexaFluor®488 
conjugated – see text) 
 
Rat 
 
 
Rat 
FC - 1/10 
 
 
FC – 1/100 
Bernhard Nieswandt 
(University Hospital 
Würzberg, Germany) 
Bernhard Nieswandt 
(University Hospital 
Würzberg, Germany) 
 
Gr1-APC 
 
Rat FC – 1/3000 EBioscience (Hatfield, UK) 
CD11b-PerCP-Cy5.5 
 
Rat FC – 1/1000 EBioscience (Hatfield, UK) 
CD3e-Cy7 
 
Rat FC – 1/200 EBioscience (Hatfield, UK) 
CD19-APC-Cy7 
 
CD45.2-eF780 
 
CD19-APC 
 
Streptavidin-PE 
Rat 
 
Rat 
 
Rat 
 
Rat 
FC – 1/100 
 
FC – 1/200 
 
FC – 1/100 
 
FC – 1/100 
BD Pharmingen™ (Oxford, 
UK) 
EBioscience (Hatfield, UK) 
 
BD Pharmingen™ (Oxford, 
UK) 
EBioscience (Hatfield, UK) 
 
GPIbα 
 
 
  
Platelet 
depletion – 1.5 
µg/g 
 
Emfret (Eibelstadt, 
Germany) 
SECONDARY 
IgG-H&L-Cy3® 
(hamster) 
 
Goat IF – 1/500 Abcam (Cambridge, UK) 
AlexaFluor®488 (rat) 
 
Goat IF – 1/500 Invitrogen (Paisley, UK) 
AlexaFluor®488 
(hamster) 
 
Goat IF – 1/500 Invitrogen (Paisley, UK) 
AlexaFluor®647 (rat) 
 
Goat IF – 1/500 Invitrogen (Paisley, UK) 
IgG-FITC (rabbit) 
 
Donkey IF – 1/150 Dako Cytomation 
IgG-H&L-Biotin 
(hamster) 
 
Goat IHC – 1/100 
 
Vector laboratories 
(Peterborough, UK) 
*1 hour incubation time. ** Overnight incubation. WM, whole-mount;  
IF, immunofluorescence; IHC, immunohistochemistry; FC, flow cytometry 
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2.2  Mice 
All animal experimentation was performed under a license from the UK Home Office. 
Constitutive deletion of CLEC-2 (Clec-2-/-) and conditional deletion of CLEC-2 (Clec-
2fl/fl) on a C57BL/6 background have been previously described (Hughes et al., 2010; 
Finney et al., 2012). Clec-2fl/flPF4-Cre mice have been described previously (Finney et 
al., 2012) and Clec-2fl/flERT2-Cre mice were generated by breeding Clec-2fl/fl mice to mice 
expressing ERT2Cre recombinase driven by the ROSA26 locus obtained from Jackson 
Laboratories (B6.129-Gt(ROSA)26Sortm1(cre/ESR1)Tyj/J), backcrossed 8 times onto a 
C57BL/6 background. Mice with a conditional deletion of podoplanin (Pdpnfl/fl) were 
generated at Taconic Artemis and provided on a C57BL/6 background. Pdpnfl/fl mice were 
crossed to mice expressing PGK-Cre recombinase (Pdpnfl/flPGK-Cre), obtained from 
Cancer Research UK, Manchester, mediating constitutive deletion of podoplanin from the 
two-cell stage (Lallemand et al., 1998). Pdpnfl/fl mice were also crossed to mice expressing 
Cre recombinase driven by the nestin promoter (Nes-Cre), obtained from Cancer Research 
UK, London, to delete podoplanin in the neural tube (Petersen et al., 2002). αIIb-/- mice on 
a C57BL/6 background were provided by Professor John Frampton, University of 
Birmingham, UK (Emambokus & Frampton, 2003). Embryos from NBEAL-2-deficient 
mice (Nbeal-2-/-) on a C57BL/6 background were provided by Professor Bernhard 
Nieswandt, University of Wurzburg, Germany (Deppermann et al., 2013). Genotyping 
was performed by PCR using primers listed in Table 2.2, using genomic DNA isolated 
from ear/tail tissue. 
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Table 2.2  PCR Primers 
Primer Sequence 
Clec-2 wildtype forward primer GATGAGTCTGCTAGGGATGC 
Clec-2 knockout forward primer CAGAGGAAGAAAACTCAGAAGG 
Clec-2 common reverse primer AGCCTGGAGTAACAAGATGG 
Clec-2fl forward primer TTTCTGCCTCTCTGCCTTGC 
Clec-2fl reverse primer CGTCATGAACAGAAAACTGACG 
PF4-Cre forward primer  CCCATACAGCACACCTTTTG 
PF4-Cre reverse primer TGCACAGTCAGCAGGTT 
ERT2-Cre primer 1 CCT GAT CCT GGC AAT TTC 
ERT2-Cre primer 2 
ERT2-Cre primer 3 
AAA GTC GCT CTG AGT TGT TAT 
GGA GCG GGA GAA ATG GAT ATG 
Pdpnfl wildtype/floxed forward primer TATGTATGTCTACCCCAACTCCTG 
Pdpnfl wildtype/floxed reverse primer TAAGTACACTGTCGCTGTCTTCG 
Pdpnfl knockout forward primer AGATGTGATGATATGTGGTACTTGC 
Pdpnfl knockout reverse primer GTACACGGTTCTTAACGGTGG 
PGK-Cre common primer TCGTTGCATCGACCGGTAAT 
PGK-Cre forward primer GCGCAGGTCTCCTCTTCCTC 
PGK-Cre wildtype reverse primer GACCAATGAAACGTGGGCG 
αIIb forward primer CAGACTCCTGGCTCATCTAC 
αIIb reverse primer TCTGCCTAACTCTGCTTTCC 
αIIb Cre forward primer TCGATGCAACGAGTGATGAG 
αIIb Cre reverse primer 
Nes-Cre forward primer 
Nes-Cre reverse primer 
TTCGGCTATACGTAACAGGG 
GCCTGCATTACCGCTCGATGCAACGA 
GTGGCAGATGGCGCGGCAACACCATT 
 
2.2.1 Genomic DNA extraction 
Ear clippings from adult mice or embryonic tissue samples were digested in lysis buffer 
(100 mM Tris-hydrochloride; pH 8.5, 5 mM ethylenediamine tetra-acetic acid (EDTA), 
0.2% sodium dodecyl sulphate (SDS) and 200 mM sodium chloride (NaCl) with 
proteinase K (1.25 mg/ml per sample)) overnight at 56°C. Samples were centrifuged at 
16000 g for 5 min at 4°C and the supernatant extracted and added to isopropanol. Samples 
were centrifuged at 16000 g for 5 min at 4°C. Supernatants were removed and pellets 
were air dried before resuspending in ddH20 ready for PCR amplification using the 
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primers listed in Table 2.2. 
2.2.2 Tamoxifen-induced depletion of CLEC-2 
Clec-2fl/fl or Clec-2fl/flERT2-Cre mice were treated with tamoxifen by intraperitoneal 
injection (i.p.) or in the diet. For i.p. injections, 100 µl of tamoxifen (20 mg/ml in corn oil) 
was injected each day for 5 days (unless stated otherwise). Alternatively, mice were fed 
TAM400 diet (400 mg tamoxifen in citrate form per kg of diet (Harlan Laboratories, 
Indianapolis, IN)) for two weeks, or continuously. Mice on tamoxifen diet were weighed 
each day for 7-14 days and any mice that lost >20% of their starting total body weight 
were culled in line with the UK Home Office regulations. 
2.2.3 Generation of radiation chimeras 
Fetal livers were dissected from embryos obtained from Clec-2+/- crossed time matings, or 
from Pdpnfl/+PGK-Cre crossed time matings at E16.5. Genotyping of embryos was 
performed as described in Section 2.2.1. Fetal livers were processed individually in a 
sterile tissue culture hood. A single cell suspension was made by passaging fetal livers 
through a series of 19-, 6- and 2-gauge needles into phosphate buffered saline (PBS). 
Cells were washed twice in PBS, pellets resuspended in 800 µl of 90% fetal bovine serum 
(FBS)/10% dimethyl sulfoxide (DMSO) solution and immediately cooled to –80°C before 
storing in liquid nitrogen. On the day of reconstitution, fetal liver cells were thawed, 
washed twice in PBS and resuspended in 200 µl of PBS per mouse (4 injections are 
expected per fetal liver). Live cell counts were determined using 0.4% trypan blue 
solution. Counts of approximately 1x106 cells in each 200 µl injection volume were 
expected. 
 
Male C57BL/6 mice were provided from Harlan Laboratories at 6 weeks of age. Mice 
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were given one week to rest upon arrival, followed by one week on Baytril. Mice were 
irradiated twice with 500 rads, 3 hours apart, followed by an intravenous (i.v.) injection of 
fetal liver cells 1 hour later.  
2.2.4 Systemic inflammatory challenge 
Wild-type or Clec-2-/- chimeras, or tamoxifen-treated Clec-2fl/fl or Clec-2fl/flERT2-Cre mice 
were fed normal diet for 6 weeks before administration of lipopolysaccharide (LPS) 
(Escherichia coli serotype O11:B4) in sterile PBS, or PBS only, by i.p. injection (doses 
stated in results). Mice were terminally anaesthetised by i.p. injection of 150 mg/kg of 
Euthatal. Blood was drawn by cardiac puncture into 10% acid-citrate dextrose (ACD: 120 
mM sodium citrate, 110 mM glucose, 80 mM citric acid) and further diluted into 200 µl of 
20 mM EDTA. Mice were perfused through the atrium with 4% paraformaldehyde 
(PFA)/PBS followed by PBS only until the liver was clear of erythrocytes. Organs were 
harvested for analysis. For measuring evans blue absorbance, mice were administered 
evans blue dye (4 ml/kg at 2%) by i.p injection and sacrificed as described above. Brains 
were isolated, weighed and half of the brain was fixed in 4% PFA/PBS for histology. The 
other half of the brain was homogenised in a 1:3 volume of PBS by sonication. Any 
undigested material was pelleted at 16000 g for 30 min. An aliquot of supernatant was 
added to an equal volume of trichloroacetic acid (TCA) into a 96 well plate and left 
overnight at 4°C. Plates were centrifuged at 3000 g for 30 min and the absorbance of 
supernatants at 610 nm were read using a VersusMax Microplate reader (Molecular 
Devices, Berkshire, UK). Whole blood counts were taken from peripheral blood samples 
before being processed to obtain evans blue absorbance measurements. Whole blood was 
centrifuged at 6000 g for 5 min, plasma volumes were recorded and an aliquot of plasma 
was added to an equal volume of TCA and treated as detailed above. Absorbance 
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measurements from the brain supernatant or blood plasma were normalised to brain 
weights or plasma volumes, respectively, and the absorbance value from the brain 
supernatant was represented as a ratio to plasma absorbance.  For the thioglycolate 
challenge model, tamoxifen-treated Clec-2fl/fl or Clec-2fl/flERT2-Cre mice were left for 6 
weeks on normal diet before administration of 3% sodium thioglycolate in 1 ml sterile 
PBS, or PBS only, in combination with evans blue dye (4 ml/kg at 2%) by i.p. injection. 
Mice were sacrificed 4 hours later and evans blue absorbance in the brain and blood 
plasma were measured as previously described.  For the Salmonella infection model, 
tamoxifen-treated Clec-2fl/fl or Clec-2fl/flERT2-Cre mice were left for 6 weeks on normal 
diet before administration of 5x105 colony forming units (CFU) of attenuated Salmonella 
Typhimurium in sterile PBS, or PBS only, by i.p. injection. The bacteria were prepared by 
Jessica Hitchcock. Briefly, Salmonella Typhimurium were incubated overnight in Luria-
Bertani broth (Invitrogen, Paisley, UK) at 37°C with aeration (180 rpm). Bacteria were 
harvested at the mid-log phase (optical density (OD)λ600nm of 0.8-1.2). Bacterial 
cultures were centrifuged at 6000 g for 5 min at 4°C and washed twice in PBS with 
centrifugation before resuspending in 1 ml PBS. OD was measured and bacteria within the 
desired range were diluted to give 5x105 CFU in 200 µl sterile PBS. The infection dose 
was confirmed using the Miles and Misra CFU counting technique by plating serial 
dilutions of bacteria onto agar plates and incubating overnight at 37°C. 7 days post 
Salmonella infection, mice were administered 25 µg LPS in 200 µl sterile PBS, or PBS 
only, in combination with evans blue dye (4 ml/kg at 2%), by i.p. injection. Mice were 
sacrificed after 24 hours and evans blue absorbance in the brain and blood plasma was 
measured as previously described. 
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2.3   Microscopy 
2.3.1 Immunohistochemistry 
Time mated females (day of plug = E0.5), were culled by Schedule 1 methods. Embryos 
were photographed and whole embryos, or dissected embryo heads, were fixed overnight 
in Bouin’s fixative. Embryos were transferred to 70% ethanol before being processed for 
paraffin embedding and sectioning (Pathology Department, QE Hospital).  
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Method for sectioning through embryonic brains. Coronal sections were 
taken by sectioning from the rostral (anterior) side of the embryo to the caudal (posterior) 
side. In general, sections were collected from just past the eyes, at a point in which the 
lateral ventricles and a large area of brain parenchyma, choroid plexus and sub-arachnoid 
tissue can be visualised. 
 
 
Sections were immersed in xylene before successively rehydrating in 100%, 90%, 70%, 
50%, 30% ethanol and dH20. Slides for haematoxylin and eosin (H&E) staining only were 
placed in Harris’s haematoxylin solution for 3 min, rinsed in running tap water, dipped in 
0.3% acid alcohol, incubated for 5 min in Scotts tap water (25 mM sodium bicarbonate, 
0.1 M magnesium sulphate) and dipped in 1% eosin, before placing back into dH20 and 
Coronal	  
  
Ventricle 
Choroid	  plexus	  
Parenchyma	  
Sub-­‐arachnoid	  space	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successively dehydrating in 50%, 70%, 90%, 100% ethanol and then xylene overnight. 
Slides were mounted using VectaMount mounting media (Vector Laboratories, 
Peterborough, UK) ready for imaging.  
 
For podoplanin staining, following rehydration (Section 2.3.1), slides were boiled in 
citrate buffer (10 mM citric acid monohydrate; pH 6.0) for 15 min. For F(ab)2-HRP 
staining, slides were boiled in citrate buffer (1 mM EDTA, 0.1 % tween-20, pH 8.0) for 
50 min. All slides were cooled to room temperature and rinsed in PBS before 
permeabilising in 0.3% tween-20/PBS for 10 min. Sections were circled with an 
ImmEdge™ hydrophobic pen (Vector Laboratories, Peterborough, UK) and incubated in 
3% H202 for 10 min at room temperature. Slides were washed in PBS and blocked for one 
hour at room temperature in 3% BSA/PBS, 0.1% tween-20 (PBST), or 10% goat 
serum/PBST for podoplanin or F(ab)2-HRP staining, respectively. Primary antibody 
(diluted in 10% blocking solution/PBST) was incubated overnight at 4°C, followed by 
washing in PBST for 3 x 10 min (minimum). For podoplanin staining, slides were further 
incubated with secondary antibody (goat anti-hamster biotin) for 45 min at room 
temperature, followed by washes in PBST for 3 x 10 min (minimum). Slides were 
incubated with Avidin/Biotinylated enzyme complex from the VECTASTAIN® kit 
(Vector Laboratories, Peterborough, UK) for 30 min at room temperature, followed by 
washing for 3 x 10 min in PBST. Slides for both podoplanin and F(ab)2-HRP staining 
were processed with 3.3’-Diaminobenzidine (DAB) liquid substrate for 30 seconds 
(Vector Laboratories, Peterborough, UK). Slides were immediately placed into dH20 and 
stained with haematoxylin, dehydrated and mounted as described above. 
 
Analysis was performed using a Zeiss Axiovert Zoom brightfield microscope using either  
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5 X or 10 X air objectives, or 40 X or 63 X oil objectives. Images were processed using 
Adobe Photoshop 8.0. 
2.3.2 Immunofluorescence 
Embryos were photographed and whole embryos, or dissected embryo heads, were fixed 
overnight in 4% PFA/PBS. Embryos were incubated overnight in 20% sucrose, followed 
by 30% sucrose overnight, before embedding in optimum cutting temperature (O.C.T) 
media (Tissue-Tek®, Thermo Fisher Scientific, Loughborough, UK) and snap freezing in 
liquid nitrogen. Samples were stored at -80°C. Cryosections between 10-20 µm were cut 
using a Cryostat (Bright instruments, Huntington, UK) onto Shandon™ColorFrost™ Plus 
microscope slides (Thermo Fisher Scientific, Loughborough, UK). Slides were 
immediately placed on dry ice and then stored at -80°C. In preparation for immuno-
staining, slides were removed and left to dry at room temperature for 30 min, before 
fixing in ice cold acetone for 20 min at -20°C. Slides were left to dry for 30 min at room 
temperature before washing in PBS for 10 min. Sections were circled with an ImmEdge™ 
hydrophobic pen and incubated with ammonium chloride (20 mM) for 15 min at room 
temperature. Slides were washed in PBS and further permeabilised in 0.3% Tween-
20/PBS before blocking in 1% BSA, 5% goat serum/PBST for 1 hour at room 
temperature. Slides were incubated in primary antibody (diluted in 10% blocking 
solution/PBST) for 1 hour at room temperature (*Table 2.1), or overnight at 4°C (**Table 
2.1), followed by washing for 3 x 10 min (minimum) in PBST. Slides were incubated in 
secondary antibody (diluted in PBST) for 45 min at room temperature, followed by 3 x 10 
min washes in PBST. Where applicable, further primary and secondary antibody 
incubations were performed, depending on species reactivity combinations. Where 
applicable, slides were incubated in TO-PRO-3 Iodide (Invitrogen, Paisley, UK) (diluted 
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1:1000 in PBS) for 10 min at room temperature. Slides were washed in PBS before 
mounting using VectaMount mounting media. Slides were analysed by confocal 
microscopy using a Leica SP2 confocal microscope. Images were processed with Adobe 
Photoshop 8.0. 
 
2.3.3   Wholemount Immunofluorescence - ultramicroscopy 
Embryos were prepared for ultramicroscopy as described by Hägerling et al (Hägerling et 
al., 2013). Embryos at E10.5, E11.5 or E12.5 were fixed for 4, 6 or 8 hours, respectively, 
in 4% PFA/PBS at 4°C. Embryos were permeabilised (0.5 % triton-X-100/PBS) for 2 
days at 4°C and blocked in 1% BSA, 1% goat serum, 0.5% tween-20/PBS for 1 week at 
4°C. Embryos were incubated in primary antibodies (diluted in blocking solution) for 1 
week at 4°C, followed by washing in PBST for 2 days. Embryos were incubated with 
secondary antibodies (diluted in 10% blocking solution/PBS), followed by washes in 
PBST for 2 days. All solutions were previously filtered using a 0.22 µm filter. Embryos 
were embedded in 1% ultrapure, low melting point agarose. The agarose was warmed to 
45°C and a small amount was placed into a mould on ice for 2 minutes before fully 
immersing the embryo into the agarose. Once set, samples were transferred to glass vials 
and successively dehydrated in 50%, 70%, 95%, 100% methanol and again in 100% 
methanol (anhydrous) for 1 hour per step. Samples were optically cleared by incubating 
overnight in benzyl alcohol:benzyl benzoate solution (BABB) (1:2):methanol (50:50) and 
then overnight in BABB only, ready for ultramicroscopy. 
 
Optically cleared wholemount immunofluorescent samples were imaged on an LaVision 
Ultramicroscope (La Vision BioTec, Bielefeld). Stacks were captured at different 
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magnifications with a step size of 1 µm. 3D reconstruction, morphometric analysis and 
analysis of ultramicroscopy stacks were performed using IMARIS software (Version 
7.6.0, Bitplane). 
2.3.4 Wholemount immunofluorescence – hindbrain model 
Embryos at E12.5 were isolated and hindbrains were dissected out and labelled by 
immunofluorescence, following the protocol by Fantin et al (2013) (Fantin et al., 2013). 
Briefly, the whole embryo head was isolated using forceps and the rostral half of the head 
was removed. The hindbrain was dissected out and placed into PBS in a 96 well plate. 
Hindbrains were fixed in 4% PFA for 2 hours on ice, washed in PBS and blocked in 10% 
goat serum in PBST for 30 min at room temperature. Hindbrains were incubated in 
primary antibody (diluted in blocking solution) overnight at 4°C and washed 5 x 30 min in 
PBST. Hindbrains were incubated in secondary antibody (diluted in blocking solution) 
overnight at 4°C and washed for 5 x 30 min in PBST. Hindbrains were flat mounted onto 
glass slides using VectaMount, overlaid with a glass coverslip and stored at 4°C. Slides 
were imaged by confocal microscopy using a Leica SP2 confocal microscope. Image 
analysis was performed using IMARIS software (Version 7.6.0, Bitplane). 
 
2.3.5 Transmission electron microscopy (TEM) 
All sample preparation for transmission electron microscopy (TEM) was performed in a 
fume hood. Heads of whole embryos at E11.5 were removed and the noses cut off. 
Embryo heads were washed in PBS before fixing overnight in 2.5% glutaraldehyde in 0.1 
M sodium cacodylate buffer (pH 7.4) (Na Cacodylate) for 1 hour at 4°C. Samples were 
washed with Na Cacodylate buffer for 3 x 10 min prior to incubation in osmium tetroxide 
(1% working solution/Na Cacodylate buffer) (Agar Scientific, Stansted, UK) for 1 hour at 
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4°C (all subsequent steps were performed with rotation at room temperature). Samples 
were washed for 3 x 10 min in Na Cacodylate buffer, followed by washing in dH20, 
before successively dehydrating in 70%, 80%, 90%, 96% and 2 x 100% ethanol for 30 
minutes per step. Samples were immersed in 1:1 propylene oxide (Agar Scientific, 
Stansted, UK): epon resin overnight, before transferring into 100% epon resin overnight. 
Samples were transferred to a rubber mould, oriented, immersed in resin and placed in an 
oven at 60°C for 4 days before being removed and stored at room temperature. Samples 
were sectioned and stained at the Centre for Electron Microscopy (School of Metallurgy 
and Materials, University of Birmingham, UK). Ultrathin sections of 90-100 nm were cut 
using a microtome (Leica Reichert Ultracut S, Milton Keynes, UK) and stained with lead 
citrate (7.5 mM lead nitrate, 0.1 M sodium citrate and 1 M sodium hydroxide) and 30% 
uranyl acetate in methanol. Samples were imaged on a Jeol 2100 200kV LaB6 TEM. 
Images were processed using Adobe Photoshop 8.0. 
2.4 Flow cytometry 
2.4.1 CLEC-2 expression on platelets in whole blood 
Blood samples were taken either directly from the tail vein into 200 µl of 20 mM EDTA, 
or by terminal bleeding, whereby mice were terminally anaesthetised with isofluorane 
anaesthesia, a laparotomy was performed exposing the descending aorta and blood was 
drawn into 10% ACD. Blood was further diluted into 200 µl of 20 mM EDTA.  
 
17D9 CLEC-2 antibody was conjugated using an AlexaFluor®488 Monoclonal Antibody 
Labelling Kit (Invitrogen, Paisley, UK). 17D9 CLEC-2-488 antibody was diluted in PBS 
and added to whole blood for 20 min in the dark. Samples were analysed using a BD 
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FACSVerse™ (BD Bioscience, Oxford, UK) or BD FACSCalibur™ (BD Biosciences, 
Oxford, UK). Analysis was performed in FlowJo v10. 
 
2.4.2 CLEC-2 expression on platelets and leukocytes in whole blood 
Blood samples were taken as described in Section 2.4.1. Samples were centrifuged at 3000 
g for 4 min, supernatants were discarded and pellets were resuspended in Ammonium-
Chloride-Potassium (ACK) lysing buffer (0.15 M ammonium chloride (NH4Cl), 1 mM 
potassium bicarbonate (KHCO3, 0.1 mM disodium EDTA (Na2EDTA)) for 5 min at room 
temperature. Samples were centrifuged at 3000 g for 4 min and pellets were resuspended 
in flow cytometry (FC) buffer (2 % FBS, 2 mM EDTA in PBS) before further 
centrifugation at 3000 g for 4 min. Supernatants were discarded and sample pellets were 
resuspended in antibodies (Table 2.1) diluted in FC-buffer for 20 min on ice, in the dark.  
The unconjugated CLEC-2 antibody, INU1, was conjugated using an AlexaFluor®488 
Monoclonal Antibody Labelling Kit (Invitrogen, Paisley, UK). Samples were washed in 
FC-buffer and centrifuged at 3000 g for 4 min. Supernatants were discarded and pellets 
resuspended in FC-buffer before passing through a 50 µm filter (Partec Cell Trics® UK 
Limited, Kent, UK). Samples were centrifuged at 3000 g for 4 min and resuspended in 
FC-buffer only, or in 1 µg/ml Di-acetate (DAPI), diluted in FC-buffer. Samples were 
analysed using a CyANTM ADP analyzer (Beckman Coulter, High Wycombe, UK). 
Analysis was performed in FlowJo v10. 
2.4.3 DNA extraction from whole blood 
Blood samples were taken from the tail vein into 200 µL of 20 mM EDTA. Samples were 
incubated in ACK lysing buffer for 5 min at room temperature, followed by centrifugation 
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at 1400 rpm for 5 min. Supernatants were discarded and pellets were processed to isolate 
genomic DNA using the DNeasy® Blood and Tissue Kit (Qiagen, Manchester, UK). PCR 
amplification was performed using primers listed in Table 2.2. 
2.5 Platelet lifetime measurements 
2.5.1 Platelet half life  
Mice were injected intravenously with 150 µl of 4 mg/ml N-Hydroxysuccinimidobiotin 
(NHS-Biotin) in PBS buffer. At 0, 1, 2, 3, 4, 5 and 7 days post injection, whole blood was 
sampled from the tail vein into buffer containing 5 mM EDTA and 10% FBS in PBS 
(FC2-buffer). Whole blood counts were measured using an ABX Pentra 60 blood counter 
(BIVDA, London, UK). Samples were washed in FC2-buffer and centrifuged at 6000 g 
for 10 min. Supernatants were discarded and pellets were resuspended in CD41-FITC, 
Streptavidin-PE, or the equivalent IgG controls, diluted in FC2-buffer and kept on ice for 
30 minutes in the dark. Samples were washed in FC2-buffer, centrifuged at 6000 g for 10 
min and supernatants were discarded and pellets resuspended in FC2-buffer for analysis 
using a BD FACSCalibur™ (BD Biosciences, Oxford, UK). Analysis was performed in 
FlowJo v10. 
2.5.2 Platelet recovery 
Mice were injected intravenously with anti-GPIbα, diluted in sterile PBS. At 0, 1, 3, 5, 6, 
7 and 11 days post injection, whole blood was sampled from the tail vein into 20 mM 
EDTA. Platelet counts were measured using the whole blood counter. Expression of 
CLEC-2 on platelets in Clec-2fl/fl and Clec-2fl/flPF4-Cre mice was confirmed by flow 
cytometry (Section 2.4.1) 
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2.6  Cell culture 
The rat choroid plexus epithelial cell (CPEC) line, Z310, was kindly provided by Dr Wei 
Zheng (Purdue University, IN, USA). Cells were grown in DMEN media supplemented 
with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 10 ng/ml recombinant 
rat epidermal growth factor (EGF) (Peprotech, London, UK) at 37°C, 10% CO2. Cells 
were passaged using standard methods, including trypsin detachment and live cell 
counting using 0.4% trypan blue solution. 
2.6.1 Trans-epithelial electrical resistance measurements 
BD cell inserts with pore sizes of 0.45 µm (Scientific Laboratory Supplies, Yorkshire, 
UK) were placed in a 24 well plate and 700 µl of media (-EGF) was added to the bottom 
of the well. CPECs were seeded onto the insert at a density of 1x104 in 200 µl of media. 
Where applicable, washed wild-type mouse platelets (Section 2.6.3) were added to the 
media above the insert at a final concentration of 1x108/ml. Electrical resistance across 
CPEC monolayers was measured each day for 5 days using a Millicell-ERS Volt-Ohm 
meter (Millipore, Co Durham, UK), according to the manufacturers instructions. The 
media was changed on day 3 and where applicable, supplemented with washed wild-type 
mouse platelets, added at a final concentration of 1x108/ml. Measurements were 
normalised by subtracting measurements taken from wells containing a BD cell insert 
without cells seeded. Measurements were then multiplied by the area of the filter, giving a 
resistance reading in Ω/cm2. Images of cell monolayers were captured each day using a 
Zeiss Axiovert Zoom brightfield microscope with a 5 X air objective and processed using 
Image J64. 
 63 
2.6.2 Scratch wound assay 
Surfaces of wells within a 24 well plate were coated with 0.5% gelatin/PBS for 10 min at 
37°C. CPECs were seeded at a density of 1x105 in 800 µl of media and grown to 
confluence over 48 hours. Media was removed and the underside of the plate was marked 
to identify points for imaging. Scratches were made through the CPEC monolayer using a 
20 µl pipette tip and 800 µl of media was re-introduced. Images of the scratches were 
taken at the designated points at 0, 12, 24, 32 and 48 hours. 24 hours was identified as the 
optimal time-point, with no further cell growth at 32 and 48 hours. To determine the affect 
of platelets on CPEC behaviour, media was supplemented with platelets at a final 
concentration of 1x107/ml or 1x108/ml, from either wild-type or megakaryocyte/platelet 
specific CLEC-2-deficient platelets (Section 2.6.3). Images were taken at 0 and 24 hours 
of incubation. All images were taken using a Zeiss Axiovert Zoom brightfield microscope 
with a 5 X air objective. Image analysis was performed in Image J64. 
2.6.3 Preparation of washed mouse platelets 
Mice were terminally bled under isofluorane anaesthesia. A laparotomy was performed 
exposing the descending aorta and blood was drawn into 10% ACD. Blood was further 
diluted into 200 µl of Tyrode’s-HEPES buffer (134 mM NaCl, 0.34 mM Na2HPO4, 2.9 
mM KCL, 12 mM NaHCO3, 20 mM HEPES, 5 mM glucose, 1 mM MgCl2, pH 7.3) and 
centrifuged in a microcentrifuge for 5 min at 2000 rpm. Platelet rich plasma (PRP) and the 
top third of erythrocytes were isolated and further centrifuged for 6 min at 200 g. 
Prostacyclin (10 µg/ml) was added to PRP and centrifuged for 6 min at 1000 g. Platelet 
pellets were resuspended in Tyrode’s-HEPES buffer to a concentration of 1 x109/ml. 
Platelets were left rested for at least 30 min before use. 
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2.7  Statistical analysis 
Statistical analysis was performed as appropriate for the specific data distribution and is 
detailed in the individual methods sections or in the figure legends. Where data was not 
found to be significant, this is not stated, or referred to as not significant. 
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3.1  Introduction 
 
The discovery of podoplanin as an endogenous ligand for the platelet receptor CLEC-2 
triggered nearly a decade of research into its physiological role and significance (Suzuki-
Inoue et al., 2007). A key early finding was the characterisation of the CLEC-2 signalling 
pathway, incorporating the signalling molecule SYK, adaptor protein SLP-76 and the 
enzyme PLCγ2 (Suzuki-Inoue et al., 2006). Previous studies had shown that mice 
deficient in SYK, SLP-76 or PLCγ2 developed subcutaneous haemorrhages in the skin 
and oedema in the back by mid-gestation (Turner et al., 1995; Cheng et al., 1995; Wang et 
al., 2000; Clements et al., 1999). Shortly after, podoplanin-deficient mice were generated 
and shown to harbor the same phenotype, which was shown to be attributable to the 
impaired separation of the blood and lymphatic vasculature (Fu et al., 2008). 
 
Initial studies by our group set out to investigate a role for CLEC-2 in the development of 
this phenotype, for which mice with a constitutive loss of CLEC-2 (Clec-2-/-), or mice 
with a specific loss of CLEC-2 in the megakaryocyte/platelet lineage (Clec-2fl/flPF4-Cre), 
were generated (Figure 3.1). Clec-2-/- mice were born at Mendelian frequency up to birth, 
however, 90% died within the first 24 hours due to respiratory failure. During 
development, as expected, Clec-2-/- mice presented with a number of developmental 
defects, most notably the formation of the characteristic blood-lymphatic mixing 
phenotype by E14.5. A specific role for CLEC-2 on platelets was considered, since Clec-
2fl/flPF4-Cre and Sykfl/flPF4-Cre mice also exhibit this phenotype and there is no available 
evidence to support there being significant expression of CLEC-2 on another 
haematopoietic cell, at this stage of development (Finney et al., 2012). However, it should 
be noted that PF4-Cre is expressed on sub-populations of other lineages, leaving open the 
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possible involvement of another cell type (Calaminus et al., 2012). The mechanism of 
blood-lymphatic mixing has been extensively studied and is thought to be mediated by a 
combination of lymphatic-venous connections and retrograde flow through the thoracic 
duct (Discussed in Section 1.4.3) (Hess et al., 2014; Bohmer et al., 2010; Suzuki-Inoue et 
al., 2010).   
 
Interestingly, when looking earlier in development, Clec-2-/- mice were found to develop 
haemorrhages throughout the fore-, mid- and hindbrain by E12.5, which were localised to 
the developing brain parenchyma and ventricles (Figure 3.2). A similar pattern of 
consistent haemorrhaging was observed in SYK-deficient mice, albeit, histological 
analysis revealed haemorrhages to be less severe and restricted to the parenchyma (Figure 
3.2). Furthermore, the loss of CLEC-2 or SYK in the megakaryocyte/platelet lineage 
using the PF4-Cre transgene resulted in mild cerebral haemorrhaging (Figure 3.2) 
(Finney et al., 2012).  
 
These neurovascular defects were believed to be unrelated to defects in lymphatic 
development, since the lymphatic system is absent from the brain and haemorrhaging in 
the cerebral vasculature was coincident with, or possibly occured before, blood-lymphatic 
mixing. Interestingly, a cerebral phenotype has not been reported in podoplanin-deficient 
mice, although the loss of T-synthase, a key glycosyltransferase enzyme responsible for 
glycosylation of the podoplanin extracellular domain, results in the formation of a 
disorganised microvascular network, with defective recruitment of ECM and pericytes, 
leading to haemorrhaging throughout the brain parenchyma and ventricles by E12.0, and 
lethality by E14.0 (Xia et al., 2004). Haemorrhages were not observed in endothelial 
specific T-synthase deficient mice, which exhibited blood-lymphatic mixing, consistent 
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with the neurovascular defect being independent of the defect in lymphatic development 
(Fu et al., 2008).  
 
The aim of this chapter was to further characterise and investigate the mechanism of 
developmental defects within the central nervous system of CLEC-2-deficient mice. To 
achieve this, a podoplanin-floxed mouse was generated and crossed to a PGK-Cre or 
Nestin-Cre mouse to delete podoplanin ubiquitously at the two-cell stage, or specifically 
in neural progenitors, respectively. State-of-the-art 3-dimensional microscopy was used to 
show the localisation and extent of cerebral haemorrhages and to visualise the patterning 
of the developing vasculature. Immunofluoresence staining and electron microscopy were 
employed to further investigate the integrity of the developing NVU. To investigate a 
possible role for haemostasis in the neurovascular defect, mice deficient in the major 
platelet integrin subunit αIIb, or mice deficient in the neurobeachin-like-2 (NBEAL-2) 
protein, which lack platelet α-granules, were studied.  
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3.2  Results 
3.2.1 Generation of CLEC-2-deficient mice 
Clec-2fl/fl mice were generated as described in Figure 3.1, where the presence of Cre 
recombinase resulted in the excision of the floxed CLEC-2 allele, producing a non-
functional CLEC-2 gene. A ubiquitously active, general cre deleter (rosa(SA-CrepA) was 
used at Taconic Artemis to generate mice constitutively deficient in CLEC-2 (Clec-2-/-), 
while the Clec-2fl/fl mouse was crossed to the PF4-Cre transgene (Clec-2fl/flPF4-Cre) to 
mediate specific deletion of CLEC-2 in the megakaryocyte/platelet lineage (Tiedt et al., 
2007). Expression of the wild-type, floxed or knock-out CLEC-2 alleles, and the presence 
of the PF4-Cre locus were confirmed by PCR as shown in Figure 3.1.  
 
In this initial study, three Clec-2-/- mice survived up to P30 before being culled due to ill 
health (Finney et al., 2012). Since this time, no Clec-2-/- mice out of the expected 85.5 
survived past 24 hours (Table 3.1). To investigate the influence of the background of the 
mice on their viability, Clec-2-/- mice on a C57BL/6 background were backcrossed onto a 
129s/v background, but no viable Clec-2-/- offspring were obtained (Table 3.1).  
 
Clec-2fl/flPF4-Cre mice, by contrast, were born at Mendelian frequency, were viable and 
appeared normal (Table 3.2). Upon dissection, Clec-2fl/flPF4-Cre adult mice exhibited a 
blood-lymphatic mixing phenotype in the abdomen, which will be discussed in Chapter 5.  
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3.2.2 Histological analysis of the developing brain in CLEC-2-deficient embryos 
Progressing from published observations showing haemorrhaging in the CNS of Clec-2-/- 
mice at E12.5 (Figure 3.2), earlier developmental time points were investigated. 
Haemorrhages were seen to develop between E10.5 and E11.5 in Clec-2-/- embryos, 
becoming more substantial by E12.5 (Figure 3.3A). Closer inspection of H&E sections at 
E12.5 showed haemorrhages to displace large areas of the neuro-epithelium and protrude 
into ECM tissue (Figure 3.3B).   
 
At this early stage in development, the only endogenous ligand for CLEC-2, podoplanin, 
is expressed throughout the developing neural tube on neuro-epithelial cells, as 
characterised by its co-expression with the intermediate filament protein, nestin (Figure 
3.4A and B). By E14.5, podoplanin expression becomes restricted to the choroid plexus 
and the ependymal lining of the ventricle wall (Figure 3.4A). Despite the high expression 
of podoplanin in the neural tube, coinciding with the development of haemorrhages in 
both CLEC-2 and T-synthase deficient embryos, to date no study has described this 
phenotype in podoplanin-deficient mice. 
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3.2.3 Generation and characterisation of podoplanin-deficient mice 
To investigate a role for podoplanin in the development of cerebral haemorrhages, a 
floxed podoplanin mouse was generated (Figure 3.5) and crossed to mice expressing Cre 
recombinase driven by the maternal PGK-1 promoter, to mediating constitutive 
recombination of the floxed allele from the two-cell stage (Lallemand et al., 1998), 
resulting in a non-functional podoplanin gene (Pdpnfl/flPGK-Cre). Pdpnfl/flPGK-Cre mice 
were found at Mendelian frequency up to E18.5 but found to be lethal at birth, with only 
one Pdpnfl/flPGK-Cre mouse surviving past P0 that was later culled due to ill health before 
weaning (Table 3.3). Breeding analysis from pairs set up to generate 50% heterozygous 
and wild-type offspring, compared to pairs set up to generate 50% heterozygous and 50% 
podoplanin-deficient offspring, revealed an increase in the number of pups dying by P1 
and a significant decrease in the number of viable pups post-weaning in the latter breeding 
pair (Figure 3.6). Due to the marginal difference in total litter sizes recorded, it is likely 
that due to the severity of the phenotype in Pdpnfl/flPGK-Cre mice at birth, most pups will 
have been eaten prior to the litter being recorded.  
 
In line with previous studies, podoplanin-deficient mice presented with a characteristic 
pattern of blood filled vessels on the surface of the skin at E14.5 and E16.5, indicative of a 
blood-lymphatic mixing phenotype (Figure 3.21). Reminiscent of CLEC-2-deficient 
embryos, Pdpnfl/flPGK-Cre embryos developed cerebral haemorrhages between E10.5 and 
E11.5 that become more prominent by E12.5 (Figure 3.7). H&E sections revealed 
haemorrhages through vast areas of the neuro-epithelium at E12.5, protruding into the 
surrounding ECM tissue. Blood vessels in Pdpnfl/flPGK-Cre embryos often appeared 
distended from the surrounding neuro-epithelium, in contrast to the intimate association of 
blood vessels with the surrounding tissue in Pdpnfl/fl littermates (Figure 3.7). Taken 
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together, the cerebral phenotype observed in podoplanin-deficient embryos mimics that of 
embryos deficient in its only known endogenous ligand, CLEC-2.  
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3.2.4 Cerebral haemorrhages in podoplanin-, CLEC-2- and SYK-deficient mice 
persist up to E14.5 
In both Clec-2-/- and Pdpnfl/flPGK-Cre embryos, haemorrhages did not readily resolve and 
could be seen by histology at E14.5 and E16.5 to occupy large areas of the developing 
neuro-epithelium, accumulating in the ventricles (Figure 3.8). Immunofluorescence 
staining of wild-type and Clec-2-/- embryos at E14.5 demonstrated that the haemorrhages 
in the parenchyma and in the ventricles were rich in CD41+ platelets (Figure 3.9). 
Haemorrhages were also found to persist in Syk-/- embryos, where large areas of the neuro-
epithelium were displaced by erythrocyte-rich haemorrhages (Figure 3.10). In Clec-
2fl/flPF4-Cre embryos, substantial haemorrhages could be seen in the parenchyma of 2/6 
embryos at E12.5, persisting in 1/6 embryos to E14.5 (Figure 3.11). As discussed in 
Finney et al (2012), the phenotype in Clec-2fl/flPF4-Cre mice was more variable and less 
severe, possibly owed to residual CLEC-2 expression during early development. 
Furthermore, although haemorrhages were consistently observed in the CNS upon 
dissection, it is likely that small haemorrhages were missed by histology, given that it was 
not feasible to section the entire embryo. These results demonstrate that haemorrhages in 
podoplanin-, CLEC-2- and SYK-deficient mice do not readily resolve and persist in the 
developing nervous system past mid-gestation. 
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3.2.5 Ultramicroscopy as a tool to visualise the developing vasculature in CLEC-2- 
and podoplanin-deficient mice 
To investigate the cause of cerebral haemorrhaging in Clec-2-/- and Pdpnfl/flPGK-Cre 
embryos, a more in depth analysis of the developing vasculature was required. Due to the 
limitations of 2-dimensional microscopy, the planar illumination based microscope 
modality, ultramicroscopy, was used to visualise the developing cerebral vasculature in 3-
dimensions. Ultramicroscopy creates stacks of optical sections that are analysed and 
reconstructed into a single 3D image, thereby allowing the localisation and scale of 
haemorrhages to be better studied.  The vasculature in Clec-2-/-, Pdpnfl/flPGK-Cre and 
wild-type littermates (+/+ includes Pdpnfl/fl littermates) was analysed at E10.5 and E12.5 
by immunofluorescently labeling embryonic heads with PECAM-1. Prior to the 
appearance of haemorrhages, the vasculature at E10.5 appeared tortuous and abnormally 
patterned in Clec-2-/- and Pdpnfl/flPGK-Cre embryos, compared to the organised, 
characteristic branching patterns of wild-type embryos (Figure 3.12A). By E12.5, 
haemorrhages were clearly visible throughout the developing fore-, mid- and hindbrain in 
CLEC-2- and podoplanin-deficient mice, as indicated by dense areas of PECAM-1 
staining (Figure 3.12B, red arrows). The size and localisation of haemorrhages can only 
fully be appreciated by a complete spatial reconstruction of the entire embryonic brain 
that is provided by the ultramicroscopy approach. Higher magnification images of the 
vasculature at E12.5 revealed the presence of large haemorrhages amongst aberrantly 
patterned vascular networks in Clec-2-/- and Pdpnfl/flPGK-Cre embryos (Figure 3.12B, 
right panel, red dashed lines outline haemorrhages). Developing blood vessels were 
discontinuous and appeared prone to haemorrhage compared to the intricately branched 
sheets of vessels that were observed in wild-type (+/+) littermates (Figure 3.12B, right 
panel). 
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Imaris software was used to quantify the area and branching patterns of the developing 
vasculature of Clec-2-/- and Pdpnfl/flPGK-Cre embryos compared to littermate controls. 
Due to the complexity and size of the images obtained, regions were cropped to 
dimensions of x-503 µm, y-503 µm, z-100 µm for analysis. An algorithm was optimised 
to create a surface over the PECAM-1 vascular network, allowing surface area 
measurements to be extracted (Figure 3.13B and Figure 3.14A and C). Once optimised, 
the parameters were applied equally to all samples. To extract measurements of filament 
length and branch points, the filament tracer tool was used, which again required 
optimisation (Figure 3.13C). Both the surface area and filament tracer tools allowed for 
haemorrhagic areas to be excluded (Figure 3.14C). Nevertheless, in highly complex areas 
of the images, surface and filament traces could not be perfectly extracted. At E10.5, the 
total surface area and total length of all vessels were comparable between Clec-2-/- 
embryos and wild-type littermates, while in Pdpnfl/flPGK-Cre embryos, there was a trend 
for the vessel area and vessel length to be reduced compared to wild-type littermates, 
although this difference was not significant (Figure 3.14B). By E12.5, the surface area of 
vessels and the total vessel length in Pdpnfl/flPGK-Cre embryos was similar to wild-type 
littermates, and while an increase was observed in Clec-2-/- embryos, this was not 
significant (Figure 3.14D). The total number of vessel branch points and the number of 
branched vessels was comparable between Clec-2-/-, Pdpnfl/flPGK-Cre embryos and wild-
type littermates at both E10.5 and E12.5 (Figure 3.14B and D). Taken together, it was 
concluded that there was no major change in vessel branching in podoplanin- or CLEC-2-
deficient embryos. However, it cannot be excluded that a more subtle change was masked 
by limitations in the analysis, as described above.  
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3.2.4 Quantifying vascular networks using the hindbrain model 
Due to the difficulty experienced in quantifying blood vessel network parameters from 
complex 3-dimensional images, a new method was trialed, developed by Fantin et al 
(2013) that allowed the architecture of the vasculature in the hindbrain to be studied. The 
hindbrain model was specifically designed to study cerebral angiogenesis, given that the 
hindbrain tissue is isolated from its surrounding vascular plexus (Fantin et al., 2013). 
Preliminary analysis of hindbrains from Clec-2-/-, Pdpnfl/flPGK-Cre embryos and wild-
type littermates, revealed a trend towards a small (<20%) increase in the surface area of 
vessels, number of branch points and branched vessels in Clec-2-/- and Pdpnfl/flPGK-Cre 
embryos, corresponding with a decrease in the average vessel length (Figure 3.15), albeit 
these were not significant. Further imaging and analysis could provide a more detailed 
insight into the patterns of vessel sprouting, for example, specifically focusing on 
PECAM-1 dense tip cell projections and monitoring vessel growth at different embryonic 
stages.  
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3.2.5 Quantifying pericyte coverage in CLEC-2- and podoplanin-deficient mice 
Both ultramicroscopy and hindbrain model imaging showed that despite vessels appearing 
tortuous in CLEC-2 and podoplanin-deficient embryos, they were able to successfully 
sprout from the PNVP and extend through the neuro-epithelium. This indicated that the 
initial stages of angiogenesis driven primarily by the VEGF and Wnt-β-catenin pathways 
were largely unperturbed (Walls et al., 2008; Breier et al., 1992; Obermeier et al., 2013). 
As a result, further work was focused on the maturation of cerebral vessels, a process by 
which nascent angiogenic vessels, are transformed into a structurally supported vascular 
network, through the recruitment of mural cells, ECM proteins and neurons. Amongst 
these mural cells are pericytes, which overlay endothelial cell junctions to support smaller 
arterioles, venules and capillaries (Armulik et al., 2010). Immunostaining of tissue 
sections revealed a significant reduction in the number of NG2+ pericytes recruited to 
PECAM-1+ blood vessels in the neuro-epithelium of Clec-2-/-and Pdpnfl/flPGK-Cre 
embryos, compared to wild-type littermates at E11.5 (Figure 3.16). Similar to the 
observations taken from the analysis of H&E sections, blood vessels often appeared 
distended from the surrounding neuro-epithelium (Figure 3.16). 
In light of the clear visualisation of vascular networks that was seen by whole-mount 
immuno-staining of isolated hindbrains (Figure 3.15), this model was used to quantify 
pericyte recruitment to developing cerebral vessels, in order to verify observations seen 
from tissue sections. Pericyte coverage on hindbrain vessels was quantified by comparing 
the intensity of immunostaining for the pericyte marker NG2, relative to that of PECAM-1 
positive blood vessels (Figure 3.17). No significant difference in pericyte coverage was 
observed between Clec-2-/-and Pdpnfl/flPGK-Cre embryos, compared to wild-type 
littermates at E12.5. 
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3.2.6 Ultrastructural analysis of cerebral microvessels by electron microscopy 
To investigate the ultrastructure of developing cerebral microvessels in more detail, 
CLEC-2- and podoplanin-deficient embryos were taken at E11.5 and processed for 
electron microscopy. In wild-type littermate controls, the blood vessel endothelium could 
be seen to enclose a lumen containing a nucleated fetal red blood cell (Figure 3.18). At 
this stage of development, the thick, supportive basal lamina characteristic of mature 
microvessels could not be observed, but tight junctions were seen connecting adjacent 
endothelial cells. Pericytes and neuro-epithelial cells were visibly associated with the 
endothelium, providing structural support for developing microvessels. By contrast, 
although endothelial cell junctions appeared well established in Clec-2-/-and Pdpnfl/flPGK-
Cre embryos, shown by visible endothelial cell flaps, vascular lumens appeared expanded 
and the endothelium was rich in vacuoles, appearing fragile, tortuous and prone to 
haemorrhage (Figure 3.18). Large gaps were visible between the blood vessel 
endothelium and the surrounding pericytes and neuro-epithelial cells, precluding their 
critical structurally supportive role. 
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3.2.7 Generation of neural-specific podoplanin-deficient mice 
Earlier in this Chapter, podoplanin was shown to be expressed throughout the neural tube 
at E11.5, where it was co-expressed with the intermediate filament protein nestin (Figure 
3.4). To confirm that podoplanin expression on neuro-epithelial cells is required for the 
development and integrity of cerebral vessels, Pdpnfl/fl mice were crossed to mice 
expressing cre recombinase under the control of the nestin promoter (Nes-Cre). There are 
at least three Nes-Cre lines that have been generated and this transgenic line was chosen 
because of its early onset, targeting neural progenitors from E8.5, before the onset of brain 
vascularisation (Petersen et al., 2002). Pdpnfl/flNes-Cre mice were present at Mendelian 
frequency up to E14.5, but were found to be lethal at birth, with only one pup successfully 
weaned (Table 3.4). By comparing mating pairs that were expecting all heterozygous or 
wild-type offspring, to pairs expecting 50% Pdpnfl/flNes-Cre mice, it was apparent that 
Pdpnfl/flNes-Cre mice were lethal within the first post-natal days, with smaller litter sizes 
recorded, more deaths by P1 and fewer pups successfully weaned (Figure 3.19). Analysis 
of more offspring may increase the certainty of these initial observations which are 
currently not statistically significant.  
 
The successful deletion of podoplanin on neuro-epithelial cells by the nestin promoter was 
confirmed by immunofluorescence staining on tissue sections from E11.5 Pdpnfl/flNes-Cre 
embryos, compared to the maintained expression of podoplanin that was seen in Pdpnfl/fl 
littermate controls (Figure 3.4C). 
 
 
 
 80 
3.2.8 Histological analysis of Pdpnfl/flNes-Cre embryos 
Pdpnfl/flNes-Cre embryos appeared identical to Pdpnfl/flPGK-Cre and Clec-2-/- embryos, 
with haemorrhages developing in the fore-, mid and hindbrain between E11.5 and E12.5 
(Figure 3.20A). H&E sections revealed a comparable phenotype to constitutive CLEC-2- 
and podoplanin-deficient mice, with haemorrhages displacing vast regions of the neuro-
epithelium and collecting in the ventricles by E12.5 (Figure 3.20B). Haemorrhages were 
still present at E14.5, occupying large areas of the developing neural tissue (Figure 
3.20C). 
 
Intriguingly, Pdpnfl/flNes-Cre embryos developed a characteristic pattern of blood-filled 
vessels on the surface of the skin at E14.5 and E16.5, reminiscent of the blood-lymphatic 
mixing phenotype observed in Pdpnfl/flPGK-Cre embryos (Figure 3.21). This suggests that 
nestin may be expressed outside of neural cells during development. 
 
 
 
 
 
 
 
 
 
 81 
3.2.9 Defining the mechanism by which CLEC-2 activated platelets influence 
cerebral vascular development 
Taken together, results so far suggest that podoplanin on neuro-epithelial cell progenitors, 
interacts with CLEC-2-expressing haematopoietic cells, to drive the maturation of 
cerebral vessels and prevent haemorrhage. During development, the only known 
haematopoietic cells with significant CLEC-2 expression are platelets, and it has been 
shown that the loss of CLEC-2 in this lineage results in cerebral haemorrhaging (Figure 
3.12) (Finney et al., 2012). Furthermore, the loss of the downstream tyrosine kinase SYK, 
both constitutively and in the megakaryocyte/platelet lineage, mirrors the observations in 
CLEC-2-deficient mice, thus indicating a specific role for CLEC-2-induced platelet 
activation in cerebral vascular development (Figure 3.10) (Finney et al., 2012). A role for 
podoplanin-CLEC-2 interactions in a developing vascular environment as apposed to 
within a fully mature vascular network is supported by the absence of cerebral 
haemorrhage in mice where CLEC-2 was depleted post-development (discussed in 
Chapter 5). In a developmental setting, nascent angiogenic vessels continually remodel 
their extracellular matrix coating to allow for the generation of new vascular networks. 
This presents a pathway for platelets to interact with surrounding podoplanin-expressing 
neuro-epithelial cells. In support of this, platelets were often seen outside of blood vessels 
within the neuro-epithelium on frozen sections of wild-type embryos, early in 
development (Figure 3.22). Despite efforts to ensure all embryos were collected within 
the same time frame, rapid changes early on in development are likely to account for the 
variability in results (Figure 3.22B). Very rarely were platelets seen outside of mature 
blood vessels within the vascular beds that surround the neural tube. Furthermore, by 
E14.5, platelets were rarely seen outside of blood vessels within the neuro-epithelium 
itself. A small number of platelets were identified outside of blood vessels in each group, 
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likely due to the inherent errors introduced when dealing with 2-dimensional imaging 
(Figure 3.22). 
 
To begin to understand a mechanism by which CLEC-2-induced platelet activation 
safeguards the developing cerebral vasculature from lethal haemorrhage, embryos 
deficient in αIIb were studied, which together with β3 forms the major platelet integrin. 
Haemorrhages were seen to develop in the nervous system of αIIb-/- embryos by E11.5, 
persisting at E12.5 and appearing to resolve by E14.5 (Figure 3.23A). The neuro-
epithelium of αIIb-/- embryos at E10.5 appeared disorganised on H&E histological 
sections, with nucleated cells penetrating the ventricle walls (Figure 3.23B). By E11.5, 
eosin-stained erythrocytes accumulated in the ventricles, persisting to E12.5. 
Haemorrhages at E11.5 and E12.5 were consistently observed, but were less substantial 
than in CLEC-2-, podoplanin- and SYK-deficient embryos, with no large haemorrhagic 
areas seen in the neuro-epithelial tissue. By E14.5, cerebral haemorrhages in αIIb-/- 
embryos had largely resolved, and histologically, the developing neural system appeared 
identical to littermate controls (Figure 3.23B). 
 
In addition to their adhesive properties, platelets are powerful secretory cells that release a 
range of bioactive molecules upon activation. In this study, a role for platelet α-granules 
was considered, because they are enriched in both angiogenic and haemostatic molecules, 
such as VEGF and VWF (Deppermann et al., 2013). Neurobeachin-like-2 (NBEAL-2) 
was identified as an important regulator in the biogenesis of platelet α-granules and as the 
causative gene for Grey platelet syndrome, a rare congenital disorder characterised by a 
mild thrombocytopenia and moderate bleeding tendency, due to the absence of α-granules 
(Albers et al., 2011; Kahr et al., 2011; Gunay-Aygun et al., 2011). Deppermann el al 
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(2013) used a mouse model of Grey platelet syndrome (Nbeal-2-/-) that recapitulates many 
of the phenotypic tendencies of patients, including an absence of characteristic α-granules, 
although a small number of aberrantly formed α-granule-like structures could be observed 
(Deppermann et al., 2013). The loss of NBEAL-2 caused a mild cerebral haemorrhagic 
phenotype in 2/12 embryos at E12.5, while 4/4 littermate controls appeared normal 
(Figure 3.24A). On H&E coronal sections, no clear haemorrhagic regions could be 
observed, with only occasional blood vessels appearing dissociated from an otherwise 
organised neuro-epithelium (Figure 3.24C). By E14.5, all Nbeal-2-/- embryos appeared 
identical to littermate controls, with the integrity of blood vessels and their surrounding 
cell network appearing identical to littermate controls (Figure 3.24B and C). These results 
suggest only a minor role for platelet α-granule secretion in maintaining the integrity of 
the cerebral vasculature.  
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3.3  Discussion 
 
The primary aim of the work in this chapter was to investigate the basis of the cerebral 
haemorrhagic defect in CLEC-2 deficient mice. This has involved the generation and 
characterisation of podoplanin-deficient mice to assist in dissecting the mechanism by 
which CLEC-2 and podoplanin influence the development of the cerebral vasculature. 
 
Initial characterisation of Clec-2-/- mice described the presence of haemorrhages in the 
CNS at E12.5 (Finney et al., 2012). The timing and presentation of haemorrhages were 
reminiscent of those seen by Tang et al (2010) who previously generated Clec-2-/- mice, 
localising haemorrhages to the parenchyma at E12.0 (Tang et al., 2010). From this stage 
in development, podoplanin becomes increasingly restricted to the ependymal lining of 
the ventricle walls and the choroid plexus (M. C. Williams et al., 1996). It therefore 
became important to investigate the role of CLEC-2 and podoplanin at earlier 
developmental time points, when podoplanin is expressed throughout the neural tube on 
neuro-epithelial cells.  
 
To delete podoplanin at this early stage in development, a PGK-Cre transgene was used, 
generating a podoplanin-deficient mouse strain on a C57BL/6 background. The lethality 
of Pdpnfl/flPGK-Cre offspring was reminiscent to that observed in podoplanin-deficient 
mice generated on a 129sv background, whereby the majority of pups died at birth, and is 
in contrast to mice previously generated on a C57BL/6 background, where 20% of 
offspring were viable (Uhrin et al., 2010; Schacht et al., 2003; Ramirez et al., 2003). The 
reason for these differences in viability are unknown, but appear not to be entirely 
dependent on the strain background, but may instead reflect the efficiency of the genetic 
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deletion.  
 
This is the first report to describe cerebral haemorrhaging in CLEC-2- and podoplanin- 
deficient mice to develop between E10.5 and E11.5, a critical time point for neural 
vascularisation. A comparable pattern of haemorrhaging was seen in a mouse model 
inducing deletion of podoplanin on neural progenitors, indicating a specific role for 
podoplanin on neuro-epithelial cells. Interestingly, subcutaneous haemorrhages were also 
observed in the skin of Pdpnfl/flNes-Cre embryos at E14.5, reminiscent of the 
characteristic blood-lymphatic phenotype observed in CLEC-2- and podoplanin-deficient 
embryos. Nestin is widely recognised for its expression on neuro-epithelial 
stem/progenitor cells in the developing CNS, becoming more highly expressed in the 
proliferative ventricular zones by E14.5, and further restricted to a population of 
ependymal cells by E16.5, mimicking the expression pattern of podoplanin (Sugawara et 
al., 2002). Interestingly, a number of reports have described nestin to additionally function 
as a marker for proliferating endothelial cells in both adult CNS and non CNS tumours, as 
well in normal adult tissues, including the human pancreas (Sugawara et al., 2002; 
Teranishi et al., 2007; Klein et al., 2003). Furthermore, developmental expression of 
nestin in proliferating endothelial cells was reported specifically in angiogenic tissues in 
rats (Mokrý & Nemecek, 1998). Together, these reports provide confounding evidence to 
support nestin expression on proliferating endothelial cells. The importance of these 
studies in the context of the cerebral phenotype observed in podoplanin- and CLEC-2-
deficient mice is minimal, given that podoplanin is only expressed on lymphatic 
endothelium, which is absent in the brain. Nevertheless, it remains important to 
investigate the pattern of recombination of podoplanin by the Nes-Cre transgene used in 
this study. This will be achieved by introducing the Nes-Cre transgene into the Rosa26Yfp 
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reporter mouse (obtained from Jackson Laboratories), which produces yellow fluorescent 
protein (YFP) in all cells expressing cre recombinase (Srinivas et al., 2001). A similar 
strategy was recently used by two independent groups to investigate the expression of 
PF4-Cre outside of the megakaryocyte/platelet lineage (Pertuy et al., 2014; Calaminus et 
al., 2012). Embryos will be collected at different time-points during development and the 
expression of nestin will be investigated by co-staining with a range of cell markers, e.g. 
endothelial cell markers. Future studies may also compare the other available Nestin-Cre 
transgenic mouse models (Tronche et al., 1999; Zimmerman et al., 1994). 
 
Results so far imply a role for podoplanin specifically on neuro-epithelial cells in 
preventing cerebral haemorrhage during development. The CLEC-2 expressing cell type 
proposed to interact with podoplanin in this setting is platelets, given that there is no 
evidence for significant CLEC-2 expression on any other circulating cell during 
development. The varying severity of the cerebral phenotype resulting from a 
megakaryocyte/platelet specific deletion of CLEC-2 or SYK is also apparent in the 
context of the blood-lymphatic mixing phenotype, for which a wealth of research has been 
conducted. This variability is thought to result either from incomplete deletion of the 
genes resulting in a small fraction of platelets expressing CLEC-2 early in development, 
or the expression of CLEC-2 in megakaryocyte progenitors prior to deletion of the gene, 
due to the delay in Cre expression downstream of the PF4-promoter (Finney et al., 2012). 
The latter theory is supported by the observation that deleting CLEC-2 or SYK in all 
haematopoietic lineages using a Vav-Cre transgene results in a phenotype comparable to 
PF4-Cre mediated deletion (Bertozzi, Schmaier, et al., 2010b; Finney et al., 2012). 
Furthermore, as discussed in detail in Section 1.41, blood-lymphatic mixing is also 
observed in mice lacking functional megakaryocytes (Meis-1-/-), or following the 
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inducible ablation of the megakaryocyte/platelet lineage using diphtheria toxin or aspirin 
treatment, although it should be noted that the latter studies are dependent on the 
selectivity of PF4-Cre and that aspirin is not specific to the megakaryocyte-lineage (Uhrin 
et al., 2010; Carramolino et al., 2010). Together these studies support a role for CLEC-2 
on platelets, in vascular development.  
 
With this in mind, the mechanism by which activated platelets guide and maintain 
vascular integrity during development was investigated. Strikingly, a haemorrhagic 
phenotype was observed in mice deficient in one of the subunits of the major platelet 
integrin αIIbβ3 at E12.5. Thus, haemorrhaging is presumably influenced by a loss of 
integrin αIIbβ3-mediated platelet adhesion and/or aggregation. Although this role of the 
integrin is a component of classical haemostatic function of platelets, this is the first 
description of haemorrhaging associated specifically with the loss of this pathway during 
development. Remarkably, however, haemorrhages in αIIb-deficient mice appeared to 
resolve by E14.5, whereas in Clec-2-/- and Pdpnfl/flPGK-Cre embryos haemorrhages were 
still prominent at this stage. This suggests an additional mechanism is influenced by the 
loss of CLEC-2 activation, possibly the angiogenic development of cerebral vessels, 
leading to a persistent haemorrhagic phenotype. In addition, CLEC-2 drives integrin-
dependent platelet aggregation that functions to plug the vessel wall during development. 
 
3-dimensional imaging of the vasculature at E10.5 and E12.5 showed that vessels 
successfully invade the neural tube from the PNVP by angiogenesis to form a primitive 
vascular network. However, these nascent vessels appeared tortuous and prone to 
haemorrhage, indicating the defect lies in the transformation of these ‘leaky’ vessels into a 
structurally supported vascular system. Several independent studies have shown that 
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disrupting key signalling mechanisms that are involved in the recruitment of mural cells 
and ECM proteins to nascent developing vessels, also culminates in cerebral 
haemorrhaging around the same stage in development (McCarty et al., 2002; Hellström et 
al., 2001; Proctor et al., 2005; Bader et al., 1998; Zhu et al., 2002). For example, integrins 
are key ECM proteins that coat the albuminal vessel wall and mediate the recruitment of 
perivascular cells, such as pericytes, to aid the maturation of nascent vessels. Mice with a 
specific loss of the integrin subunit β8 in the neuro-epithelium develop tortuous vessels, 
owed to defective associations between the endothelium and the surrounding neuro-
epithelial and glial cells, reminiscent of the results observed by electron microscopy in 
Clec-2-/- and Pdpnfl/flPGK-Cre embryos (Proctor et al., 2005). Similarly, the PDGFβ-
PDGFRβ axis stimulates the recruitment and spreading of perivascular cells across the 
endothelium. PDGFRβ-/- mice also developed cerebral haemorrhages during development, 
resulting from endothelial hyperplasia in nascent blood vessels, leaving them fragile and 
tortuous. Similar to what was observed in the present study, no significant differences 
were observed in the density, length and branching of vessels, eluding to a role for 
PDGFRβ in the maturation of an already established primitive vascular network. The 
fragility of nascent vessels in PDGFRβ-/- mice was instead shown to be attributed to the 
defective recruitment of pericytes (Hellström et al., 2001). A reduction in pericyte 
recruitment was also observed on tissue sections from Clec-2-/- and Pdpnfl/flPGK-Cre 
embryos, albeit this phenotype was not replicated in the preliminary analysis of whole-
mount, immuno-stained, hindbrains. The question therefore remains as to which of these 
pathways are related to the role of CLEC-2 and platelets in the development of the 
cerebral vasculature.  
 
In addition to their adhesive properties, platelets are powerful secretory cells, releasing a 
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range of bioactive molecules upon activation. In this study, a specific role for α-granules 
was considered, given their enrichment in growth factors such as VEGF and various other 
haemostatic proteins, including VWF. However, the mild haemorrhagic phenotype 
observed in NBEAL-2-deficient mice, with less than 20% exhibiting haemorrhaging, 
argued against a major role for platelet α-granule secretion in cerebral vascular 
development and was consistent with the mild bleeding diathesis observed in adult Nbeal-
2-/- mice (Deppermann et al., 2013).  
 
Independent of α-granules, platelets release a number of lipid mediators, including a range 
of prostanoids, leukotrienes and the bioactive lipid S1-P, while also critically supporting 
the formation of lysophosphatidic acid (LPA).  Platelets support the generation of LPA 
through a process that is primarily mediated by binding of extracellular autotaxin to 
integrin αIIbβ3 (Fulkerson et al., 2011). Interestingly, mice deficient in the G-protein 
coupled LPA receptor, LPA4, were prone to haemorrhage during gestation as a 
consequence of the defective recruitment of mural cells to developing blood vessels 
(Sumida et al., 2010). A strikingly similar phenotype was observed in mice deficient in 
the S1-P receptor, S1P1, both globally and specifically on endothelial cells. A defect in the 
recruitment of mural cells to developing vessels led to extensive haemorrhaging 
throughout the developing brain and other organs, culminating in embryonic lethality by 
E12.5 (Liu et al., 2000; Allende et al., 2003). Studies in which circulating S1-P levels 
were eliminated, resulted in an even more severe phenotype, with severe haemorrhaging 
in the brain by E11.5 and delayed neural tube closure, indicating the involvement of 
multiple S1-P receptors (Mizugishi et al., 2005). 
 
In a recent study, podoplanin and CLEC-2 were reported to play a critical role in the 
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maintenance of integrity of high endothelial venules through release of S1-P. Whereby the 
release of S1-P from platelets was found to be CLEC-2-mediated, stimulating up-
regulation of V-cadherin in high endothelial venules and preventing blood flow into 
lymph nodes (Hess et al., 2014). It is possible that a similar mechanism takes place during 
the development of the cerebral vasculature, with S1-P regulating the integrity of 
endothelial tight junctions. Future studies will involve characterising mice that are 
deficient in platelet-derived S1-P to determine whether it plays any role in maintaining 
cerebral vascular integrity during development. 
 
Taken together, a model is proposed whereby during the initial vascularisation of the 
neural tube, podoplanin on neuro-epithelial cells interacts with CLEC-2, stimulating 
platelet activation. While platelet aggregates plug the vessel wall to prevent haemorrhage, 
secreted molecules such as S1-P may function to recruit cells and matrix components to 
developing vessels to drive their maturation and integrity. In the absence of these 
interactions, vessels become tortuous and prone to haemorrhage (Summarised in Figure 
3.25). 
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CHAPTER 4 
EXPRESSION OF MURINE CLEC-2 IN THE 
HAEMATOPOIETIC SYSTEM 
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4.1  Introduction 
 
Until now, the focus of research on CLEC-2 and podoplanin has been on their roles in 
development, but equally important is their role post-development, in particular in 
maintenance and repair pathways, as these share overlapping features with development. 
Given the discrepancies in the literature between transcript and protein expression of 
CLEC-2, it is essential to characterise the expression profile of CLEC-2 in the steady state 
and during inflammation in order to investigate these questions. Models of CLEC-2 
depletion independent of changes in development must also be established. 
 
Over a decade ago, CLEC-2 (gene name Clec1b) was identified in a transcriptomics study 
of human myeloid cells, with Clec1b mRNA detected in monocytes, DCs and 
granulocytes (Colonna et al., 2000). A later study identified human Clec1b mRNA in fetal 
liver, bone marrow and in whole blood, although interestingly, Clec1b mRNA was absent 
from leukocytes (Figure 4.1). More recent studies that used specific antibodies to CLEC-
2, described robust surface expression of CLEC-2 on human platelets, while showing its 
absence from the surface of leukocytes isolated from whole blood, including monocytes, 
DCs, neutrophils, T- and B-lymphocytes (Suzuki-Inoue et al., 2006; Tang et al., 2010; 
Gitz et al., 2014). Together these data show that high-level expression of CLEC-2 is 
restricted to the platelet lineage in peripheral blood in humans.  
 
A much wider mRNA expression profile was detected in the murine system, with Clec1b 
transcripts detected in placenta, lung, liver, lymph nodes, spleen and bone marrow (Figure 
4.2) (Xie et al., 2008; Wu et al., 2009). In the haematopoietic system, serial gene 
expression analysis (SAGE) identified murine CLEC-2 to be a predominantly 
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megakaryocyte/platelet specific protein (Senis et al., 2006). Surface expression of CLEC-
2 was later confirmed on platelets, but was additionally reported for liver Kupffer cells 
and peripheral blood neutrophils, the latter identified by an independent monoclonal 
antibody (mAb), 17D9 (Tang et al., 2010; Kerrigan et al., 2009). Interestingly, CLEC-2 
expression was lower on neutrophils resident in the bone marrow and in those isolated 
from inflammatory sites than circulating neutrophils, suggesting that CLEC-2 is up 
regulated on these cells during trafficking. In the same study, CLEC-2 expression was 
induced on peripheral blood monocytes in response to toll-like receptor (TLR) 1or 2 
stimulation, while absent under resting conditions (Kerrigan et al., 2009). The group of 
Reis e Sousa used the same antibody, 17D9 (which they had generated), to confirm 
expression of CLEC-2 on platelets and neutrophils, while also reporting CLEC-2 
expression on splenic DCs, peritoneal macrophages, a subset of natural killer cells and B-
lymphocytes, in the steady state. Furthermore, CLEC-2 expression was increased on 
splenic neutrophils, monocytes subsets, DCs, B-lymphocytes and natural killer cells 
following LPS stimulation (Mourao-Sa et al., 2011). This wide CLEC-2 surface 
expression profile does not correlate with the distribution of Clec1b transcript levels 
identified in the BioGPS database (Figure 4.2) and in leukocyte populations, as described 
in ‘The immunological genome project’ (Figure 4.3). Significant Clec1b levels were 
found only in a population of splenic macrophages, a thioglycolate-elicited population of 
peritoneal DCs and a population of bone marrow-derived neutrophils (Figure 4.3) (Wu et 
al., 2009; Heng et al., 2008). An independent study has since verified CLEC-2 to be 
present at both the mRNA and protein level (using recombinant podoplanin as a ‘CLEC-
2-specific’ ligand) in DCs, albeit at low level, isolated from lymph nodes and skin. 
Furthermore, CLEC-2 expression was shown to be increased on the surface of DCs in 
response to LPS challenge (Acton et al., 2012). 
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A limitation of the study by Mourão-Sá et al (2011), in which a wide expression pattern of 
CLEC-2 was observed, is that data for representative staining of leukocytes in CLEC-2-
deficient mouse models was described, but not shown (Mourao-Sa et al., 2011). Thus, the 
details of the full spectrum of experiments on the CLEC-2-deficient cells are not known.  
 
The aim of this Chapter was to investigate the expression of CLEC-2 on circulating 
haematopoietic cells in adult mice, using the commercially available anti-CLEC-2 
antibody, 17D9, developed by Mourão-Sá et al (2011) and a second murine anti-CLEC-2 
antibody, INU1, that was developed by the group of Bernhard Nieswandt (Mourao-Sa et 
al., 2011; May et al., 2009). The specificity of these antibodies was validated by flow 
cytometry on cells isolated from adult CLEC-2-deficient mice. Two methods of CLEC-2 
depletion in adult mice were characterised for this study, including the generation of Clec-
2-/- fetal liver chimeras and tamoxifen-inducible deletion of CLEC-2 using the ERT2Cre 
transgene. 
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4.2 Results 
4.2.1 Generation of tamoxifen-inducible CLEC-2-deficient mice 
It has previously been shown that constitutive deletion of CLEC-2 (Clec-2-/-) results in 
embryonic lethality. For this reason, a mouse model was generated in which CLEC-2 is 
ubiquitously deleted in adult mice. Clec-2fl/fl mice were crossed to mice expressing Cre 
recombinase upstream of an estrogen receptor T2 cassette (ERT2) driven by the ROSA26 
locus (Gt(ROSA)26Sortm1Sor) (Figure 4.4) (Soriano, 1999; Hayashi & McMahon, 2002). 
Clec-2fl/flERT2Cre mice continuously produce Cre recombinase, which is sequestered in 
the cytoplasm by the ERT2 moiety until tamoxifen is administered, stimulating the release 
of Cre recombinase, which translocates to the nucleus to excise the floxed allele (Figure 
4.4).   
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4.2.2 Initial characterisation of platelets in Clec-2fl/flERT2Cre mice 
To characterise the efficiency of recombination of the Clec-2fl/fl allele by the ERT2Cre 
transgene, Clec-2fl/fl and Clec-2fl/flERT2Cre mice were administered tamoxifen by i.p. 
injection and surface CLEC-2 levels on platelets from whole blood were monitored using 
17D9 anti-CLEC-2 antibody. 5 consecutive days of tamoxifen dosing led to robust 
depletion of 17D9 staining from the platelet surface after 1 week, which was maintained 
at 7 weeks, demonstrating loss of CLEC-2. By 12 weeks, an average of 18% recovery of 
CLEC-2 protein was detected on the platelet surface (Figure 4.5). It was found that 
reducing injections to 1 or 3 consecutive days was insufficient to provide complete 
CLEC-2 depletion from the platelet surface in 6 week old mice (Figure 4.6). However, in 
3 week-old mice, a single injection was sufficient to induce full depletion of CLEC-2 on 
the platelet surface, although after 4 weeks, a small amount of CLEC-2 was recovered 
(Figure 4.7). These results demonstrate that i.p. injection of tamoxifen successfully 
induces depletion of CLEC-2 from platelets, but the age of mice and the timeline of their 
use should be considered in experimental design.  
 
 
 
 
 
 
 0.8 
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4.2.3 Characterising CLEC-2 depletion on platelets and leukocytes in tamoxifen 
treated Clec-2fl/flERT2Cre mice 
To monitor CLEC-2 depletion on leukocyte populations, many of which have much 
greater half-lives to that of platelets, alternative tamoxifen administration routes were 
compared to i.p. injection, due to concerns over the prolonged build up of corn oil in the 
abdomen, which can be detrimental in certain experimental models (e.g. intravital 
microscopy) and cause prolonged discomfort to the animal. Tamoxifen was administered 
in the diet (TAM400, Harlan Laboratories) with an estimated daily dose of 40 mg per kg 
body weight. It is common for mice to experience significant weight loss on tamoxifen 
diet (see Chapter 5) and so initially 2 weeks of tamoxifen diet was followed by 
conventional diet for 10 weeks. CLEC-2 expression on leukocytes in peripheral blood was 
measured using 17D9 at 1 and 12 weeks by flow cytometry. Cells were gated as described 
in Figure 4.8. CLEC-2 depletion on platelets was partial following 1 week on diet, with 
full deletion seen at 2 weeks (data not shown), which was maintained at 12 weeks (Figure 
4.9). 17D9 binding was comparable on B-lymphocytes in Clec-2fl/fl and Clec-2fl/flERT2Cre 
mice at 1 week, while at 12 weeks a partial reduction was seen in Clec-2fl/flERT2Cre mice 
(Figure 4.9). 17D9 binding to Gr1+Mac-1+ myeloid cells (a neutrophil rich population, 
which will be referred to throughout the text as neutrophils) was comparable between 
Clec-2fl/fl and Clec-2fl/flERT2Cre mice at 1 and 12 weeks (Figure 4.9). No significant 
binding of 17D9 was observed on T-lymphocytes. 
  
To investigate depletion of CLEC-2 at the genomic level, DNA was extracted from whole 
blood of Clec-2fl/fl and Clec-2fl/flERT2Cre mice treated with tamoxifen diet for 2 weeks 
followed by 5 weeks conventional diet, or following 7 weeks on continuous tamoxifen 
diet. Despite the marked presence of Clec1b KO DNA after 2 weeks of tamoxifen 
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treatment, a significant level of floxed Clec1b was still present (Figure 4.10). This was 
markedly reduced following 7 weeks of tamoxifen diet.  
 
These results are consistent with binding of 17D9 to CLEC-2 on platelets and on B-
lymphocytes, but indicate that 17D9 may also bind to a second site on myeloid cells and 
on B-lymphocytes (due to the partial rather than complete reduction in binding). Two 
weeks of tamoxifen diet induced full and sustained excision of the Clec1b gene from 
platelets, but only partial depletion from leukocytes. Genomic Clec1b DNA levels 
indicate that full deletion on leukocytes requires continuous tamoxifen treatment in the 
diet for a period greater than 7 weeks. Therefore it is important to determine whether 
17D9 binding to CLEC-2 ‘depleted’ cells is due to residual levels of CLEC-2, or to 17D9 
binding to an alternative ligand.  
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4.2.4 Investigating the specificity of 17D9 anti-CLEC-2 antibody on leukocytes in 
whole blood 
To further investigate the specificity of 17D9 and the expression profile of CLEC-2 on 
circulating leukocytes, a number of additional experimental tools were employed. Firstly, 
tamoxifen-inducible CLEC-2-deficient mice were treated for up to 6-12 months in order 
to take into account the extended life span of some leukocytes. During this time period 
Clec-2fl/fl and Clec-2fl/flERT2Cre mice developed a number of phenotypic abnormalities that 
will be discussed in Chapter 5. Secondly, radiation chimeras were generated and 
reconstituted with CLEC-2-deficient  (Clec-2-/-), or wild-type (+/+) fetal liver cells 
(C57BL/6). Chimeras were left for 6 weeks to allow donor cells to establish the 
haematopoietic compartment. Fetal liver chimeras were generated on both a C57BL/6 and 
on a BoyJ background to allow for donor and recipient cells to be distinguished. Cells 
from either C57BL/6 or BoyJ origin were distinguished by their expression of distinctive 
isoforms of the common leukocyte marker CD45, CD45.1 or CD45.2, respectively. The 
isoforms are functionally identical but can be used for antibody-mediated recognition 
(Figure 4.11). Therefore, leukocytes that may have not turned over during the 6-week 
irradiation and re-establishment period could be identified. 
 
To investigate the expression of CLEC-2 during immune challenge, systemic 
inflammation was induced in chimeras by i.p. injection of LPS. LPS is a cell wall 
component of gram-negative bacteria, such as the common bacterium Escherichia Coli 
(E.Coli), and is known to effectively stimulate the innate immune system. An effective 
immunological response was measured by a simultaneous drop in platelet and white blood 
cell counts, which were usually concurrent with a small increase in mean platelet volume 
and circulating monocytes (Figure 4.12 and Figure 4.13). Mice in which the platelet count 
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did not sufficiently drop were eliminated from the study (Figure 4.13, red circles). It is 
important to note that the data in this chapter was focused only on CLEC-2 expression on 
platelets and leukocytes in whole blood. Splenic and lymph node leukocyte subsets were 
analysed independently by Guillaume Desanti alongside this study and will be referred to 
in the discussion. 
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4.2.5 Comparing 17D9 and INU1 in un-manipulated C57BL/6 controls 
In addition to comparing multiple models of CLEC-2 depletion in adult mice, within some 
of these models, a direct comparison was made between 17D9 and a second CLEC-2 
antibody, INU1. It is important to note that by flow cytometry INU1 gave a much lower 
shift in fluorescence intensity than 17D9. When compared on platelets isolated from 
whole blood of unmanipulated control C57BL/6 mice, the geometric mean for INU1 was 
around 60% lower than 17D9, shown by the left hand shift of the histogram (Figure 4.14). 
INU1 binding was in line with isotype controls on leukocytes, arguing against significant 
CLEC-2 expression on circulating leukocytes. These results highlighted the importance of 
studying CLEC-2-deficient cells in order to determine the specificity of 17D9. 
 
4.2.6 Investigating CLEC-2 expression on platelets  
Robust expression of CLEC-2 was seen on circulating platelets using either 17D9 or 
INU1 in both tamoxifen-treated Clec-2fl/fl mice and +/+ fetal liver chimeras, while no 
CLEC-2 expression was seen on platelets isolated from CLEC-2-depleted littermates 
(Clec-2fl/flERT2Cre or Clec-2-/- chimeras) using either antibody (Figure 4.15). 
Additionally, no difference in CLEC-2 expression on platelets was observed between 
LPS-treated chimeras or controls, using either 17D9 or INU1 (Figure 4.15). Despite 
efforts to maintain instrument settings between experiments, due to the long period of 
time over which experiments were conducted, deviations in the baseline fluorescence 
intensity were introduced, which is reflected in the inter-experimental differences in 
geometric mean. Importantly, geometric means within single experiments were 
comparable, maintaining the validity of results. From this data it can be concluded that (i) 
CLEC-2 is highly expressed on platelets; (ii) both 17D9 and INU1 are suitable for 
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specifically detecting CLEC-2 on platelets; (iii) CLEC-2 is not up-regulated on platelets 
after systemic LPS challenge and (iv) both tamoxifen-inducible ERT2Cre mediated CLEC-
2 depletion (either i.p. or in the diet) and fetal liver chimeras represent effective models 
for long-term sustained depletion of CLEC-2 in the circulation.  
 
4.2.7 Investigating CLEC-2 expression on B-lymphocytes 
In contrast to the partial depletion of CLEC-2 on B-lymphocytes from Clec-2fl/flERT2Cre 
mice following 2 weeks of tamoxifen diet (Figure 4.9), no significant difference in 17D9 
binding was observed between Clec-2fl/fl and Clec-2fl/flERT2Cre mice following 6 months 
of tamoxifen diet (Figure 4.16Ai). A comparable level of binding was also observed with 
INU1 that was not lost following 6 months of tamoxifen treatment in Clec-2fl/flERT2Cre 
mice (Figure 4.16Ci). This suggests that both 17D9 and INU1 bind to a second site on B-
lymphocytes in this model. Furthermore, the CLEC-2-specific site that was labelled by 
17D9 following 2 weeks of tamoxifen treatment, was not apparent following prolonged 
tamoxifen treatment. On the other hand, both 17D9 and INU1 detect a ligand on B-
lymphocytes isolated from +/+ fetal liver chimeras that was absent from Clec-2-/- 
chimeras (Figure 4.15A-Dii-iii). A similar level of 17D9 or INU1 binding was also 
observed on B-lymphocytes isolated from untreated C57BL/6 controls (Figure 4.14), 
thereby supporting that CLEC-2 is expressed on B-lymphocytes in the steady state. 
Additionally, no increase in binding of 17D9 or INU1 to B-lymphocytes was observed 
following LPS challenge (Figure 4.16A-Dii-iii). LPS can cause a shift in the fluorescence 
of isotype controls, but was accounted for by comparing geometric means as apposed to 
the percentage of positive cells (Figure 4.15 C-Diii). Taken together these results suggest 
that (i) B-lymphocytes isolated from peripheral blood express CLEC-2 that can be 
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specifically detected by 17D9 and INU1, albeit INU1 exhibits much weaker binding; (ii) 
CLEC-2 is not upregulated on circulating B-lymphocytes during systemic LPS challenge 
and (iii) 17D9 and INU1 bind to a second site on B-lymphocytes isolated from peripheral 
blood of tamoxifen-treated mice. 
 
4.2.8 Investigating CLEC-2 expression on neutrophils (Gr1+Mac-1+) 
No difference in the binding of 17D9 or INU1 could be observed on peripheral blood 
neutrophils isolated from Clec-2fl/fl or Clec-2fl/flERT2Cre mice following 2 weeks of 
tamoxifen diet (Figure 4.9), or from Clec-2fl/fl or Clec-2fl/flERT2Cre mice following 6 
months on tamoxifen diet (Figure 4.17A-Di). This suggests that both 17D9 and INU1 bind 
to an alternative site on neutrophils. Interestingly, 17D9 binding to circulating neutrophils 
from +/+ chimeras was substantially higher than in untreated C57BL/6 mice that were 
measured at the same time, and was much lower in Clec-2-/- chimeras (Figure 4.17A-Bii-
iii and Figure 4.14). This suggests that CLEC-2 is upregulated on peripheral blood 
neutrophils in the chimeric model, which can be specifically detected by 17D9. In 
addition, 17D9 binding was increased on Clec-2-/- chimeras following LPS challenge, 
thereby demonstrating that 17D9 binds to a second site on peripheral blood neutrophils 
during systemic inflammation (Figure 4.17A-Bii-iii). Although INU1 exhibited 
substantially weaker binding, there was a trend for increased binding of INU1 to 
circulating neutrophils isolated from +/+ chimeras (Figure 4.17C-Dii-iii). On the other 
hand, INU1 did not detect a second site on neutrophils isolated from Clec-2-/- chimeras 
following systemic LPS challenge (Figure 4.17C-Dii-iii). Together these results suggest 
that (i) 17D9 detects a low level of CLEC-2 on peripheral blood neutrophils in the steady 
state (INU1 binding is too weak to robustly detect this); (ii) CLEC-2 is upregulated on 
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circulating neutrophils in the chimeric model; (iii) 17D9 binds to a second site on 
circulating neutrophils during systemic inflammation and (iv) both 17D9 and INU1 detect 
an alternative ligand on circulating neutrophils isolated from tamoxifen-treated mice.  
 
4.2.9 Investigating CLEC-2 expression on T-lymphocytes 
No evidence for CLEC-2 expression was observed using the 17D9 or INU1 antibodies on 
T-lymphocytes isolated from peripheral blood using either the ERT2Cre model or the 
chimeric model (Figure 4.18). Therefore, it can be concluded that CLEC-2 is not 
expressed at a significant level on T-lymphocytes. 
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4.3  Discussion 
 
The primary aim of the work in this chapter was to investigate the expression of CLEC-2 
on leukocytes in peripheral blood. Alongside this investigation, the same models were 
used to determine the expression level of CLEC-2 on leukocytes derived from secondary 
lymphoid tissues. This line of work builds on previous publications that showed surface 
expression of CLEC-2 on a range of leukocyte subsets in the steady state, including 
peripheral blood neutrophils (Kerrigan et al., 2009; Tang et al., 2010), splenic DCs, 
peritoneal macrophages, subsets of natural killer cells and B-lymphocytes (Mourao-Sa et 
al., 2011) and on splenic neutrophils, DCs, B-lymphocytes, natural killer cells and other 
monocyte subsets following inflammation (Kerrigan et al., 2009; Mourao-Sa et al., 2011). 
Importantly, neither study showed results to confirm antibody specificity by also staining 
CLEC-2-deficient cells. This comparison has since been made by Acton et al (2012), 
albeit they only analysed DCs derived from the bone marrow, skin or lymph nodes, and 
used recombinant podoplanin to detect CLEC-2 as apposed to the commercially available 
17D9 anti-CLEC-2 antibody used in the previous studies (Acton et al., 2012). In this 
thesis, the expression level of CLEC-2 on platelets and leukocyte subsets was investigated 
using two antibody clones to CLEC-2, 17D9 and INU1, and using two animal models of 
CLEC-2 depletion, a tamoxifen-inducible system and Clec-2-/- fetal liver chimeras. 
 
In agreement with the literature, CLEC-2 was expressed at a high level on platelets 
isolated from peripheral blood, and on platelets isolated from the spleen or mesenteric 
lymph node (Guillaume Desanti, data not shown). This was shown by robust and 
sustained knockdown of CLEC-2 on platelets following two weeks or long-term 
tamoxifen-induced CLEC-2 depletion in the ERT2Cre model, or through the generation of 
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Clec-2-/- fetal liver chimeras.  
 
While CLEC-2 was expressed on circulating B-lymphocytes in the steady state, this was 
not upregulated during systemic LPS challenge. Furthermore, no significant level of 
CLEC-2 was detected on B-lymphocytes isolated from the spleen or lymph nodes in the 
steady state, or following systemic LPS challenge (Guillaume Desanti, data not shown). In 
the present study, both 17D9 and INU1 bound to an alternative site on B-lymphocytes, 
isolated from tamoxifen-treated Clec-2fl/flERT2Cre mice. The expression profile of CLEC-
2 on B-lymphocytes contradicts findings by Sousa et al (2011), who showed evidence for 
17D9 binding to wild-type splenic B-lymphocytes in the steady-state, which was 
upregulated during systemic LPS challenge (Mourao-Sa et al., 2011). In light of the 
current findings, this is suggested to represent binding to a second, uncharacterised site, 
and highlights the importance of comparing 17D9 binding on wild-type cells to that of 
CLEC-2-depleted cells, derived from a well-characterised animal model. Future studies 
will also confirm that the levels of CLEC-2 detected on B-lymphocytes were not derived 
from platelet microparticles. Platelet microparticles are derived from activated platelets 
and are abundant in the circulation, where they share many functional properties to 
platelets, including their ability to adhere to leukocytes (Italiano et al., 2010). Platelet 
microparticles are characterised by their small size and expression of CD41 and therefore 
should have been removed when gating for leukocytes (Figure 4.8). However, the absence 
of CD41-positive platelet microparticles on B-lymphocytes will be confirmed using flow 
cytometry studies.   
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Interestingly, CLEC-2 was shown to be expressed at a low level on peripheral blood 
neutrophils in the steady state and markedly upregulated in the chimeric model. 
Conversely, no specific CLEC-2 expression was found on neutrophils isolated from the 
spleen or lymph nodes in the steady state, or following systemic LPS challenge 
(Guillaume Desanti, data not shown). Again, this contradicts findings by Sousa et al 
(2011), who showed an increase in 17D9 binding to splenic neutrophils during LPS-
induced inflammation (Mourao-Sa et al., 2011). In the present study, 17D9 was shown to 
bind to an off-target site on neutrophils following long-term tamoxifen treatment, or 
following LPS stimulation. The present study does, however, agree with the work of 
Kerrigan et al (2010), who showed higher expression of CLEC-2 on peripheral blood 
neutrophils (Gr1+Mac-1+) compared to those isolated from the bone marrow or 
inflammatory sites. It was proposed that in this scenario, CLEC-2 may be involved in 
trafficking (Kerrigan et al., 2009). This theory is supported by the recent observation that 
CLEC-2 is required on dendritic cells to support its entry into lymphatic vessels and 
trafficking to lymph nodes, a process that is dependent on its interaction with podoplanin-
expressing LECs and FRCs, respectively (Acton et al., 2012).  
 
In this study, CLEC-2 expression was confirmed on platelets, while shown to be absent 
from leukocyte subsets isolated from the spleen and lymph nodes, which is in contrast to 
previously published literature. This data was supported by quantitative PCR for Clec1b 
on cell sorted leukocyte populations isolated from the spleen or mesenteric lymph node, 
showing significant Clec1b mRNA levels only in a population of F4/80+ splenocytes, 
which was not upregulated during inflammation (Guillaume Desanti, data not shown). 
Clec1b mRNA was not detected in any other leukocytes isolated from secondary 
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lymphoid tissue in the steady state, or following systemic inflammatory challenge, 
including in T-lymphocytes, B-lymphocytes, natural killer cells, neutrophils or DCs, 
which correlates with Clec1b transcript levels identified in the ‘The immunological 
genome project’ (Figure 4.3) (Guillaume Desanti, data not shown) (Heng et al., 2008).  
 
Given the wide expression profile of podoplanin on stromal FRCs, follicular DCs, in 
tumour environments and throughout the lymphatic network that connects lymphoid 
tissue, it is likely that podoplanin-CLEC-2 interactions play many key, yet undiscovered 
roles in immune regulation and responses. This is not hampered by the restricted 
expression profile of CLEC-2 on leukocytes in secondary lymphoid tissues, given that 
CLEC-2-podoplanin interactions have been implicated in leukocyte trafficking, a key 
mechanism in immune regulation. Furthermore, it is well established that platelets interact 
with leukocytes to regulate their adhesive and migratory properties, in addition to directly 
regulating the structural integrity and function of lymphoid tissue (van Gils et al., 2009; 
Wagner & Burger, 2003; Herzog et al., 2013). 
 
Together these data show that CLEC-2 is expressed on platelets, B-lymphocytes and at 
low levels on neutrophils in peripheral blood and is restricted to platelets in secondary 
lymphoid tissues in adult mice. While there was no evidence for CLEC-2 up-regulation 
following systemic inflammation, only LPS immunisation was studied and it cannot be 
ruled out that other inflammatory stimuli may elicit different responses. Due to the 
complexity of DC subsets, more in depth analysis is required to deduce the expression 
pattern of CLEC-2 on DCs isolated from different tissues, in the steady state, and during 
inflammation. However, it can be concluded that both 17D9 and INU1 are capable of 
binding to multiple ligands on leukocytes that can be induced in different models, for 
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example, following tamoxifen treatment, or in response to injury/repair mechanisms that 
are induced in the chimeric model. It is therefore essential to consistently compare 17D9 
binding to binding on CLEC-2 depleted cells. 
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CHAPTER 5 
INVESTIGATING A POSSIBLE ROLE FOR CLEC-2 
AND PODOPLANIN IN SAFE-GUARDING THE 
BARRIERS OF THE ADULT BRAIN 
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5.1  Introduction 
 
Chapter 3 described a role for podoplanin and CLEC-2 in the development of the BBB, 
with a specific role for platelet-derived CLEC-2. In Chapter 4, it was shown that during 
adulthood, surface expression of CLEC-2 was restricted to circulating platelets and B-
lymphocytes, with low levels on circulating neutrophils and DC subsets isolated from the 
skin and lymph nodes (Acton et al., 2012). Given the importance of podoplanin and 
CLEC-2 interactions in cerebral vascular development, it was hypothesised that they may 
also play a role in the maintenance of the BBB in the steady state, or in response to 
challenge. 
 
Initial studies aimed to determine the distribution of podoplanin in the adult mouse brain. 
In Chapter 3, it was shown that podoplanin becomes restricted to the ependymal lining of 
the ventricles and to the choroid plexus from E14.5. The same pattern of expression has 
been reported in adult mice by multiple groups (M. C. Williams et al., 1996; Kaji et al., 
2012). However, one group, who originally reported the same finding, later performed a 
second immunohistological study and showed podoplanin also to be expressed on a broad 
range of neural cells, including cranial osteoclasts, dura mater, arachnoid, pia mater, as 
well as in the meninges and on Schwann cells, glial cells and satellite cells of the spinal 
cord (Tomooka et al., 2013). Furthermore, within the brain parenchyma, unidentified 
populations of cells were said to co-express podoplanin and the astrocyte marker GFAP 
within the cerebral cortex, hippocampus and the thalamus (Tomooka et al., 2013). To 
date, the function of podoplanin on these cell types has not been identified, yet the wide 
tissue distribution of podoplanin suggests it may have multiple roles within the nervous 
system. Furthermore, no study has reported changes in podoplanin expression in response 
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to challenge, for example during ageing or inflammation.  
 
From work conducted in Chapter 4 and in published literature, we know that platelets 
isolated from peripheral blood and secondary lymphoid tissues express high levels of 
CLEC-2. Beyond a role for platelets in maintaining vascular integrity, it is well known 
that platelets critically support multiple pathways in immune homeostasis, whether this be 
in the amplification or resolution of inflammation (Summarised in Section 1.1.4). Within 
the cerebral vasculature, which is uniquely adapted to tightly regulate immune 
homeostasis (Figure 1.6), inappropriate platelet activation has been shown to associate 
with changes in BBB permeability. For example, in HIV-infected individuals, platelet 
activation was coupled to an increase leukocyte migration across the BBB (Davidson et 
al., 2012). Additionally, in a mouse model of malaria, increased platelet adhesion to the 
endothelium caused infected erythrocytes to adhere and obstruct cerebral blood flow (Sun 
et al., 2003). Furthermore, as discussed in Chapter 3, platelets are a key source of LPA 
and following systemic LPS insult, increased LPA was directly linked to increased BBB 
permeability (On et al., 2013).  
 
A role for CLEC-2 in maintaining BBB integrity has not been studied, however, CLEC-2 
is known to play a critical role in maintaining vascular integrity at other sites of 
inflammation. The source of podoplanin in this setting is unknown, but is said to be on 
infiltrating F4/80 positive macrophages (Boulaftali et al., 2013). As discussed previously, 
CLEC-2-expressing platelets have been shown to ‘piggy back’ into inflammatory sites on 
the back of leukocytes (Herzog et al., 2013). Furthermore the group of Shannon Turley 
showed that CLEC-2 expression on DCs was critical for DC trafficking to inflammatory 
sites (Acton et al., 2012). Together these studies imply multiple mechanisms by which 
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CLEC-2 and podoplanin may interact to regulate immune homeostasis in the brain during 
inflammation.  
 
The aim of this chapter was to investigate a role for CLEC-2 in the maintenance and 
repair of the cerebral vasculature in response to inflammatory challenge. This was 
achieved by stimulating the immune system of CLEC-2-deficient mice and further 
assessing the integrity of the BBB. The expression pattern of podoplanin in the brains of 
adult mice in the steady state or following immune challenge was also studied, with an 
aim to dissect out a potential mechanism for their interaction.  
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5.2  Results 
5.2.1 Identifying a suitable adult CLEC-2-deficient mouse model 
The initial aim of the work in this Chapter was to identify a suitable CLEC-2-deficient, 
adult mouse model, to study the role of CLEC-2 in cerebral vascular integrity, since 
constitutive deficiency of CLEC-2 during development caused neonatal lethality. Deletion 
of CLEC-2 specifically in the megakaryocyte/platelet lineage (Clec-2fl/flPF4-Cre) 
overcame this lethality, however, the platelet count in these mice was reduced by 30% 
compared to Clec-2fl/fl littermates (Figure 5.1). The reduced platelet count was confirmed 
not to be due to a defect in platelet production (Figure 5.2) or lifetime (Figure 5.3).  
Instead, Finney et al (2012) showed that adult Clec-2fl/flPF4-Cre mice harbored defective 
lymphatics, with blood visible in mesenteric lymphatic vessels, and a build-up of chylous 
fluid was noted in the abdomen (Finney et al., 2012). With this in mind, it is likely that the 
reduced platelet count was due to blood-lymphatic mixing and therefore, a greater net 
vascular volume. It is possible that due to the longer lifetime of white blood cells and red 
blood cells, they are able to compensate for the linked vasculatures, resulting in largely 
unaffected cell counts (Figure 5.1). In the present study, it was also found that Clec-
2fl/flPF4-Cre mothers were unable to adequately wean entire litters (Figure 5.4). The cause 
for this remains to be established, but given that lymphatics play a crucial role in milk 
production for newborns, it is likely that Clec-2fl/flPF4-Cre mothers were unable to 
sufficiently nourish their offspring, resulting in a large number of deaths within first 
postnatal days (Figure 5.4).  Given that litter sizes are rarely recorded immediately after 
birth, the reduction in total litter size most likely reflects the loss of pups before P1 
(Figure 5.4). In conclusion, given the significantly lower platelet count in Clec-2fl/flPF4-
Cre mice, this was considered an unsuitable model to investigate the role of CLEC-2 in 
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the maintenance and repair of the blood-brain barrier. 
 
To remove the developmental influence of CLEC-2, Clec-2fl/fl mice were crossed to mice 
expressing Cre recombinase driven by the ERT2 transgene, which mediates induced 
recombination of the floxed allele following tamoxifen administration (Section 4.2.1; 
Figure 4.4). Platelet counts and other peripheral blood cell counts in Clec-2fl/flERT2Cre 
mice treated with tamoxifen diet for 12 weeks were identical to Clec-2fl/fl controls, making 
this a more suitable model (Figure 5.5). 
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5.2.2 Investigating the effect of ageing on Clec-2fl/fl and Clec-2fl/flERT2Cre tamoxifen 
treated mice 
One of the greatest challenges to the immune system is ageing, which has been shown to 
play a fundamental role in the regulation of immune homeostasis in the CNS, with direct 
links to the development and/or progression of a number of neurodegenerative disorders 
(Perry & Teeling, 2013). To investigate any influence of CLEC-2 depletion on the 
integrity of the BBB during ageing, Clec-2fl/flERT2Cre mice and Clec-2fl/fl littermates were 
fed tamoxifen diet from 8 weeks old for 6-12 months. At 6 months, blood could be seen to 
accumulate in the ascites fluid of the abdomen in Clec-2fl/flERT2Cre mice but not in Clec-
2fl/fl controls, persisting at 10 and 12 months, albeit this did not noticeably increase in 
severity. Between 10 and 12 months, the health of Clec-2fl/flERT2Cre mice, but not Clec-
2fl/fl controls, began to deteriorate rapidly, with fur coats appearing starry and grey in 
colour and small patches of alopecia were noticeable around the head and nose (Figure 
5.6B and C). Isinguinal lymph nodes were noticeably blood-filled in Clec-2fl/flERT2Cre 
mice at 12 months (Figure 5.6C). Interestingly, circulating white blood cell counts were 
seen to decrease from 3 to 12 months in Clec-2fl/flERT2Cre and Clec-2fl/fl mice, while 
circulating monocytes increased significantly in Clec-2fl/flERT2Cre mice, only at 6 and 10 
months (Figure 5.5). These data suggest that tamoxifen elicited immunosuppressive 
effects regardless of CLEC-2 depletion, but despite this, Clec-2fl/flERT2Cre mice appeared 
to have a sustained active innate immune response, reflected in the sustained increase 
circulating monocytes, suggesting they have a sustained low-grade level of inflammation. 
Platelet counts did not change significantly over the 12 months, but a significant increase 
in mean platelet volume was seen in Clec-2fl/flERT2Cre mice at 12 months, the cause for 
this is unknown (Figure 5.5). The increase in circulating monocytes in CLEC-2-deficient 
mice was reflected by a consistent increase in spleen size from 10 months, albeit this was 
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not significant (Figure 5.7A). No significant difference was observed in the weights of 
other tissues, including the heart, lung, kidneys, brain or liver dissected from Clec-
2fl/flERT2Cre or Clec-2fl/fl  littermates (Figure 5.7A). Between 10 and 12 months, the ill 
health of Clec-2fl/flERT2Cre mice was reflected in a small decline in total body weight 
compared to the steady increase in weight of Clec-2fl/fl littermates over the 12 month 
period (Figure 5.7B). Within the first week of tamoxifen diet, it was common for Clec-
2fl/flERT2Cre and Clec-2fl/fl littermates to experience weight loss that almost always 
recovered by two weeks. It was considered that mice initially found it difficult to 
transition to the new diet. Occasionally mice lost >20% of their body weight during the 
first week of tamoxifen diet and were culled in line with UK Home Office regulations. 
Mice that were fed tamoxifen diet continuously did not experience significant weight gain 
over the 6-month period compared to mice treated with tamoxifen intraperitoneally, for 
which weights were shown to increase steadily over the 6-month period (Figure 5.7B). 
 
These results showed that inducible deletion of CLEC-2 in adult mice gave rise to a 
distinct phenotype to that of Clec-2-/- chimeras and Clec-2fl/flPF4-Cre mice. No reduction 
in platelet count was observed and there was no evidence for blood-lymphatic mixing on 
tissue sections (data not shown). However, blood was seen in the lymph nodes of Clec-
2fl/flERT2Cre mice, similar to what was observed in Clec-2-/- chimeras and Clec-2fl/flPF4-
Cre mice, previously shown to result from defective vascular integrity (Herzog et al., 
2013; Bénézech et al., 2014). The impaired integrity of the vasculature most likely also 
accounts for the blood seen in the peritoneum. During ageing, CLEC-2 depletion appeared 
to cause a consistent pro-inflammatory state that may be responsible for the rapid 
deterioration of mice between 10-12 months.  
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5.2.3 Determining the effect of ageing on vascular permeability in CLEC-2-deficient 
mice 
The brain has been shown to become vulnerable to systemic infection with ageing, 
whereby resident microglia are ‘primed’ by repeated immune stimuli, making them either 
unresponsive, or over-activated, in response to further systemic immune challenge (Perry 
& Teeling, 2013; Püntener et al., 2012). While it has been shown that the microvascular 
endothelium increases expression of immune molecules such as MHCII and TLRs during 
ageing, few studies have addressed the impact of this ‘pro-inflammatory’ state on BBB 
integrity (Henry et al., 2009). Given the heightened monocyte counts in Clec-2fl/flERT2Cre 
mice and the disrupted integrity of lymph nodes, it was of interest to check whether 
CLEC-2 depletion had an effect on vascular integrity in the aged brain. However, no 
evidence of BBB leakage could be observed in any area of the brain following 12 months 
of tamoxifen diet (representative images are shown from the hippocampus, cortex and 
cerebellum), as detected by immunohistochemistry for IgG using F(ab)2-HRP (Figure 
5.8).  
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5.2.4 Determining the effect of systemic inflammatory challenge on vascular 
permeability in CLEC-2-deficient mice 
Systemic inflammatory challenge is well known to elicit inflammatory responses across 
CNS barriers and into the brain parenchyma. A role for platelets in the maintenance of 
barrier properties during infection has already been described. Here, the most extensively 
characterised endotoxin, LPS, was used to stimulate the peripheral immune system. LPS 
cannot cross the BBB, but acts directly on brain endothelium through TLRs, notably 
TLR4, to influence local cytokine production and stimulate the innate immune system 
(Mallard, 2012). Both 100 µg and 150 µg of LPS induced a characteristic drop in platelet 
counts after 24 hours, resulting from platelets becoming sequestered in the liver and 
spleen (Figure 5.9A). A corresponding drop in white blood cell counts reflects leukocytes 
trafficking to lymphoid organs, while the proportion of circulating monocytes increased, 
presumably to help control levels of the bacterial pathogen (Figure 5.9A). The integrity of 
the BBB in tamoxifen-treated Clec-2fl/flERT2Cre or Clec-2fl/fl mice, stimulated with LPS, 
was investigated by immunohistochemistry on paraffin sections, using F(ab)2-HRP, or by 
immunofluorescence of frozen sections, using F(ab)2-FITC. No evidence of IgG-leakage 
into the parenchymal tissue was observed in any area of the brain, shown here in the 
hippocampus and the cortex for mice treated with 150 µg of LPS (Figure 5.9B and C). To 
confirm that the drop in platelet count did not influence the sustained integrity of the 
BBB, thioglycolate was used to stimulate the peripheral immune system. Thioglycolate is 
commonly used in mouse models of peritonitis, in which it acts as a potent stimulator of 
the innate immune system. A rapid immune response is initiated, followed by a drastic 
increase in peripheral blood neutrophil counts at 2 hours, which was shown to resolve by 
4 hours (Figure 5.10C). To quantify BBB permeability, mice were injected with Evans 
blue dye and absorbance measurements were calculated from perfused brain tissue. 
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Initially, the basal level of Evans blue dye absorbance was measured in untreated Clec-
2fl/flERT2Cre and Clec-2fl/fl mice, which showed no significant difference. Brain weights 
were recorded as a marker of even perfusion of brain tissue (Figure 5.10A). Evans blue 
absorbance measurements were then taken from the brain tissue of tamoxifen-treated 
Clec-2fl/flERT2Cre and Clec-2fl/fl mice, stimulated with thioglycolate. A marginal increase 
in Evans blue absorbance was observed in the thioglycolate-treated mice, but this was not 
significant (Figure 5.10B). A drastic increase in Evans blue absorbance was measured 
from one CLEC-2-deficient mouse, but this did not correlate with a high monocyte count 
(Figure 5.10 B and C). Furthermore, no evidence of BBB permeability was observed by 
immunohistochemistry (data not shown). The data presented in this Chapter so far 
demonstrates that a single immune stimulus, or ageing in the absence of significant 
immune challenge, is not sufficient to induce any change in BBB permeability, in the 
presence or absence of CLEC-2. 
 
Recent studies have supported the absence of BBB permeability following a single 
immune stimulus and instead suggest that repeated systemic challenge substantially 
heightens inflammatory responses within the brain (Püntener et al., 2012). Tamoxifen-
treated Clec-2fl/flERT2Cre and Clec-2fl/fl mice were given a sub-lethal bolus of attenuated 
Salmonella Typhimurium (SL3261) to simulate bacterial infection. While the majority of 
bacteria are taken up by the liver and spleen, those that reach the brain can interact with 
TLR2 and TLR4 on brain endothelium and on circumventricular organs, including the 
choroid plexus, resulting in a pro-longed up regulation of MHCII and MHCI (S. E. Peters 
et al., 2009). It was proposed that subsequent systemic challenge with LPS might 
exacerbate this response, resulting in changes in BBB permeability. LPS was administered 
7 days after Salmonella infection, when the vast majority of bacteria have been cleared. 
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The deleterious effects of Salmonella treatment alone, or in combination with LPS, were 
reflected in animal weight loss (Figure 5.11B). It has been well characterised that mice 
infected with Salmonella develop thrombi in the liver vasculature by day 7, which was 
reflected by a drop in platelet count in Clec-2fl/fl mice (Figure 5.11); (Hitchcock, 
submitted). In the same study, it was shown that the loss of CLEC-2 on platelets, using the 
Clec-2fl/flPF4-Cre model, was protective against Salmonella-induced thrombus formation, 
resulting in a sustained platelet count, a phenomenon that was also observed in tamoxifen-
treated Clec-2fl/flERT2Cre mice (Figure 5.11). In line with previous results (Figure 5.9), 
LPS treatment caused a further drop in platelet count and a co-ordinate increase in platelet 
volume, while the number of circulating monocytes increased in both infected groups 
(Figure 5.11C). Preliminary results showed that Salmonella infection alone had no 
significant effect on BBB permeability, and although a marked variation in Evans blue 
absorbance was seen in both Clec-2fl/flERT2Cre and Clec-2fl/fl mice treated with Salmonella 
in combination with LPS, this was not significant. The analysis of further mice would be 
required to confirm these outcomes (Figure 5.11A). In cases where an increase in Evans 
blue absorbance from brain tissue was observed, this could not be seen by 
immunohistochemistry for IgG leakage on brain sections (data not shown).  
 
Special consideration was taken to eliminate any immunosuppressive effects of tamoxifen 
treatment (apart from in aged mice) by giving mice 6 weeks of normal diet prior to 
immune challenge. However, it has already been shown that sustained tamoxifen 
treatment was required to obtain a pro-longed depletion of CLEC-2 at the genomic level, 
on circulating leukocytes (Figure 4.10). Therefore, in the current model, while it is certain 
that CLEC-2 is depleted on platelets, it cannot be excluded that residual levels of CLEC-2 
remain on B-lymphocytes, neutrophils or DCs, which could also play important roles in 
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maintaining BBB integrity. For this reason, C57BL/6 mice were irradiated and 
reconstituted with wild-type or Clec-2-/- fetal liver cells and left for 6 weeks to reconstitute 
the haematopoietic niche. No evidence of BBB permeability was seen under basal 
conditions, or following systemic challenge in wild-type or Clec-2-/- chimeras, nor was 
their evidence for increased permeability at the choroid plexus (Figure 5.12). In line with 
Home Office restrictions, the dose of LPS was lower than the previous experiments (25 
µg), but still considered sufficient to stimulate the innate immune system, confirmed by 
the drop in platelet and white blood cell counts and an increase in circulating monocytes 
(Figure 4.12).  
 
Taken together, the data presented in this Chapter showed that ageing, or systemic 
immune challenge with LPS, thioglycolate, Salmonella or Salmonella + LPS, did not 
induce BBB permeability under the applied conditions, in the presence or absence of 
CLEC-2. Therefore, it can be concluded that CLEC-2 depletion does not pre-dispose the 
cerebral vasculature to alterations in BBB permeability. However, in the absence of a 
robust model to induce BBB permeability in healthy, untreated mice, a role for CLEC-2 in 
maintenance and repair pathways cannot be excluded. 
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5.2.5 Characterising podoplanin expression in the CNS of healthy adult mice 
In order to investigate a role for CLEC-2 in regulating cerebral vascular integrity, a more 
in depth analysis into the expression profile of its only endogenous ligand, podoplanin, 
was required. In support of previous studies, immunohistochemistry for podoplanin on 
brain sections from untreated C57BL/6 mice, detected its expression on the apical surface 
of the choroid plexus, the ependymal lining of the ventricle walls and on the interface 
between the cortex and the meninges (Figure 5.13). Interestingly, podoplanin could also 
be detected on vessels descending from the meninges into the cortex and on other 
unidentified vessels throughout the brain (Figure 5.13). Immunostaining of sequential 
brain sections for collagen IV and podoplanin, identified isolated podoplanin-positive 
vessels that were negative for collagen IV (Figure 5.14, top panel), while vessels co-
expressing collagen IV and podoplanin were also observed (Figure 5.14, bottom panel). 
Interestingly, podoplanin was often found to line areas of the brain in contact with CSF, 
including the choroid plexus, ependyma and meninges, and so it was no surprise to see 
podoplanin-positive cells lining the venous sinus and descending between the two cerebral 
hemispheres (Figure 5.14B, yellow arrows). However, the origin and function of these 
cells was unknown. Interestingly, single podoplanin-positive cells that were reminiscent 
of lymphatic endothelial cells, were seen to penetrate the adjacent parenchymal tissue 
(Figure 5.14B, white arrow). It is well accepted that the brain lacks a lymphatic system, 
however, the marked presence of the lymphatic markers, podoplanin and Lyve-1, on cells 
that border the major structures of the CSF drainage system, begin to challenge this view. 
Furthermore, in this study, podoplanin and Lyve-1 positive-cells were seen to line isolated 
vessels throughout the brain parenchyma, suggesting that they were lymphatic in origin 
(Figure 5.14C).  
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Taken together, these results postulate a new line of research to investigate the existence 
of a lymphatic-like drainage system in the brain, in which podoplanin may play a role.  
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5.2.6 Characterising podoplanin expression in the adult brain in response to 
challenge 
Previous studies have described podoplanin up-regulation or down-regulation to cause 
either pro- or anti- inflammatory effects, depending on the tissue and its local environment 
(Section 1.8.3). For example, Salmonella infection was associated with induced 
expression of podoplanin on blood endothelium, which was linked to venous thrombosis 
(Hitchcock, submitted). In aged tamoxifen-treated Clec-2fl/flERT2Cre and Clec-2fl/fl mice, 
podoplanin was detected on vessels within the cortex, in line with observations in control 
mice. There was no evidence for increased expression of podoplanin in any area of the 
brain during ageing, or following systemic challenge with LPS, thioglycolate, Salmonella 
or Salmonella + LPS, nor were any changes observed between +/+ and Clec-2-/- fetal liver 
chimeras treated with LPS or PBS only (data not shown). Diffuse expression of 
podoplanin was observed at varying levels around capillaries in the hippocampus in 
C57BL/6 brain sections and aged Clec-2fl/flERT2Cre mice. Tomooka et al (2013) reported 
co-expression of podoplanin with the astrocyte marker GFAP, however the pattern of 
staining seen here did not correlate with that of astrocytes and was instead thought to be 
non-specific (Figure 5.13 and Figure 5.15) (Tomooka et al., 2013). 
 
Earlier in this thesis, constitutive deficiency of podoplanin was shown to be lethal (Table 
3.2), as was Nes-Cre driven deletion of podoplanin (Table 3.3). Furthermore, tamoxifen-
inducible deletion of podoplanin in adult mice was associated with lethality, and where 
mice were viable, only a partial deletion of podoplanin was observed (Guillaume Desanti, 
data not shown). For these reasons, it was not possible in this study to investigate the 
effects of podoplanin depletion on BBB permeability, in the adult brain. However, 
podoplanin has also been detected on MS-inducing TH17 cells and F4/80+ macrophages 
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isolated from the spleen and the inflamed peritoneum, albeit, the mechanisms that guide 
their recruitment, and the contribution of individual subsets to the enhancement or 
resolution of inflammation, remain controversial (Section 1.8.3) (A. Peters et al., 2011; 
Hou et al., 2010). Through the generation of Pdpnfl/fl and Pdpnfl/flPGK-Cre fetal liver 
chimeras, it was confirmed that the loss of podoplanin on haematopoietic cells did not 
pre-dispose mice to impaired BBB integrity following systemic infection with Salmonella 
Typhimurium (Figure 5.16). In line with previous results, there were no obvious changes 
in podoplanin expression throughout the brain following systemic bacterial infection (data 
not shown). These results demonstrate that podoplanin expression in the brain is unaltered 
during ageing, or in response to systemic inflammatory challenge, whether this be in the 
presence or absence of CLEC-2, or the presence or absence of haematopoietic podoplanin.  
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5.2.7 Investigating a role for podoplanin in leukocyte trafficking 
A key finding in this study was the observation of podoplanin lining the areas of the brain 
in contact with CSF. CSF is produced by the choroid plexus and flows through the four 
ventricles of the brain into the sub-arachnoid space, where it drains through arachnoid 
granulations into the venous sinuses. Venous sinuses provide an entry route for venous 
circulating blood cells and an exit route for CSF into the venous system (Johansson et al., 
2008). For this reason, the sub-arachnoid space is a key surveillance channel for immune 
cells, such as F4/80+ and CD11b+ DCs. This was demonstrated using immunofluorescence 
staining on embryo tissue sections to identify F4/80+ cells and CD11b+ DCs, which were 
seen to circulate around the brain parenchyma in CSF (Figure 5.17A). There was no 
change in the number of F4/80+ or CD11b+ DCs in CLEC-2-deficient embryos, nor was 
their any evidence for their infiltration into the parenchymal tissue (Figure 5.17C). 
Interestingly, F4/80+ and CD11b+ DCs could be seen to adhere to podoplanin-positive 
ependyma and choroidal epithelium in both wild-type and CLEC-2-deficient embryos 
(Figure 5.17D). These preliminary observations imply that podoplanin interacts with 
immune cells in the CSF through an independent ligand to CLEC-2. Prior to this finding, 
an in vitro model was tested to mimic barrier properties of choroidal epithelium, whereby, 
the electrical resistance was measured across choroid plexus epithelial cell monolayers 
(confirmed to express podoplanin, data not shown). Platelets were found to have no effect 
on the resistance of choroid plexus epithelial cell monolayers (Figure 5.18). However, 
platelets were shown to increase the migration of choroid plexus epithelial cells, which 
was found to be CLEC-2-dependent (Figure 5.19). Further studies are required to 
investigate the function of podoplanin on the choroid plexus, a structure known to be the 
key site of leukocyte trafficking. It is possible that multiple mechanisms exist to traffic 
both CLEC-2 and non-CLEC-2 expressing leukocytes.  
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5.3  Discussion 
 
The primary aim of the work described in this chapter was to determine whether CLEC-2 
and podoplanin play any role in the maintenance or repair of the cerebral vasculature in 
the steady state, or in response to challenge, such as inflammation. Age is the most 
common risk factor for a number of inflammatory-associated diseases, including arthritis, 
cancers, atherosclerosis and neurodegenerative diseases. While a multitude of risk factors 
contribute to the development of age-related disease over time, a significant factor is the 
decline in function of the adaptive immune system, resulting in a low-grade chronic-
inflammatory state (Perry & Teeling, 2013). Monocyte numbers were consistently 
increased at 6 and 10 months following tamoxifen-induced CLEC-2 depletion, suggesting 
that the loss of CLEC-2 may accelerate the development of a chronic inflammatory state. 
Interestingly, draining isinguinal lymph nodes were noticeably blood-filled in 6-12 month 
old tamoxifen-treated Clec-2fl/flERT2Cre mice, reminiscent of Clec-2fl/flPF4-Cre mice, 
Clec-2-/- chimeras and Pdpn-/- chimeras, which supports the hypothesis that CLEC-2 on 
platelets interacts with podoplanin on lymph node FRCs to support the integrity of HEVs 
(Herzog et al., 2013). Interestingly Bénézech et al (2014) showed that loss of lymph node 
vascular integrity was directly linked to an impaired adaptive immune response (Bénézech 
et al., 2014). It would therefore be interesting to investigate any association between 
podoplanin and CLEC-2 in the decline of immune function during ageing.  
 
During ageing, peripheral inflammatory signals are continually communicated to the 
CNS, causing resident cells such as microglia to become ‘primed’ and sensitised to future 
inflammatory challenges (Püntener et al., 2012). Furthermore, the expression of pro-
inflammatory molecules, such as MHCII, were increased on the endothelium of 
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normal/healthy aged patients (Godbout et al., 2005). Despite the pro-inflammatory state of 
aged Clec-2fl/flERT2Cre mice and the drastic defects on vascular integrity in other tissues, 
no change was observed in BBB permeability. Given the unique resistant barrier 
properties of the cerebral microvasculature, this was not entirely surprising, but suggested 
that the loss of CLEC-2 did not pre-dispose to a loss of barrier function. A similar 
scenario was seen following a single systemic inflammatory challenge with LPS or 
thioglycolate, where no change in BBB function was observed in CLEC-2-sufficient or 
CLEC-2-deficient mice. Peripheral LPS challenge has been shown to elicit a much higher 
inflammatory response in aged mice, however, due to the deteriorating health of aged 
Clec-2fl/flERT2Cre mice, it was not possible to study this model (Henry et al., 2009). 
Püntener et al (2012) reported increasing levels of cytokines in the brain parenchyma 
following repeated LPS challenges, which eventually declined, indicative of tolerance. 
Alternatively, following bacterial infection with Salmonella, they observed a sustained 
pro-inflammatory response, with pro-longed up-regulation of MHCII on the 
microvascular endothelium (Püntener et al., 2012). In the present study, it was found that 
despite the pro-inflammatory state of the microvasculature, no change in BBB 
permeability was observed in the presence of absence of CLEC-2, following Salmonella 
infection alone, or following a second systemic stimulus of LPS. Together, these studies 
imply that systemic inflammatory mediators are transmitted into the CNS across an intact 
BBB. Furthermore, loss of CLEC-2 does not affect BBB integrity in the inflammatory 
models used. In this study, the induction of BBB permeability in control mice was not 
achieved and therefore, it was not possible to investigate a role for CLEC-2 in the 
prevention of BBB permeability, or in its repair. Future work would involve testing new 
models, such as the hypoxia/reoxygenation model that has been shown to induce BBB 
permeability in a model of stroke (Suidan et al., 2013).  
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In this study, the effects of CLEC-2 depletion on the infiltration of leukocytes and 
microglial function were not explored. In neurodegenerative disorders such as MS, 
systemic infections have been shown to induce relapse of disease by exacerbating 
inflammatory responses within the CNS. Similarly, systemic infection was associated with 
rapid cognitive decline in patients with Alzheimer’s disease and the exacerbation of 
disease symptoms in a mouse models of prion disease. Importantly, these effects were 
reported to take place in the presence of an intact BBB (Perry & Teeling, 2013; 
Cunningham et al., 2005). In these neuro-degenerative disease models, the progression of 
disease symptoms was commonly associated with increased cytokine levels in the brain 
parenchyma. These cytokines are unable to cross the BBB, but transmit messages to 
resident microglia via perivascular macrophages that are situated at circumventricular 
organs, albeit, the detailed mechanism of transmission is not known (Dantzer et al., 2008). 
In this study, podoplanin was detected in all areas of the brain lining CSF, specifically the 
meninges and choroid plexus, which are key entry and exit routes for leukocytes 
trafficking to and from the venous system. It was postulated that podoplanin might act as a 
regulator of epithelial barrier function and therefore, a regulator of leukocyte trafficking, 
across the choroid plexus. In preliminary studies, the loss of CLEC-2 had no effect on 
blood-CSF barrier integrity in vitro; however, CLEC-2-expressing platelets significantly 
increased the migratory properties of choroid plexus epithelial cells in an in vitro 
migration assay that was shown to be CLEC-2 dependent. In cancer cell lines, the 
acquisition of a migratory phenotype has been shown to be linked to down-regulation of 
epithelial markers, such as E-cadherin, resulting in increased cell motility (Martin-Villar 
et al., 2006). It can be suggested that the binding of CLEC-2-expressing cells to 
podoplanin, induces an alteration in epithelial barrier function, to specifically aid 
leukocyte migration across an otherwise intact choroidal epithelium. Future work will 
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investigate the expression of key junctional proteins such as ZO-1 and CL-1 on choroidal 
epithelium, in the presence and absence of podoplanin. However, this research is currently 
limited to in vitro studies, due to the lack of a robust model to deplete podoplanin in adult 
mice. 
 
While F4/80+ and CD11b+ DCs from both +/+ and Clec-2-/- fetal liver chimeras were seen 
to interact with podoplanin-expressing ependyma and choroidal epithelium, it cannot be 
confirmed that they were effectively trafficked across these barriers. Given that CLEC-2 
expression was shown to be restricted to subsets of leukocytes, it is likely that CLEC-2-
independent mechanisms exist to regulate leukocyte trafficking into the brain 
parenchyma. For example, podoplanin is known to interact with the chemokine CCL21, 
yet the significance of this interaction has not been explored (Kerjaschki et al., 2004). 
Additionally, a role for platelets cannot be ruled out, given the critical interplay between 
platelets and leukocytes in mediating leukocyte tethering, rolling and migration across 
endothelium (Ley et al., 2007). This process is highly dependent on platelets or leukocytes 
binding to endothelial P-selectin, which is stored and released from Weibel-Palade bodies 
in endothelial cells. Interestingly, Weibel-Palade bodies that are found in endothelial cells 
in the brain parenchyma do not store P-selectin, however, P-selectin is stored in Weibel-
Palade bodies that reside in meningeal endothelial cells (Engelhardt, 2008). While in vivo 
visualisation of leukocyte trafficking across the choroid plexus is limited by the depth of 
the tissue, leukocyte tethering to meningeal vessels has been visualised by intravital 
microscopy in a mouse model of MS, whereby disease progression was directly linked to 
platelet function (Langer et al., 2012). Furthermore, platelets were seen within T-
lymphocyte-rich MS lesions, which have previously been shown to be abundant in 
podoplanin-expressing TH17 cells. These studies demonstrate the capacity of platelets and 
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leukocytes to infiltrate inflamed nervous tissue and suggest new points of interaction 
between CLEC-2 and podoplanin that should be further investigated (Langer et al., 2012; 
A. Peters et al., 2011).  
 
The trafficking of platelets and leukocytes across meningeal vessels is particularly 
interesting, given that earlier in this chapter, podoplanin was shown to be expressed on 
isolated meningeal vessels. Future work should investigate the significance of this finding 
and identify whether podoplanin can interact with CLEC-2-expressing platelets or 
leukocytes on the meningeal endothelium, to mediate their adhesion and trafficking into 
the CNS parenchyma. Platelets, in particular, are powerful secretory cells that release a 
number of chemokines and soluble factors that can influence the recruitment and adhesion 
of leukocytes to the endothelium (Danese et al., 2007). It would be interesting to 
investigate whether podoplanin-induced platelet activation through CLEC-2, contributes 
to this process. This hypothesis represents a novel mechanism of action for CLEC-2 and 
podoplanin, given that podoplanin expression has not been reported on any other blood 
endothelial vessel in the steady state.  
 
A final consideration is whether podoplanin-expressing vessels play any role in CSF 
drainage in the brain. An association between CSF and lymph has been reported for over 
100 years, where tracer molecules were injected into the CSF and eventually found in 
lymphatic vessels, reviewed in (Koh et al., 2005). However, few studies have attempted to 
characterise their connections. It has been shown that CSF moves by bulk flow through 
the ventricles into the sub-arachnoid space, where it is absorbed into the venous sinuses 
through arachnoid granulations (Johansson et al., 2008). While one group described the 
venous sinuses to be a direct exit route for CSF into the venous system, another suggested 
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that this pathway of CSF drainage was used only under circumstances of increased 
intracranial pressure. Instead, they proposed that in the steady state, CSF flows from the 
sub-arachnoid compartment, along olfactory nerves, where it drains over the cribiform 
plate and into the nasal submucosa, where the CSF is absorbed by extracranial lymphatics 
(Papaiconomou et al., 2002; Mollanji et al., 2002). The present study reported the 
expression of two lymphatic specific markers, podoplanin and Lyve-1, that line areas of 
the brain involved in CSF drainage into the lymphatic compartments. Podoplanin and 
Lyve-1 were also seen on isolated vessels in brain parenchyma. These results postulate a 
role for podoplanin in CSF drainage into the lymphatic system and open up a new line of 
research for future study. In Chapter 3, the generation of a podoplaninfl/fl mouse was 
described that can be used as a useful tool to target the tissue-specific deletion of 
podoplanin in the adult brain, for example, on the endothelium, or on the choroid plexus. 
Molecular dyes of varying molecular weight can be used to monitor CSF flow and the 
passive, or regulated movement of molecules across the barriers of the brain, in 
podoplanin sufficient or podoplanin-deficient mice.  
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CHAPTER 6 
GENERAL DISCUSSION 
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6.1  Summary of results 
 
In this thesis, a unique mechanism was described for the receptor CLEC-2 on platelets and 
its endogenous ligand podoplanin in directing the development and integrity of the 
cerebral vasculature. It is proposed that podoplanin on neuro-epithelial cells induces 
platelet activation through its receptor, CLEC-2, mediating αIIbβ3-dependant platelet 
aggregation to plug the vessel wall, while secreted molecules (possibly S1-P) may direct 
supporting mural cells to the vessel wall, together preventing lethal haemorrhage.  
 
In order to investigate a role for CLEC-2 in cerebral vascular integrity during adulthood, 
the surface expression profile of CLEC-2 on leukocytes in adult mice was first 
investigated. CLEC-2 was found to be expressed at a high level on platelets isolated from 
the blood and secondary lymphoid organs, while CLEC-2 expression on leukocytes was 
restricted to peripheral blood B-lymphocytes and, at low level on neutrophils, with CLEC-
2 expression induced in the chimeric model. No evidence was found for CLEC-2 up-
regulation on platelets or leukocytes following systemic LPS challenge. By using animal 
models, in which CLEC-2 was depleted during adulthood, the loss of CLEC-2 was shown 
to be dispensable for maintaining blood-brain barrier integrity during adulthood in the 
steady state, or in response to systemic LPS challenge. However, a role for CLEC-2 and 
podoplanin in vascular repair, a process that shares many mechanistic similarities with 
vascular development, is still to be investigated. 
 
 
 
 
 136 
6.2  Evolution of platelets and CLEC-2 
 
We have come along way since the first identification of platelets, described as ‘novel 
morphological elements’ with important roles in haemorrhage and thrombosis, reviewed 
in (Ribatti & Crivellato, 2007). It is now well appreciated that platelets play fundamental 
roles that extend beyond these pathways and that their origin may lie in their nucleated 
evolutionary ancestors. Anucleate platelets are specialised cell fragments, unique to 
mammals. Non-mammalian vertebrates have nucleated thrombocytes and invertebrates 
harbor an even more primitive cell, the amebocyte (or haemocyte), which is their only 
blood cell and as such elicits a multitude of functions (McNicol & Israels, 2008). In fact, 
amebocytes are reminiscent of macrophages, expressing immune molecules such as TLRs. 
It is thought that platelets and leukocytes diverged from this single cell type, evolving to 
perform their specialised roles (Semple et al., 2011). It is highly likely that platelets may 
have retained some immune-like molecules to augment their roles in inflammatory 
processes. In support of platelets functioning as inflammatory cells, proteomics studies 
provided evidence for platelets to secrete a vast range of proteins upon activation, which 
included some inflammatory mediators, such as interleukin-1 (Coppinger et al., 2007). In 
addition, platelets have been shown to secrete a range of molecules that are involved in 
pro- and anti-angiogenic pathways, including VEGF, S1-P, TGF-β, PDGF, Ang-1, PF4 
and matrix metalloproteases (Italiano et al., 2007). These additional roles for platelets are 
thought to reflect the high platelet counts in mammals, given that adverse effects of 
haemostasis only occur when the platelet count falls below 5 x1010, a third lower than the 
physiological range (15-40 x1010) (Levin, 2012; Navarro-Nunez et al., 2013). The 
secretion of bioactive molecules relies on platelet activation, which can be induced 
through multiple receptors. The work in this thesis focused on the platelet ITAM receptor, 
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CLEC-2. While other ITAM receptors can be traced back as far as zebrafish; due to the 
divergence of the C-type lectin family, only one ortholog was identified in zebrafish 
(CLEC14), while other C-type lectins, including CLEC-2, were found to be restricted to 
mammals (Hughes, 2010). Similarly, the sequence domain within the podoplanin gene 
that permits its interaction with platelet CLEC-2, was found to emerge after the 
divergence of avians and mammals (Kaneko et al., 2006). It can therefore be considered, 
that mammalian anucleate platelets have adapted to their specialised roles outside of 
haemostasis by exploiting novel receptor-ligand interactions, such as CLEC-2 and 
podoplanin, which have evolved to become physiologically fundamental for survival.  
 
6.3  Platelets in cerebral vascular development; clinical implications 
 
Thrombocytopenia is the most common risk factor for intraventricular haemorrhage (IVH) 
in pre-term infants, affecting over 12 000 infants every year (Ballabh, 2010). At the time 
of onset, cerebral haemorrhage is generally asymptomatic, but often results in substantial 
morbidity and mortality in neonates. Outcomes can be within a range of neurological 
disorders, including cerebral palsy, hydrocephalus, mental retardation and cognitive 
deficits that can cause a number of developmental disabilities (Ballabh, 2010). While 
diagnostic methods for IVH have significantly improved, there has been little clinical 
development of preventative medicines, which is reflected by the consistent level of 
mortality rates over the past three decades (Hanley, 2009). A significant proportion of 
IVH cases are derived from germinal matrix haemorrhaging, an area of the developing 
neural tube that is located beneath the ventricular ependymal. IVH is associated with 
blood leakage into the developing brain ventricles, attributable to increased fragility and 
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disturbed blood flow in developing cerebral vessels (Winkler et al., 2011). The fragility of 
vessels has been postulated to result from a paucity of pericytes, specifically in the 
germinal matrix region (Braun et al., 2007). The molecular mechanisms that govern 
pericyte recruitment were discussed in Section 1.6.4, notably involving the PDGF-β, Ang-
1, TGF-β and S1-P signalling axes, with the present findings further implicating the 
CLEC-2-podoplanin axis. However, these pathways have not been targeted for therapeutic 
intervention of IVH. In the United States of America, glucocorticoids remain one of the 
only clinical drugs administered for the prevention of germinal matrix-derived IVH and 
are given to up to 75% of women in preterm labor, which encompasses over 12.5% of all 
births (Vinukonda et al., 2010). The molecular mechanisms that govern their effects are 
unknown, but they were recently shown to elicit anti-angiogenic properties through 
inhibition of VEGF, while increasing levels of TGF-β to guide the maturation and 
stabilisation of germinal matrix vessels and prevent haemorrhage (Vinukonda et al., 
2010). In addition, it was recently reported that platelet infusions in high-risk preterm 
infants enhance haemostasis and reduce the risk of IVH (Coen, 2013). These findings 
provide exciting new prospects to target the CLEC-2-podoplanin axis, or other associated 
pathways for non-invasive therapeutic prevention of IVH. Additionally, these findings 
argue against the use of anti-platelet drugs such as clopidogrel during pregnancy to reduce 
the risk of cerebral haemorrhage mid-gestation. 
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6.4  Targeting platelet interactions in inflammation 
 
In this thesis, evidence was provided to argue against a role for CLEC-2 and podoplanin 
in safeguarding the integrity of the BBB in the steady state, or in response to systemic 
inflammatory challenge. Simultaneously, no evidence for podpolanin expression on cells 
that constitute the BBB could be observed during inflammation to complement this 
finding. Instead, podpolanin was found to be highly expressed on the choroid plexus, 
venous sinus and on meningeal vessels, key sites of immune cell trafficking. A role for the 
CLEC-2-podoplanin axis in immune cell trafficking has already been shown, whereby 
CLEC-2-expressing DCs interact with podoplanin on lymphatic vessels and lymph node 
FRCs to guide their recruitment (Acton et al., 2012). At the lymph node, it has been 
shown that podoplanin-expressing FRCs induce platelet activation through CLEC-2, 
initiating the release of S1-P (Herzog et al., 2013). Interestingly, S1-P gradients have been 
shown to be critical in directing immune cell trafficking between secondary lymphoid 
organs and inflammatory sites (Chun & Hartung, 2010). In a recent study, using targeted 
depletion of podoplanin-expressing FRCs in mice, it was demonstrated that while 
trafficking of naïve T-lymphocytes is chemokine-dependent, once activated, retention of 
T-lymphocytes in the lymph node is instead dependent on their relative expression of the 
S1PR (Denton et al., 2014). A role for the S1PR in T-lymphocyte trafficking is supported 
by a recent study, whereby inhibition of the S1-P pathway was associated with reduced 
pathogenesis of MS. The recently licensed drug for treatment of MS, FTY720 
(fingolimod), directly mimics S1-P when phosphorylated in vivo, interacting with S1PRs 
to antagonise their function. It has been shown that FTY720 down-regulates S1PRs on 
lymphocytes, preventing their egress from lymphoid tissue to the CNS. This is coupled to 
a reduced clinical score in the MS animal model, EAE (Mohammad et al., 2014). In other 
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models, FTY720 was also shown to inhibit DC trafficking, thereby suppressing the 
activation of T-lymphocytes and reducing disease pathogenesis (Idzko et al., 2006). There 
are however concerns over disrupting the intricate balance of the immune system, with 
some studies showing long-term exacerbation of auto-inflammatory disease and others 
claiming an increased risk of infections resulting from impaired leukocyte trafficking 
(Mohammad et al., 2014). In Section 5.3 it was discussed that MS lesions are rich in 
podoplanin-expressing TH17 cells and that platelets are directly implicated in the 
progression of MS (Langer et al., 2012; A. Peters et al., 2011). In addition, work in this 
thesis identified podoplanin on meningeal vessels and in the sub-arachnoid compartment, 
which are key points of surveillance for leukocytes in the CNS. This thesis also 
demonstrated for the first time that in addition to CLEC-2 expression on circulating 
platelets, CLEC-2 is also expressed on circulating B-lymphocytes and at low levels on 
circulating neutrophils. Together, these findings raise the possibility that CLEC-2 on 
platelets and leukocyte subsets interact with podoplanin in the CNS to regulate the 
recruitment of immune cells. Future studies should investigate this hypothesis both in the 
steady state, and in animal models of disease that are associated with increased leukocyte 
infiltration into the brain parenchymal tissue, such as the EAE model. 
 
6.5  Final considerations 
 
Since the mergence of the CLEC-2-podoplanin pathways nearly a decade ago, a number 
of high impact studies have demonstrated that they occupy fundamental roles in 
development, including the correct separation of the blood and lymphatic vasculatures, the 
formation of lymph nodes and in cerebral vascular development. More specifically, 
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CLEC-2 on platelets and platelet signalling through SYK has been specifically implicated 
during development. Beyond development, the role of the CLEC-2 signalling pathway 
outside of its classical haemostatic function remains largely elusive, but is considered to 
play diverse roles throughout the body, likely reflecting the wide tissue expression pattern 
of podoplanin during adulthood. Importantly, there are many aspects of podoplanin 
biology that remain unanswered. Firstly, podoplanin signalling pathways, for which the 
majority of research has been conducted in tumour environments or in vitro (Section 
1.3.3), thereby presenting prosperous new lines of research that may lead to therapeutic 
targets. Secondly, the significance of the emerging ligands for podoplanin, such as 
chemokine CCL21 and galectin-8, which have been implicated in a multitude of 
pathways, including in immune cell trafficking and the dissemination of Salmonella 
infection, respectively (Denton et al., 2014; Thurston et al., 2013). Finally, the binding 
partners of podoplanin, which include the tetraspanin CD9 and the hyaluronan receptor 
CD44 (Lyve-1), which are specifically implicated in regulating podoplanin function 
(Section 1.3.4), yet their significance in in vivo molecular processes remains to be 
established. A third potential binding partner for podoplanin that was identified in this 
thesis is the intermediate filament protein, nestin. Like podoplanin, nestin is highly 
expressed on neural progenitors during development and becomes simultaneously down-
regulated following cell differentiation (Sugawara et al., 2002). Nestin-driven deletion of 
podoplanin results in a characteristic blood-lymphatic mixing phenotype (Section 3.2.8), 
which is thought to result from the loss of podoplanin on lymphatic endothelium, given 
the evidence for nestin expression on proliferating endothelial cells (Sugawara et al., 
2002). Future studies should establish the extent of podoplanin-nestin co-expression and 
the significance of this relationship. 
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To summarise, this thesis has discussed many of the emerging roles of podoplanin and 
CLEC-2 in both physiological and pathophysiological molecular pathways. Future studies 
will investigate the mechanisms that govern these processes, specifically investigating the 
pathological elements of their interactions, thereby paving the way for new therapeutic 
targets with wide potential clinical implications.  
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